WO2010051188A1 - P2x3, receptor antagonists for treatment of pain - Google Patents

P2x3, receptor antagonists for treatment of pain Download PDF

Info

Publication number
WO2010051188A1
WO2010051188A1 PCT/US2009/061409 US2009061409W WO2010051188A1 WO 2010051188 A1 WO2010051188 A1 WO 2010051188A1 US 2009061409 W US2009061409 W US 2009061409W WO 2010051188 A1 WO2010051188 A1 WO 2010051188A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
mmol
optionally substituted
aryl
heterocyclyl
Prior art date
Application number
PCT/US2009/061409
Other languages
French (fr)
Inventor
Christopher S. Burgey
Zhengwu J. Deng
Diem N. Nguyen
Daniel V. Paone
Anthony W. Shaw
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Priority to AU2009309019A priority Critical patent/AU2009309019B2/en
Priority to EP09824018.7A priority patent/EP2358371B1/en
Priority to MX2011004570A priority patent/MX2011004570A/en
Priority to EP14185280.6A priority patent/EP2860178B1/en
Priority to CN200980153515.2A priority patent/CN102271682B/en
Priority to US13/125,935 priority patent/US8598209B2/en
Priority to CA2741666A priority patent/CA2741666C/en
Priority to JP2011534616A priority patent/JP5592388B2/en
Priority to ES09824018.7T priority patent/ES2534199T3/en
Publication of WO2010051188A1 publication Critical patent/WO2010051188A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the invention relates generally to compounds which act as modulators, e.g., antagonists of the P2X3 receptor, compositions and therapeutic uses thereof.
  • Purines acting via an extracellular purinoreceptor, have been implicated as having a variety of physiological and pathological roles. (See, Burnstock (1993) Drug Dev. Res. 28:195-206.) Purinoreceptors (P2) have been generally categorized as either metabotropic nucleotide receptors or ionotropic receptors for extracellular nucleotides.
  • Metabotropic nucleotide receptors (usually designated P2Y or P2Y( n ), where "n" is a subscript integer indicating subtype) are believed to differ from ionotropic receptors (usually designated P2X or P2X (n) in that they are based on a different fundamental means of transmembrane signal transduction: P2Y receptors operate through a G protein-coupled system, while P2X receptors are Hgand-gated ion channels.
  • P2Xi cDNA was cloned from the smooth muscle of the rat vas deferens (Valera et al. (1994) Nature 371 :516-519) and P2X 2 cDNA was cloned from PC12 cells (Brake et al. (1994) Nature 371 :519-523).
  • Five other P2X receptors have been found in cDNA libraries by virtue of their sequence similarity to P2Xj and P2X 2 - P2X 3 : Lewis et al. (1995) Nature 377:432-435, Chen et al.
  • Purinergic receptors in particular, P2X receptors
  • P2X receptors are known to function as homomultimeric cation-permeable ion channels and, in some cases, as heteromeric channels consisting of two different P2X receptor subtypes (Lewis et al., Nature 377:432-435 (1995); Le et al., J. Neurosci. 18:7152-7159 (1998); Torres et al., MoI. Pharmacol. 54:989-993 (1998)).
  • the P2X 2 and P2X 3 subunits form functional channels when expressed alone, and can also form a functional heteromultimeric channel that has properties similar to currents seen in native sensory channels when co-expressed.
  • At least one pair of P2X receptor subtypes, P2X 2 and P2X 3s functions as a heteromeric channel in rat nodose ganglion neurons where it exhibits distinct pharmacological and electrophysiological properties (Lewis et al, supra (1995)).
  • Native P2X receptors are known to form rapidly activated, nonselective cationic channels upon activation by ATP.
  • the channels formed by P2X receptors generally have high Ca 2+ permeability (P( Ca ) /P(Na) )•
  • the P2X 3 purinergic receptor is a ligand-gated cation channel that is selectively permeable to small cations.
  • Known Hgands for P2X receptors include natural nucleotides, for example, ATP, UTP, UDP, or synthetic nucleotides, for example 2-methylthioATP.
  • ATP 5 in addition to its function as an intracellular energy donor, is now recognized as an important neurotransmitter or cotransmitter, in both the central and peripheral nervous system (Ralevic, V., et al., Pharmacol. Rev., 50:413-492 (1998)). It is released from a variety of cell types, including nerve fibers, upon stimulation and produces diverse effects on many tissues by activation of specific membrane receptors including purinoreceptors (P2 receptor) (See Burnstock, G., Pharmacol. Rev., 24:509-581 (1972); Burnstock, G., Cell Membrane Receptor for Drugs and Hormones: A Multidisciplinary
  • ATP can stimulate sensory nerve endings resulting in intense pain and a pronounced increase in sensory nerve discharge.
  • ATP released from damaged cells can evoke pain by activating P2X 3 homomeric receptors, or P2X 2 /P2X 3 heteromeric receptors expressed on nociceptive nerve endings of sensory nerves. This is consistent with reports of the induction of pain by intradermally applied ATP in the human blister-base model; the identification of P2X 3 containing receptor on nociceptive neurons in the tooth pulp; and with reports that P2X antagonists are analgesic in animal models.
  • P2X 3 receptor gene disruption results in a diminished sensitivity to noxious chemical stimuli and reduced pain.
  • the nociceptive effects of exogenously administered ATP and P2X containing receptor agonists have also been demonstrated in laboratory animals. See Bland- Ward et al., Dr. J. Pharmacol. 122:366-371 (1997); Hamilton et al., Br. J. PhamacoL 126:326- 332 (1999).
  • the peripheral nociceptive actions of P2X activation and stimulation of spinal P2X containing receptor also contribute to nociception as indicated by the ability of intrathecally (i.t.) administered P2 receptor agonists to increase sensitivity to acute and persistent noxious stimuli in rodents.
  • P2X 3 containing receptors P2X 3 and/or ?2Xm
  • P2X 3 and/or ?2Xm P2X 3 containing receptors
  • compounds which block or inhibit activation of P2X 3 receptors serve to block the pain stimulus.
  • receptor antagonists to compounds which normally activate the P2X 3 receptor and/or P2X 2 /P2X 3 heteromeric channels, such as ATP could successfully block the transmission of pain.
  • modulators of P2X receptors e.g., P2X 3 receptor may find use as analgesics.
  • compounds that block or inhibit activation of P2X 3 receptors also serve to treat genitourinary, gastrointestinal and respiratory diseases, conditions and disorders or receptor antagonists to compounds which normally activate the P2X 3 receptor and/or P2X 2 /P2X3 heteromeric channels, such as ATP are useful for treatment of genitourinary, gastrointestinal and respiratory diseases, conditions and disorders.
  • P2X receptors have been studied in a number of neurons including sensory, sympathetic, parasympathetic, mesenteric, and central neurons (Zhong, et al. (1998) Br. J Pharmacol. 125:771-781). These studies indicate that purinergic receptors play a role in affterent neurotransmission from the bladder, and that modulators of P2X receptors are potentially useful in the treatment of bladder disorders such as urinary incontinence and other genitourinary diseases or conditions.
  • P2X3 receptors have been shown to be expressed in human colon, and are expressed at higher levels in inflamed colon, than in normal colon (Y. Yiangou et al, Neurokastroenterol Mot (2001) 13:365-69). P2X3 receptors have also been implicated in detection of distension or intraluminal pressure in the intestine and initiation of reflex contractions (X. Bian et al. J. Physiol (2003) 551.1 :309-22), and have linked this to coilitis (G. Wynn et al., Am J Physiol Gastrointest Liver Physiol (2004) 287:G647-57).
  • P2X3 receptors also have been shown to be expressed in pulmonary neuroepithelial bodies (NEBs), implicating the receptor in pain transmission in the lung (Inge
  • the present invention aims to overcome some of the aforementioned drawbacks by providing novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.
  • the present invention relates to a novel P2X3 type receptor antagonists of structural formula I:
  • A represents pyridinyi, pyrimidinyl, or pyridinonyl
  • W and Z independently are absent or represent C(R2)2, -O-, NR2, CO, or S ⁇ Q-2;
  • R2 represents H, Q -6 alkyl, CF3, OH, CHF 2 , or CH 2 F;
  • R3 represents CR2R4R5, (CH2) n C3-10 cycloalkyl, (CH2) n C6-10 aiyl, (CH2) n C5-io heterocycle,said cycloalkyl, and heterocyclyl optionally substituted with 1 to 3 groups of Ra;
  • R2 and R3 can be combined with the nitrogen to which they are attached to form a C5-10 heterocyclyl optionally substituted with 1 to 3 groups of Ra;
  • R4 and R5 independently represent H, (CH2)nOR 2 , CHF2, (CH 2 ) n CF 3 , (CH2) n C5-10 heterocyclyl, (CH2)nC6-10 aryl C3.10 cycloalkyl, Ci-6 alkoxy, C2-6 alkenyl, C(O)i-2R 2 , or C 1-6 alkyl; said alkyl, cycloalkyl, heterocyclyl and aryl optionally substituted with 1 to 3 groups of Ra;
  • R6 represents hydrogen, OR2, -O",CF3, C(R2)2 ⁇ R2, CJ.6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-IO cycloalkyl, (CH2)nC6-10 aryl, (CH2)nC5-10 heterocyclyl, said alkyl, cycloalkyl, aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra;
  • R7 represents C ⁇ . ⁇ alkyl, C3-10 cycloalkyl, (CH2)nC5-10 heterocyclyl, or (CH2)nC6-10 aryl, said alkyl, cycloalkyl, heterocyclyl and aryl optionally substituted with 1 to 3 groups of R a ;
  • Ra represents C 1-6 alkyl, halogen, hydroxy., OR 2 (CH2)nCF3, -O- ⁇ C3.6 cycloalkyl, NR2C(O)R2 ?
  • n 0 to 4, provided that when A is pyrimidinyl WZR6 is not OH and when A is pyridinonyl WZR6 is not hydrogen.
  • This invention also relates to compositions and methods for using the compounds disclosed herein. These and other embodiments of the present invention will readily occur to those of ordinary skill in the art in view of the disclosure herein.
  • the present invention relates to a novel P2X3 type receptor antagonists of structural formula I that are useful in treating pain and diseases associated with pain.
  • An embodiment of the invention of formula I is realized when R? is Ci_6 alkyl optionally substituted with 1 to 3 groups of Ra and all other variables are as previously described.
  • Another embodiment of the invention of formula I is realized when R? is C3-10 cycloalkyl optionally substituted with 1 to 3 groups of R a and all other variables are as previously described.
  • a sub-embodiment of this invention is realized when the cycloalkyl is cyclopropyl.
  • R? is (CH2)nC6- 10 aryl optionally substituted with 1 to 3 groups of R a and all other variables are as previously described.
  • a sub-embodiment of this invention is realized when the aryl is phenyl.
  • Another sub- embodiment of this invention is realized when n is 0.
  • R? is optionally substituted (CH2)nC5-10 heterocyclyl and all other variables are as previously described.
  • a sub- embodiment of this invention is realized when the heterocyclyl is pyridinyl, morpholinyl, pyrimidinyl, imidazolyl, or oxazolyl optionally substituted with 1 to 3 groups of R a .
  • Another sub-embodiment of this invention is realized when n is 0.
  • R? is represented by structural formula Ia: wherein X is N or CH; and Rl represents H, Cl-6 alkyl, halogen, (CH2)nCF3, C3-10 cycloalkyl, C(R2)2 ⁇ H, -O-, CN, (CH2) n OR2, (CH2) n C5-10 heterocyclyl, (CH2) n C6-10 aryl, or Cl-6 alkoxy; said alkyl, cycloalkyl, heterocyclyl and aryl optionally substituted with 1 to 3 groups of Cl-6 alkyl, halogen, hydroxyl, (CH2)nCF3,or CN.
  • a sub-embodiment of the present invention is realized when X of formula Ia is N and all other variables are as previously described. Another sub-embodiment of the present invention is realized when X of formula Ia is CH and all other variables are as previously described. Another embodiment of the present invention is realized when formula Ia is linked to a carbon atom on A and all other variables are as previously described.
  • A is pyridyl and all other variables are as previously described.
  • a subembodiment of this invention is realized when -C(O)NR2R3 and -WZR ⁇ are independently attached to carbon atoms on A.
  • A is pyridyl
  • - C(O)NR2R3 is attached to a carbon atom on A
  • -WZR6 is attached to a nitrogen atom on A.
  • A is pyrimidinyl and all other variables are as previously described.
  • a subembodiment of this invention is realized when -C(O)NR2R3 and -WZR6 are independently attached to carbon atoms on A.
  • A is pyridinonyl and all other variables are as previously described.
  • a subembodiment of this invention is realized when — C(O)NR2R3 and -WZR ⁇ are independently attached to carbon atoms on A.
  • Another subembodiment of this invention is realized when -WZR ⁇ is attached to the nitrogen atom on A and -C(O)NR2R3 is attached to a carbon atom on A.
  • formula Ia is attached to a carbon atom on A.
  • Still another embodiment of this invention is realized when foruma Ia is attached to the nitrogen atom on A.
  • R6 is hydrogen, OR2, Cl -6 alkyl, C340 cycloalkyl, (CH2) n C6-10 aryl, (CH2)nC5-10 heterocyclyl, said alkyl, cycloalkyl, aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra.
  • R6 is hydrogen, Cl -6 alkyl, OR2, (CH2)nmorpholinyl, (CH2)nPy ⁇ dyl, (CH2)npiperidinyl, (CH2) ⁇ oxazolyl, (CH2) n isoxazolyl, (CH2)nphenyl, (CH2)nimidazolyl s (CH2)npyrimidinyl, cyclopropyl, cyclobutyl, preferably hydrogen,
  • R6 is hydrogen, C 1-6 alkyl, OR2, (CH2)nmorpholinyl,, (CH2)npyridyl, , (CH2)nphenyl 5 or (CH2)npyrimidinyl.
  • W and Z both are absent, and R6 is an -O- linked to a nitrogren on the ring.
  • Still another embodiment of this invention is realized when one of W and Z is absent and the other is -O-, or NR2. Still another embodiment of this invention is realized when R ⁇ is hydrogen, OR2, Cl -6 alkyl, C3.10 cycloalkyl, (CH2)nC6-10 aryl, (CH2) n C5-10 heterocyclyl, said alkyl, cycloalkyl, aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra.
  • R6 is hydrogen, Cl -6 alkyl, OR2, (CH2)nniorpholinyl, (CH2)nPyridyl, (CH2)npiperidmyl, (CH2)n ⁇ >xazoryl, (CH2)nisoxazolyl, (CH2)nphenyl > (CH2)nimiclazolyl > (CH2)npynmidinyl s cyclopropyl, cyclobutyl, preferably hydrogen, (CH2)nPvrMyl, (CH2)nmorpholinyl, (CH2)nphenyl, Cl -6 alkyl, cyclopropyl, all optionally substituted with 1 to 3 groups of Ra.
  • R2 is hydrogen and all other variables are as previously described.
  • Still another embodiment of the present invention is realized when R3 is (CH2)nC3-10 cycloalkyl and all other variables are as previously described. Still another embodiment of the present invention is realized when R3 is
  • a subembodiment of this invention is realized when R ⁇ of CR 2 R4R5 1S hydrogen.
  • a subembodiment of this invention is realized when one of R 4 and R ⁇ is C 1-6 alkyl or hydrogen and the other is (CH2)nC6-10 aryl, or (CH2)nC6-10 heterocyclyl, said alkyl, aryl and heterocyclyl optionally substituted with 1 to 3 groups of R a ,
  • a further subembodiment of this invention is realized when said aryl and heterocyclyl is (CH2)nphenyl, (CH2)nPyridyl, (CH2)npy ⁇ midinyl, (CH2)ntriazolyl, pyrazinyl, or (CH2)n ⁇ xadiazoly 1.
  • R3 is CR2R4R5 ⁇ which is an alkyl optionally substituted with 1 to 3 groups of R a and all other variables are as previously described.
  • R2 of CR2R4R5 is hydrogen, and one of R4 and R5 is C ⁇ -6 alkyl or hydrogen and the other is (CH2)nC6-10 aryl, or (CH2)nC6-10 heterocyclyl, said alkyl, aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra.
  • R2 of CR2R4R5 j s hydrogen
  • one of R 4 and R 5 is Ci_g alkyl or hydrogen and the other is (CH2)nphenyl, (CH2)nPyridyl, (CH2)nPyriniidinyl, (CH2)ntriazolyl, pyrazinyl, or (CH2)noxadiazolyl, said phenyl, pyridyl, pyrimidinyl, triazolyl, pyrazinyl and oxadiazolyl optionally substituted with 1 to 3 groups of R ⁇ .
  • R2 of CR2R4R5 is hydrogen
  • one of R 4 and R5 is Cl -6 alkyl or hydrogen and the other is (CH2)npyridy ⁇ » or (CH2)noxadiazolyl, said oxadiazolyl optionally substituted with 1 to 3 groups of Ra.
  • R3 is (CH2)nC6-
  • aryl optionally substituted with 1 to 3 groups of Ra.
  • a subembodiment of mis invention is realized when said aryl is optionally substituted phenyl.
  • R3 is (CH2)nC5- 10 heterocyclyl optionally substituted with 1 to 3 groups of Ra.
  • a subembodiment of this invention is realized when said heterocyclyl is optionally substituted (CH2)nPyridyl,
  • Ra is Ci-6 alkyl, halogen (preferably chloro or fluoro), -O-, OR 2 , CN, CF3, (CH2) n C5-10 heterocyclyl, or (CH2)nC6-10 aryl, said heterocyclyl and aryl optionally substituted with 1 to 3 groups of Ci-6 alkyl, halogen, hydroxy., (CH2)nCF3,or CN
  • R 3 , R 6 , R?, W and Z are as previously described.
  • R? is (CH2)nC6-10 aryl, or (CH2)nC6-10 heterocyclyl optionally substituted with 1 to 3 groups of Ra
  • R6 is hydrogen, Ci-6 alky ⁇ , OR2, (CH2)n ⁇ iorpholinyl, (CH2)nPy ⁇ dyl > (CH2)npiperidmyl, (CH2)noxazolyl, (CH2) n isoxazolyl, (CH2)nphenyl, (CH2)nPiperidinyl, (CH2)n ⁇ nidazolyl, (CH2)npyrimidinyl, cyclopropyl, cyclobutyl, all optionally substituted with 1 to 3 groups of Ra
  • R3 is CR2R4RS wherein R 2 of CR2R4R5 is hydrogen, and one of R 4 and R 5 is Ci-6 alkyl or hydrogen and the
  • R7 is phenyl, pyridinyl, morpholinyl, pyrimidinyl, imidazolyl, or oxazolyl optionally substituted with 1 to 3 groups of Ra.
  • Rl, R3, R6 5 X, W and Z are as previously described.
  • a subembodiment of formula Ha is realized when W and Z are absent, R ⁇ is Ci- 6 alkyl, optionally substituted with 1 to 3 groups of Ra X is CH, Rl is H, Ci -6 alkyl, halogen, or (CH2) n CF3, and R3 is CR2R4R5 wherein R2 of CR2R4R5 is hydrogen, and one of R4 and R5 is Cl -6 alkyl or hydrogen and the other is (CH2)nC6-10 aryl, or (CH2)nC6-10 heterocyclyl, said alkyl, aryl and heterocyclyl optionally substituted with 1 to 3 groups of R a .
  • R3, R6 ; R7 ; W and Z are as previously described.
  • R? is (CH2)nC6-10 aryl, or (CH2)nC6-10 heterocyclyl optionally substituted with 1 to 3 groups of Ra
  • R6 is hydrogen, Ci- 6 alkyl, OR2, (CH2)nmorpholinyl, (CH2)nPy ⁇ dyl, (CH2)npiperidinyl, (CH2) n oxazolyl, (CH2)nisoxazolyl, (CH2)nPhenyl, (CH2)npiperidinyl, (CH2)nimidazolyl, (CH2)npyrimidinyl, cyclopropyl, cyclobutyl, all optionally substituted with 1 to 3 groups of Ra, and R3 is CR2R4R5 wherein R2 of CR2R4R5 is hydrogen, and one of R4 and R5 is CI_6 alkyl or hydrogen and
  • R7 is phenyl, pyridinyl, morpholinyl, pyrimidinyl, imidazolyl, or oxazolyl optionally substituted with 1 to 3 groups of Ra.
  • R3, R6 S R7, W and Z are as previously described.
  • R7 is (CH2) n C6-10 aryl, or (CH2)nC6-10 heterocyclyl optionally substituted with 1 to 3 groups of Ra
  • R 6 is hydrogen, Cl -6 alkyl, OR2, (CH2) n morphoIinyl, (CH2)npy ⁇ dyl, (CH2)npiperidinyl, (CH2)noxazolyl, (CH2)nisoxazolyl, (CH2)nphenyl, (CH2)npipe ⁇ dmyl» (CH2)nimidazolyl, (CH2)nPyrimidinyl, cyclopropyl, cyclobutyl, all optionally substituted with 1 to 3 groups of Ra
  • R3 is CR2R4R5 wherein R2 of CR2R4R5 is hydrogen, and one of R4 and R 5 is Ci-6 alkyl or hydrogen and the other
  • R 7 is phenyl, pyridinyl, morpholinyl, pyrimidinyl, imidazolyl, or oxazolyl optionally substituted with l to 3 groups of Ra.
  • R3, R ⁇ 5, R7, W and Z are as previously described and the "+" charge on the ring is balanced by a counter balancing ion group of W, Z or R6.
  • a subembodiment of formula V is realized when W and Z are absent, R7 is (CH2)nC6-10 aryl, or (CH2)nC6-10 heterocyclyl optionally substituted with 1 to 3 groups of Ra, R6 is -O-, and R3 is CR2R4R5 wherein R2 of CR2R4R5 is hydrogen, and one of R4 and R 5 is Ci -6 alkyl or hydrogen and the other is (CH2)nC6-10 8 ⁇ or (CH2)nQ»-10 heterocyclyl, said alkyl, aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra.
  • R 7 is phenyl, pyridinyl, morpholinyl, pyrimidinyl, imidazolyl, or oxazolyl optionally substituted with 1 to 3 groups of Ra.
  • R3, Re, R7, W and Z are as previously described.
  • a subembodiment of formula VI is realized when W and Z are absent, R7 is (CH2)nC6-10 aryl, or (CH2)nC6-10 heterocyclyl optionally substituted with 1 to 3 groups of Ra, R ⁇ is hydrogen, Cl -6 alky], OR2, (CH2)nmorpholinyl, (CH2)npyridyl, (CH2)npipe ⁇ dmyl,.
  • R3 is CR2R4R5 wherein R2 of CR2R4R5 i s hydrogen, and one of R4 and R5 is Ci -6 alkyl or hydrogen and the other is (CH2)nC6-10 81 Y ⁇ ot (CH2)nC6-10 heterocyclyl, said alkyl, aryl and heterocyclyl optionally substituted with 1 to 3 groups of R a .
  • R? is phenyl, pyridinyl, morpholinyl, pyrimidinyl, imidazolyl, or oxazolyl any one of which is optionally substituted with 1 to 3 groups of Ra
  • R2 of CR2R4R5 in R i s hydrogen and one of R4 and R5 of CR2R4R5 is C 1-6 alkyl or hydrogen and the other is (CH2)nphenyl, (CH2)npy ⁇ dyl, (CH2)nPyriniid!nyl, (CH2)nt ⁇ azolyl, pyrazinyl, or (CH2)n ⁇ xadiazolyl
  • R2 of CR2R4R5 in R 3 is hydrogen
  • one of R4 and R5 of CR2R4RS is Cl -6 alkyl or hydrogen and the other is (CH2)noxadiazolyl, said oxadiazolyl optionally substituted with 1 to 3 groups of Ra
  • any variable e.g. aryl, heterocycle, Rl, R ⁇ etc.
  • its definition on each occurrence is independent at every other occurrence.
  • combinations of substituents/or variables are permissible only if such combinations result in stable compounds.
  • R a or R ⁇ When R a or R ⁇ is -O- and attached to a carbon it is referred to as a carbonyl group and when it is attached to a nitrogen (e.g., nitrogen atom on a pyridyl group) or sulfur atom it is referred to a N-oxide and sulfoxide group, respectively.
  • alkyl encompasses groups having the prefix “alk” such as, for example, alkoxy, alkanoyl, alkenyl, and alkynyl and means carbon chains which may be linear or branched or combinations thereof.
  • alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, and heptyl.
  • Alkenyl refers to a hydrocarbon radical straight, branched or cyclic containing from 2 to 10 carbon atoms and at least one carbon to carbon double bond.
  • Preferred alkenyl groups include ethenyl, propenyl, butenyl and cyclohexenyl.
  • alkenyl is C2-Cg alkenyl.
  • Preferred alkynyls are C2-C6 alkynyl.
  • Alkenyl “alkynyl” and other like terms include carbon chains containing at least one unsaturated C-C bond.
  • fluoroalkyl refers to an alkyl substituent as described herin containing at least one flurine substituent.
  • cycloalkyl refers to a saturated hydrocarbon containing one ring having a specified number of carbon atoms. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • Ci _6 includes alkyls containing 6, 5, 4, 3, 2, or 1 carbon atoms
  • alkoxy as used herein, alone or in combination, includes an alkyl group connected to the oxy connecting atom.
  • alkoxy also includes alkyl ether groups, where the term 'alkyl' is defined above, and 'ether' means two alkyl groups with an oxygen atom between them.
  • alkoxy groups examples include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, methoxymethane (also referred to as 'dimethyl ether'), and methoxyethane (also referred to as 'ethyl methy! ether').
  • aryl is intended to mean any stable monocyclic or bicycHc carbon ring of up to 7 members in each ring, wherein at least one ring is aromatic. Examples of such aryl elements include phenyl, napthyl, tetrahydronapthyl, indanyl, or biphenyl.
  • heterocycle, heterocyclyl, or heterocyclic represents a stable 5- to 7-membered monocyclic or stable 8- to 1 1-membered bicyclic heterocyclic ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O, and S, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • the heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.
  • heterocycle or heterocyclic includes heteroaryl moieties.
  • heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, 1,3-dioxolanyl, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazoHdinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyrid
  • heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benz ⁇ soxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyridinyl, ox
  • the heterocyclic group is a heteroaryl group.
  • heteroaryl refers to groups having 5 to 14 ring atoms, preferably 5, 6, 9, or 10 ring atoms; having 6, 10, or 14 ⁇ electrons shared in a cyclic array; and having, in addition to carbon atoms, between one and about three heteroatoms selected from the group consisting of N, 0, and S.
  • heteroaryl groups include, without limitation, thienyl, benzothienyl, furyl, benzofuryl, dibenzofuryl, pyrrolyl, imidazolyl, pyrazoiyl, pyridyl, pyrazinyl, pyrimidinyl, indolyl, quinolyl, isoquinolyl, quinoxalinyl, tetrazolyl, oxazolyl, thiazolyl, and isoxazoly ⁇ .
  • the heterocyclic group is fused to an aryl or heteroaryl group.
  • fused heterocycles include, without limitation, tetrahydroquinolinyl and dihydrobenzofuranyl.
  • heteroaryl represents a stable 5- to 7- membered monocyclic- or stable 9- to 10-membered fused bicyclic heterocyclic ring system which contains an aromatic ring, any ring of which may be saturated, such as piperidinyl, partially saturated, or unsaturated, such as pyridinyl, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • the heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.
  • heteroaryl groups include, but are not limited to, benzimidazole, benzisothiazole, benzisoxazole, benzofuran, benzothiazole, benzothiophene, benzotriazole, benzoxazole, carboline, cinnoline, furan, furazan, imidazole, indazole, indole, indolizine, isoquinoline, ⁇ sothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, quinazoline, quinoline, quinoxaline, tetrazole, thiadiazole, thiazo
  • heterocycloalkyls examples include azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, imidazolinyl, pyrolidin-2-one, piperidin-2-one, and thiomorpholinyl.
  • heteroatom means O, S or N, selected on an independent basis.
  • a moiety that is substituted is one in which one or more hydrogens have been independently replaced with another chemical substituent.
  • substituted phenyls include 2- flurophenyl, 3,4-dichlorophenyl, 3-chloro-4-fluoro-phenyl, 2,4fluor-3 ⁇ propylphenyl.
  • substituted n-octyls include 2,4 dimethyl-5-ethyl-octyl and 3-cyclopentyloctyl. Included within this definition are methylenes (-CH 2 -) substituted with oxygen to form carbonyl (-CO-).
  • Suitable substituents include, without limitation, halo, hydroxy, oxo (e.g., an annular -CH- substituted with oxo is -C(O)-), nitro, halohydrocarbyl, hydrocarbyl, aryl, aralkyl, alkoxy, aryloxy, amino, acylamino, alkylcarbamoyl, arylcarbamoyl, aminoalkyl, acyl, carboxy, hydroxyalkyl, , alkanesulfonyl, arenesulfonyl, alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl, acyloxy, cyano, and ureido groups.
  • Preferred substituents, which are themselves not further substituted are:
  • Halogen refers to fluorine, chlorine,, bromine and iodine.
  • the term “mammal” “mammalian” or “mammals” includes humans, as well as animals, such as dogs, cats, horses, pigs and cattle.
  • phrases "effective amount” or “therapeutically effective amount” mean a concentration of P2X receptor complex modulator sufficient to inhibit or enhance the effect of the P2X receptor complex.
  • “Pain” means the more or less localized sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings. There are many types of pain, including, but not limited to, lightning pains, phantom pains, shooting pains, acute pain, inflammatory pain, neuropathic pain, complex regional pain, neuralgia, neuropathy, tissue injury pain, and the like (Dorland's Illustrated Medical Dictionary, 28th Edition, W. B. Saunders
  • the goal of treatment of pain is to reduce the degree or severity of pain perceived by a treatment subject.
  • Treating" or “treatment of* a disease state includes: 1) preventing the disease state, i.e. causing the clinical symptoms of the disease state not to develop in a subject that may be exposed to or predisposed to the disease state, but does not yet experience or display symptoms of the disease state; 2) inhibiting the disease state, i.e., arresting the development of the disease state or its clinical symptoms; 3) or relieving the disease state, i.e., causing temporary or permanent regression of the disease state or its clinical symptoms.
  • the compounds of the present invention may contain one or more asymmetric centers and may thus occur as racemates, racemic mixtures, single enantiomers, diastereomeric mixtures, and individual diastereomers.
  • the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature.
  • the present invention is meant to include all suitable isotopic variations of the compounds of generic Formula I.
  • different isotopic forms of hydrogen (H) include protium ( 1 H) and deuterium ( ⁇ H). Protium is the predominant hydrogen isotope found in nature.
  • Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples.
  • Isotopically-enriched compounds within generic Formula I can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically- enriched reagents and/or intermediates.
  • references to the compounds of structural formula I are meant to also include the pharmaceutically acceptable salts, and also salts that are not pharmaceutically acceptable when they are used as precursors to the free compounds or in other synthetic manipulations.
  • the compounds of the present invention may be administered in the form of a pharmaceutically acceptable salt.
  • pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids. When the compound of the present invention is acidic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases.
  • Salts derived from such inorganic bases include aluminum, ammonium, calcium, copper (ic and ous), ferric, ferrous, lithium, magnesium, manganese (ic and ous), potassium, sodium, zinc and the like salts.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, as well as cyclic amines and substituted amines such as naturally occurring and synthesized substituted amines.
  • organic non-toxic bases from which salts can be formed include ion exchange resins such as, for example, arginine, betaine, caffeine, choline, N, N - dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methyl glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, and tromethamine.
  • ion exchange resins such as, for example, arginine, betaine, caffeine, choline, N, N - dibenzylethylenediamine, diethylamine, 2-diethyla
  • the compound of the present invention When the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like.
  • compositions of the present invention comprise compounds of the invention (or pharmaceutically acceptable salts thereof) as an active ingredient, a pharmaceutically acceptable carrier, and optionally one or more additional therapeutic agents or adjuvants.
  • additional therapeutic agents can include, for example, i) opiate agonists or antagonists, ii) calcium channel antagonists, iii) 5HT receptor agonists or antagonists, iv) sodium channel antagonists, v) NMDA receptor agonists or antagonists, vi) COX-2 selective inhibitors, vii) NKl antagonists, viii) non-steroidal anti-inflammatory drugs ("NSAID”), ix) selective serotonin reuptake inhibitors ("SSRl”) and/or selective serotonin and norepinephrine reuptake inhibitors (“SSNRI”), x) tricyclic antidepressant drugs, xi) norepinephrine modulators, xii) lithium, xiii) valproate, xiv) neurontin (gab
  • the pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
  • the present compounds and compositions are useful for the treatment of chronic, visceral, inflammatory and neuropathic pain syndromes. They are useful for the treatment of pain resulting from traumatic nerve injury, nerve compression or entrapment, postherpetic neuralgia, trigeminal neuralgia, small fiber neuropathy, and diabetic neuropathy.
  • the present compounds and compositions are also useful for the treatment of chronic lower back pain, phantom limb pain, chronic pelvic pain, neuroma pain, complex regional pain syndrome, migraines, chronic arthritic pain and related neuralgias, and pain associated with cancer, chemotherapy, HIV and HIV treatment-induced neuropathy.
  • Compounds of this invention may also be utilized as local anesthetics.
  • Compounds of this invention are useful for the treatment of irritable bowel syndrome and related disorders, as well as Crohn's disease.
  • the instant compounds have clinical uses for the treatment of epilepsy and partial and generalized tonic seizures. They are also useful for neuroprotection under ischaemic conditions caused by stroke or neural trauma and for treating multiple sclerosis.
  • the present compounds are useful for the treatment of tachy-arrhythmias.
  • the instant compounds are useful for the treatment of neuropsychiatric disorders, including mood disorders, such as depression or more particularly depressive disorders, for example, single episodic or recurrent major depressive disorders and dysthymic disorders, or bipolar disorders, for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder; anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, for example, specific animal phobias, social phobias, obsessive-compulsive disorder, stress disorders including post-traumatic stress disorder and acute stress disorder, and generalised anxiety disorders.
  • mood disorders such as depression or more particularly depressive disorders, for example, single episodic or recurrent major depressive disorders and dysthymic disorders
  • bipolar disorders for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder
  • anxiety disorders such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, for example, specific animal phobias, social phobia
  • Compounds of Formula I also may be used alone or in combination with other drugs in the treatment/prevention/suppression or amelioration of the diseases, conditions, or disorders such as overactive bladder, urinary incontinence, urge urinary incontinence, and urinary urgency.
  • mammals including, but not limited to, cows, sheep, goats, horses, dogs, cats guinea pigs, or other bovine, ovine, equine, canine, feline, rodent such as mouse, species can be treated.
  • the method can also be practiced in other species, such as avian species (e.g., chickens).
  • a compound of the present invention may be used in conjunction with other anti-depressant or anti-anxiety agents, such as norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAO ⁇ s), reversible inhibitors of monoamine oxidase (RJMAs), serotonin and noradrenaline reuptake inhibitors (SNRJs), ⁇ -adrenoreceptor antagonists, atypical anti-depressants, benzodiazepines, 5-HT IA agonists or antagonists, especially 5-HTIA partial agonists, neurokinin- 1 receptor antagonists, corticotropin releasing factor (CRF) antagonists, and pharmaceutically acceptable salts thereof.
  • SSRIs selective serotonin reuptake inhibitors
  • MAO ⁇ s monoamine oxidase inhibitors
  • RJMAs reversible inhibitors of monoamine oxidase
  • compounds of this invention can be administered at prophylactically effective dosage levels to prevent the above-recited conditions and disorders, as well as to prevent other conditions and disorders associated with calcium channel activity.
  • Creams, ointments, jellies, solutions, or suspensions containing the instant compounds can be employed for topical use. Mouth washes and gargles are included within the scope of topical use for the purposes of this invention.
  • Dosage levels from about 0.01 mg/kg to about 140 mg/kg of body weight per day are useful in the treatment of inflammatory and neuropathic pain, or alternatively about 0.5 mg to about 7 g per patient per day.
  • inflammatory pain may be effectively treated by the administration of from about O.Olmg to about 75 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day.
  • Neuropathic pain may be effectively treated by the administration of from about 0.01 mg to about 125 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 5.5 g per patient per day.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • a formulation intended for the oral administration to humans may conveniently contain from about 0.5 mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may ary from about 5 to about 95 percent of the total composition.
  • Unit dosage forms will generally contain between from about 1 mg to about 1000 mg of the active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg or 1000 mg.
  • the specific dose level for any particular patient will depend upon a variety of factors. Such patient-related factors include the age, body weight, general health, sex, and diet of the patient. Other factors include the time and route of administration, rate of excretion, drug combination, and the severity of the particular disease undergoing therapy.
  • the compounds of the invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous).
  • the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient.
  • compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion or as a water-in-oil liquid emulsion.
  • the compounds of the invention, or pharmaceutically acceptable salts thereof may also be administered by controlled release means and/or delivery devices.
  • the compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients.
  • the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.
  • compositions of this invention may include a pharmaceutically acceptable carrier and a compound or a pharmaceutically acceptable salt.
  • the compounds of the invention, or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more therapeutically active compounds.
  • the pharmaceutical carrier employed can be, for example, a solid, liquid, or gas.
  • solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid.
  • liquid carriers are sugar syrup, peanut oil, olive oil, and water.
  • gaseous carriers include carbon dioxide and nitrogen.
  • oral liquid preparations such as suspensions, elixirs and solutions
  • water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used; or in the case of oral solid preparations such as powders, capsules and tablets, carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be included.
  • carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be included.
  • tablets and capsules represent the most advantageous oral dosage unit form in which solid pharmaceutical carriers are employed.
  • tablets may be coated by standard aqueous or nonaqueous techniques.
  • controlled release means and/or delivery devices may also be used in administering the instant compounds and compositions.
  • any convenient pharmaceutical media may be employed.
  • water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents can be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are advantageous oral dosage units whereby solid pharmaceutical carriers are employed.
  • tablets may be coated by standard aqueous or nonaqueous techniques
  • a tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants.
  • Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
  • Each tablet advantageously contains from about 0.1 mg to about 500 mg of the active ingredient and each cachet or capsule advantageously containing from about 0.1 mg to about 500 mg of the active ingredient.
  • a tablet, cachet, or capsule conveniently contains 0.1 mg, 1 mg, 5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, or 500 mg of the active ingredient taken one or two tablets, cachets, or capsules, once, twice, or three times daily.
  • compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water.
  • a suitable surfactant can be included such as, for example, hydroxypropylcellulose.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
  • compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions.
  • the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions.
  • the final injectable form must be sterile and must be effectively fluid for easy syringability.
  • the pharmaceutical compositions must be stable under the conditions of manufacture and storage, and thus should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.
  • compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, and dusting powder. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound represented of the invention, or pharmaceutically acceptable salts thereof, via conventional processing methods. As an example, a cream or ointment is prepared by mixing hydrophilic material and water, together with about 5 wt% to about 10 wt% of the compound, to produce a cream or ointment having a desired consistency.
  • compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid, such as, for example, where the mixture forms unit dose suppositories.
  • suitable carriers include cocoa butter and other materials commonly used in the art.
  • the suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in moulds.
  • the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, and preservatives (including anti-oxidants).
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, and preservatives (including anti-oxidants).
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, and preservatives (including anti-oxidants).
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, and preservatives (including anti-oxidants).
  • other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient.
  • the instant compounds can be utilized in combination with one or more therapeutically active compounds.
  • inventive compounds can be advantageously used in combination with i) opiate agonists or antagonists, ii) other calcium channel antagonists, iii) 5HT receptor agonists or antagonists, including 5-HTj ⁇ agonists or antagonists, and 5-HT JA partial agonists, iv) sodium channel antagonists, v) N-methyl-D- aspartate (NMDA) receptor agonists or antagonists, vi) COX-2 selective inhibitors, vii) neurokinin receptor 1 (NKl) antagonists, viii) non-steroidal anti-inflammatory drugs (NSAID), ix) selective serotonin reuptake inhibitors (SSRJ) and/or selective serotonin and norepinephrine reuptake inhibitors (SSNRI), x) tricyclic antidepressant drugs, xi) norepinephrine modulators, xii) lithium, xui)
  • the present compounds can be prepared according to the procedures provided in the Examples.
  • the following Examples further describe, but do not limit, the scope of the invention.
  • NMR data is in the form of delta ( ⁇ ) values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as internal standard, determined at 300 MHz, 400 MHz or 500 MHz using the indicated solvent.
  • TMS tetramethylsilane
  • Conventional abbreviations used for signal shape are: s, singlet; d. doublet; t. triplet; m. multiplet; br. Broad; etc.
  • “Ar” signifies an aromatic signal.
  • the products can be characterized using various techniques well known in the chemical arts, including proton and carbon-13 nuclear magnetic resonance ( 1 H and 13 C NMR), infrared and ultraviolet spectroscopy (IR and UV), X-ray crystallography, elemental analysis and HPLC and mass spectrometry (HPLC-MS). Methods of protecting group manipulation, purification, structure identification and quantification are well known to one skilled in the art of chemical synthesis.
  • solvents are those which will at least partially dissolve one or all of the reactants and will not adversely interact with either the reactants or the product.
  • Suitable solvents are aromatic hydrocarbons (e.g, toluene, xylenes), halogenated solvents (e.g, methylene chloride, chloroform, carbontetrachloride, chlorobenzenes), ethers (e.g, diethyl ether, diisopropylether, tert-butyl methyl ether, diglyme, tetrahydrofuran, dioxane, anisole), nitriles (e.g, acetonitrile, propionitrile), ketones (e.g, 2-butanone, dithyl ketone, tert-butyl methyl ketone), alcohols (e.g, methanol, ethanol, n-propanol, iso-propanol, n-butanol, t-butanol
  • Suitable bases are, generally, alkali metal hydroxides, alkaline earth metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, barium hydroxide, and calcium hydroxide; alkali metal hydrides and alkaline earth metal hydrides such as lithium hydride, sodium hydride, potassium hydride and calcium hydride; alkali metal amides such as lithium amide, sodium amide and potassium amide; alkali metal carbonates and alkaline earth metal carbonates such as lithium carbonate, sodium carbonate, cesium carbonate, sodium hydrogen carbonate, and cesium hydrogen carbonate; alkali metal alkoxides and alkaline earth metal alkoxides such as sodium methoxide, sodium ethoxide, potassium tert-butoxide and magnesium ethoxide; alkali metal alkyls such as methyllithium, n-butyllithium, sec-butyllithium, t-bultyl
  • compounds of this invention contain one or more stereocenters that may be prepared as single enantiomers or diastereomers, or as mixtures containing two or more enantiomers or diastereomers in any proportion.
  • the compounds of the present invention can be prepared readily according to the following Schemes and specific examples, or modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in this art but are not mentioned in greater detail.
  • the general procedures for making the compounds claimed in this invention can be readily understood and appreciated by one skilled in the art from viewing the following Schemes.
  • Biaryl substituted pyridines are prepared according to Scheme 2. Palladium-catalyzed cross couplings can be performed on pyridine carboxylic acid 2.1. A second cross coupling is next carried out on various aryl or heteroaryl boronic acids or esters to give triaryl intermediates 23. Amide bond formation then yields the final targets 2 ⁇ .
  • Pyridine N-oxides can be prepared according to Scheme 4, Bromopyridine 4J. can undergo palladium-catalyzed Suzuki cross coupling to a variety of aryl or heteroaryl boronic acids or esters. Subsequent hydrolysis furnishes acid 42,. Oxidation with MCPBA affords the corresponding pyridine N-oxides 4J, and amide bond formation using EDC provides amides 4.4.
  • Substituted pyridinones are prepared according to Scheme 5.
  • Bromopyridinone 5J can undergo Suzuki coupling with a variety of ary] or heteroaryl boronic acids or esters to afford intermediate 5.2.
  • N-alkylation can be accomplished using cesium carbonate and an appropriate alkyl halide or tosylate. In some cases a significant amount of o-alkylation is observed.
  • N-arylation is effected using copper(I) iodide with a trans 1,2-cyclohexyl diamine ligand. Hydrolysis and amide bond formation yields final targets 5 ⁇ .
  • Scheme 6 depicts the general synthetic route to prepare compounds of type 6J5.
  • Dichloropyridine 6J is protected using Boc 2 O and subsequent vinyllation gives intermediate 62.
  • Ester deprotection and final amide coupling gives examples of type 6Ji.-
  • Amine intermediates of type TJi can be prepared from one of several intermediates as shown in Scheme 7. This method utilizes diastereoselective EIlman sulfinimine addition chemistry to generate a pair of diastereomeric sulfinamides. The diastereomers are separated by silica chromatography prior to HCl deprotection to give 2Ji. Depending on the substrate either the R or S EIlman reagent is utilized to favor the desired alpha methyl amino compound with the preferred stereo configuration shown.
  • Step A Benzyl [ ⁇ £V2 ⁇ amino-l-methyl-2-thioxoethyl] carbamate
  • dichloromethane 337 mL
  • 2,4-bis-(4-methoxyphenyl)-l,3-dithia-2,4-diphosphetane 2,4- disulfide 15.01 g. 37.1 mmol
  • the reaction was allowed to cool to ambient temperature and concentrated. Recrystallization from dichloromethane gave the title compound (13.4 g). MS 239.1 (M+l).
  • Step B Benzyl [(lS)-l-(4H-l,2,4 ⁇ . r triazol-3-y ⁇ ethyl]carbamate
  • Step C (iy>-l-(4H-L2.4-Triazol-3-vnethanamme
  • benzyl [(I S)- 1-(4H-1 ,2,4-triazol-3-yl)ethyl] carbamate (8.6 g, 34.9 mmol) in ethanol (140 mL) was added 4 M hydrochloric acid in 1,4-dioxane (43.7 mL, 175 mmol) and 10% palladium on carbon (1,858 g, 1.746 mmol) and the mixture was pressurized to 47 psi under hydrogen. After 4 h, the reaction was depressurized and filtered.
  • Step A 2-methyl T N- ⁇ (l£ r )-j ' 6-(trif ⁇ uoroniethyl)-3-pyridinyl1methylene>-2-propanesulfinamide
  • Step B 2-Methyl-N- 1 (IR)-I 46-(IT ifluoromethvi)- 3 -pyridiny llethyl ) -2-propanesulfinamide
  • the reaction mixture was warmed to 0 0 C and was quenched with saturated aqueous ammonium chloride (300 mL). The mixture was allowed to warm to ambient temperature. The organic layer was separated and the aqueous layer was extracted with dichloromethane (3x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated. The concentrate was recrystallized using ethyl alcohol (500 mL). Then white solid was filtered and dried under reduced pressure (41.6 g). MS 295.0 (M+ 1).
  • Step C (lJ?Vl-[6-(Trifluoromethyl)-3-pyridinyl1ethanamine
  • 2-methyl-N- ⁇ (l- ⁇ )-l-[6-(trifluoromethyl)-3- ⁇ yridinyl]ethyl ⁇ -2- propanesulfinamide (41.6 g, 141 mmol) in methyl alcohol (470 mL) at 0 0 C
  • hydrogen chloride 4.0 M in dioxane; 106 mL, 424 mmol
  • Step A tert-Butyl K li?)-l-[6-(trifluoromethyl)-3-pyridinyl]ethv ⁇ carbamate
  • Step B tert-Butyl ((I J?)-l- ⁇ -oxido-6-(trifluoromethyl)-3-pyridinyl]ethyl) carbamate
  • Step C (lJ?Vl-[l-Oxido-6-(triflu ⁇ romethy ⁇ -3-pyridinyl '
  • tert-butyl ⁇ (l ⁇ )-l-[l-oxido-6-(trifluoromethyI)-3- pyridinyl]ethyl ⁇ carbamate 140 mg, 0.457 mmol
  • hydrogen chloride 4.0 M in dioxane; 0.343 mL, 1,371 mmol
  • the reaction mixture was stirred for 4 h.
  • the reaction mixture was concentrated to dryness to give the hydrochloride salt of the title compound (118 mg).
  • Step A tert-Butyl faRyi-f3 ⁇ methyl-L2.4-oxadiazol-5-yl)ethyl " )carbamate
  • Step B ⁇ R)-l-(3-Methyt-L2,4-oxadiazol ⁇ 5-yl)ethanamine
  • the vessel was cooled to ambient temperature and the remaining carbon monoxide was vented. The mixture was concentrated to half of the volume. Ethyl acetate (500 mL) and water (300 mL) were added.
  • Step C JV-[C 1 ip-(5-Fluoropyridin-2-y Dmethyletie] -2-methy lpropane-2-sulfinamide
  • Step D N- ⁇ ( ⁇ R)- 1 -r5-Fluoropyridin-2-vl)ethvl1-2-methylpropane-2-sulfinamide
  • N-[(l£)'(5-fluoropyridin-2-yI)methylene]-2-methylpropane-2- sulfmamide 52.12 g, 228 mmol
  • dichioromethane 1000 mL
  • methylmagtiesium bromide 3.0 M in THF; 198 mL, 594 mmol
  • Step E ⁇ Ryi-(5-FIuoropyridin-2-yl)ethanamine
  • N-[( 1 R)- 1 -(5-fluoropyridin-2-yl)ethyl]-2-methylpropane-2- suJfinamide 34.3 g, 140 mmol
  • hydrogen chloride 4.0 M in dioxane; 105 mL, 421 mmol
  • the mixture was concentrated to dryness.
  • the residue was recrytalized using ethyl alcohol (15 mL) and ether (40 mL).
  • the white solid was filtered and dried under reduced pressure to give the hydrochloride salt of the title compound.
  • Step A tert-Bntyl f ⁇ /?H-(5-fluoropvridin-2-vDethyr
  • Step B tert-Butyl [(lJ?Vl-(5-fluoro-l-oxidopyridin-2-y ⁇ ethyllcarbamate
  • tert-butyl [(lJ ⁇ )-l-(5-fluoropyridin-2-yl)ethyl]carbamate 5.77 g, 24.0 mmol
  • dichloromethane 96 niL
  • 3-chloroperbenzoic acid (6.51 g, 26.4 mraol).
  • excess 3-chloroperbenzoic acid (0.59 g, 2.6 mmol) was added.
  • saturated aqueous sodium sulfite was added.
  • Step C ( IR)- 1 -f5-Fluoro-l ⁇ oxido ⁇ rmdin-2-yl)ethanamine To a solution of tert-butyl [(li?)-l-(5-fluoro-l-oxidopyridin-2-yl)ethyl]carbamate (1,47 g,
  • Step A Benzyl [(lR)-l-cyanoethyllcarbamate
  • Step B Benzyl ffUt 2Z)-2-amino-2-f hydroxy imino)-l-methyiethyl] carbamate
  • Step C Benzyl [ ⁇ ift-H5-methyl-1.2.4-oxadiazol ⁇ 3-vneth ⁇ llcarbarnate
  • Step D (1 R)- 1 -( 5 -Methyl- K2.4-oxadiazol-3-yl)ethanamine To a solution of benzyl [(l ⁇ )-l-(5-methyI-l,2,4-oxadiazol-3-yl)ethyl]carbamate (1.10 g,
  • Step C 2-Methyl-N- ⁇ (lZ)-[2-(trifluoromethyl)pyrimidin-5-yl1methylene ⁇ propane-2-sulfinamide
  • Step D 2-Methyl-N- ⁇ (l./?)- 1 -[2-(tnfluoromethyl)pyrimidin-5-yl]ethyUpropane-2-sulfmamide
  • Step E (1 RM- ⁇ TrifluoromethyDpyrimidin-S-yllethanamine
  • 2-methyl-N- ⁇ (l ⁇ )-l-[2-(trifluoromethyl)pyrimidin-5- yl]ethyl ⁇ propane-2-sulfinamide 7.23 g, 24.5 mmol
  • HCl 4,0 M in dioxane; 18.5 mL, 74.0 mmol
  • the mixture was stirred at ambient temperature. After 1 h, the mixture was concentrated to give the title compound (4.6 g).
  • Step B Methyl 2-(2-fluoro-4-methyiphenyl)-6-morpholin-4-ylisonicotinate
  • Step C 2-(2-Fluoro-4-methylphenyi)-6-mo ⁇ holin-4-ylisonicotinic acid
  • sodium hydroxide 1.0 M solution in water; 1.87 niL, 1.87 rnmol
  • the mixture was stirred at ambient temperature.
  • HCl 1.0 M in water; 1 ,87 niL, 1.87 mmol
  • Methanol was added and the mixture was filtered and the filtrate was concentrated.
  • Step D 2-r2-Fluoro-4-methylphenvn-6-morpholm-4-yl-N-rd5>-i-(4H-L2.4-triazol-3- yl)ethyl]isonicotinamide
  • hydrochloride salt of 2-(2 ⁇ fluoro-4-methylphenyl)-6- morpholin-4-ylisonicotinic acid 50 mg, 0.14 mmol
  • DMF 1.5 mL
  • hydrochloride sait of (lS>l-(4H-l,2,4-triazol-3-yl)ethanamine 31.5 mg, 0.17 mmol
  • EDC 35.3 mg, 0.18 mmol
  • ⁇ OBT 21.7 mg, 0.14 mmol
  • diisopropylethylamine 99.0 ⁇ L, 0.57 mmol
  • Step A Methyl 2-(2.4-difluoropheny0-6 ⁇ isopropenylisonicotinate
  • Step B 2-(2,4-Difluorophenyi)-6-(l -hydroxy- 1 -methylethypisonicotinic acid
  • methanol 5.1 mL
  • DME 5.1 mL
  • cobalt(II)mesotetraphenylporphine 6.8 mg, 10.1 umol
  • the mixture was stirred at ambient temperature.
  • tetraethylammonium borohydride (73.5 mg, 0.51 mmol) was added.
  • Step C 2-(2,4-Difluorophenyl)-6-f 1 -hydroxy- 1 -methylethy H-N- (( 1 R)- 1 - ⁇ 1 -oxido-6- (trifluoromethyDpyridin-3-yl]ethyl)isonicotinamide
  • Step B Methyl 2-(2-hydroxypropan-2 ⁇ yl>6-f4-methylphenyi)pyridine-4-carboxylate
  • Step C 2-(2-Hvdroxypropan-2-yl)-6-(4-methvbhenvD ⁇ yridine-4-carboxylic acid
  • methyl 2-(2-hydroxypropan-2-yl)-6-(4-methylphenyl)pyridine-4- carboxylate 165 mg, 0.58 mmol
  • sodium hydroxide 1 M; 1 ,16 mL, L16 mmol
  • the resulting mixture was heated to 60 0 C. After 30 min, the mixture was cooled to ambient temperature. Hydrogen chloride (96 ⁇ L, 1.16 mmol) was added. The resulting mixture was concentrated, giving the sodium chloride salt of the title compound.
  • Step D 2-f2-Hvdroxvpropan-2-vlV6-(4-methyIphenylVN-[ ⁇ 5)-l-(4H-1.2.4-triazol-3-vnethyllpyridine-4- carbpxarnide
  • Step A 2-Chloro-6 ⁇ (2,4-difIuorophenyDisonicotinic acid
  • Step B 2-(2.4-Difluorophenyl)-6-(2-rnethylpyrimidin-5-yl)isonicotinic acid
  • Step C 2-(2,4-Difluorophenyl)-6--(2-methylpyrimidin : 5 ⁇ -yl)-N : ((l J KVl-[l-oxido-6-- (trifl ⁇ oromethyl) ⁇ yridin ⁇ 3-yl]ethyl ⁇ isonicotinamide
  • 2-(2,4-difluorophenyl)-6-(2-methyrpy ⁇ midin-5-yl)isonicotinic acid (21.3 mg, 0.05 mmol) in DMF (0.5 mL) were added hydrochloride salt of (l.R)-l-[l-oxido-6- (t ⁇ fluoromethyI)pyridin-3-yI]ethanamine (27.0 mg, 0.07 mmol), HATU (0.5 M in DMF; 0.16 mL, 0.08 mmol) and diisopropylethylamine (65 ⁇ L, 0.37 mmol).
  • Step B ter t-Buty ⁇ 2-chloro-6-vinylisonicoti ⁇ ate
  • Step C tert-Butyl 2-chlprp:6-f ⁇ rrnyiis ⁇ nicotinate
  • Step D tert-Butyl 2-ch1oro-6-(2,2,2-trifiuoro-l-hydroxyethyl)isonicotinate
  • THF 40 mL
  • (trifluoromethyl)trimethylsilane 1.49 mL, 4.31 mmol
  • ground 4A° molecular sieves ground 4A° molecular sieves.
  • the mixture was cooled to 0 0 C and TBAP (1.0 M in THF; 1.86 mL, 1.86 mmol) was added dropwise. The mixture was warmed to ambient temperature.
  • Step E fert-Butyl 2-(2,4-difluorophenyl)-6-(2.2,2-trifluoro-l-hydroxyethyl)isonicotinate
  • Step F 2-(2.4-Difluorophenyl)-6-(2,2,2-trifluoro-l-hydroxyethyl)isonicotinic acid
  • Step G N-(dRVl-F6-nj-Difluoroethvn-l-oxidopyridin-3-yl]ethyli-2-r2.4-difluorophenvlV6-f2.2.2- trifluoro- 1 -hydroxyethy Disonicotinamide
  • Step A Methyl 2-chloro-6-isopropenylisonicotinate To a solution of 2-chloro-6-isopropenylisonicotinic acid (0.25 g, 1.27 mmol) in dichloromethane (4.7 mL) and methanol (1.6 mL) was added (diazomethyl)(trimethyl)silane (0.63 mL, 1.27 mmol). After the addition, the mixture was concentrated and carried onto the next step. MS 212.0 (M+l).
  • Step B Methyl 6-isopropenyl-5'-methyl-2,2'-bipyridine-4-carboxyiate
  • Step C Methyl 6-isopropyl-5'-methyl-2.2'-bipyridine-4-carboxylate To a solution of methyl 6-isopropenyl-5'-methyl-2,2'-bipyridine-4-carboxyIate (0.25 g, 0.93 mmol) in ethanol (9.3 mL) was palladium (10% on carbon; 49.6 mg, 0.047 mmol). The mixture was purged with hydrogen (3x) and stirred under hydrogen (1 atm). After 35 min, the mixture was filtered with Celite and the filtrate was concentrated. MS 271.2 (M+ 1).
  • Step D 6 ⁇ Isopropyl-5'-methyl-2,2'-bipyridine-4-carboxylic acid
  • Step E 6-Isopropyl-5'-methvi-N-((lif)-l-[2-(trifiuoromethyl)pyrimidin-5-yllethyl ⁇ -2.2'-bipyridine-4- carboxarnide
  • DMF 0.3 mL
  • hydrochloride salt of (lR)-l-[2- (trifluoromethyl)pyrimidin-5-yl]ethanamine 22.1 mg, 0.08 mmol
  • HATU 38.2 mg, 0.10 mmol
  • diisopropylethylamine 58.5 ⁇ L, 0.34 mmol).
  • Step A Methyl 2,6-bis(4-methylphenyl)pyrimidine-4-carboxyiate To a solution of methyl 2,6-dichloropyrimidine-4-carboxylate (0.39 g ; 1.87 mmol) in DMF (15 mL) were added (4-methyIphenyl)boronic acid (0.84 g, 6.17 mmol), potassium phosphate tribasic (0.79 g, 3.74 mmol) and dichloro[l,r-bis(diphenylphosphino)ferrocene]palladiura( ⁇ ) dichloromethane adduct (0.15 g, 0.19 mmol).
  • Step B 2,6-Bis(4-methylphenvDpyrimidine-4-carboxylic acid
  • Step C N-[riJ?)-l-(3-Methyl-1.2.4-oxadiazol-5-vnethvn-2.6-bis(4-methylphenyl)pyrimidine-4- carboxamide
  • Step B 5-(2,4-Difluorophenv ⁇ -N- ⁇ (lJ?)-l-[l-oxido-6-(trifluoromethyl)pyridin-3-yllethyU nicotinamide
  • hydrochloride salt of (lR)-l ⁇ [l-oxido-6-(trifluoromethyl)pyridin-3- yl)ethanamine 49.3 mg, 0.18 mmol
  • EDC 33 ,9 mg, 0.18 mmol
  • HOBT 22.6 mg, 0.15 mmol
  • triethylamine (0.10 mL, 0.74 mmol).
  • Step B Methyl 5-(4-fluorophenyl)-6-isopropoxynicotinate and methyl 5-(4-fluorophenyl)-l-isopropyl-6- OXO- 1 ,6-dihydropyridine-3 -carboxy late
  • Step C 5 ⁇ (4-Fluorophenyl)-6-isopropoxynicotinic acid and 5-(4-fluorophenyl)-l-isopropyl-6-oxo-l,6,6- dihydropyridine-3-carboxylic acid
  • Step D 5-(4-Fluoropheiiyl)-6-isopropoxy-N-[(li?)-l-(3-methyl-l,2,4-oxadiazol-5-yl)ethy ⁇ nicotinamide (example 3.24) and 5-(4-fluorophenyl)-l-isopropyt-N-[dR)-l-(3-methyl-l,2.4-oxadiazol-5-yl)ethyl1-6- oxo-l,6-dihydropyridine-3-carboxamide (example 5.61)
  • the o-alkylated product was repurified by reverse chromatography (C-18, 95% water / acetonitrile — * 5% water / acetonitrile with 0,05% ammonium hydroxide) to give 5-(4-fluorophenyl)-64sopropoxy-N-[(lR)-l-(3-methyi-l,2,4-oxadiazol-5- yl)ethyl]nicotinamide (example 3.24) (16.1 mg).
  • Step B 5-(2-Fluoro-4-methyiphenyDnicotinic acid
  • methanol 10 mL
  • THF 10 mL
  • water 5 mL
  • sodium hydroxide 1.0 M in water; 5.17 mL, 5.17 mmol
  • the mixture was stirred at ambient temperature.
  • HCl 1.0 M in water; 5.17 mL, 5.17 mmol
  • Step C 5-(2-Fluoro-4-methylphenyl)nicotinic acid I -oxide
  • Step D 5-f2-Fluoro-4-methylphenylVN-rfli?Vl-f3-methvI-L2,4-oxadiazol-5-vDethyllnicotinamide 1- oxide
  • Step A Methyl 5-(4-1IuOrOPhBnVlVo-OXO- l,6-dihydropyridine-3-carboxvlate
  • DMF 8.1 mL
  • water 2.7 mL
  • 4-fluorophenyl)boronic acid 0.05 g, 2.69 rnmof
  • paliadium(II)acetate 36.3 mg, 0.16 mmol
  • tris(3-sulfonatophenyl)phosphine hydrate sodium salt (0.31 g, 0.49 mmol) and diisopropylamine (1.54 mL, 10.77 mmol).
  • Step B Methyl 3-f4 ⁇ fluorophenyI)-2-oxo-2H-l,2'-bipyridine-5-carboxylate
  • Step C 3-(4-FluorophenylV2-oxo-2H-1.2'-bipyridine-5-carboxylic acid
  • Step D 3-f4-Fluorophenvn-N-rf li;Vl-G-methyl-1.2,4-oxadiazol-5-vnethvn-2-oxo-2H-1.2'-bipyridine-5- carboxamide
  • Step B Methyl 5-f4-fluorophenyl)-6-oxo-l-(3-oxobutan-2-yl)-L6-dihvdropyridine-3-carboxylate To a solution of methyl 5-bromo-6-oxo- 1 -(3-oxobutan-2-yl)- 1 ,6-dihydropyridine-
  • Step D 5-(4-Fl ⁇ orophenyl)-l:(3-hvdroxy-3-methylbutan-2-y ⁇ -6-oxo-l,6-dihydropyridiRe-3-carboxylic acid
  • Step E 5-(4-Fluorophenvn-l-(3-hvdroxy-3-methylbutan-2-yl)-N-r(lRVl-(3-methvl-l,2,4-oxadiazol-5- yl)ethyl]-6-oxo-1.6-dihydropyridine-3-carboxamide
  • mice After overnight food-deprivation, male Sprague-Dawley rats are slightly anesthetized (isoflurane) and injected with 1% acetic acid into the colon (1.5 ml) using a cannula of 5 cm in length. After a recovery period of 75 minutes, rats are again slightly anesthetized (isoflurane) and a latex balloon of 1.5 cm in length tightly attached to a catheter is inserted via the anus into the descending colon and rectum. Anesthesia is then immediately discontinued, 15 minutes later, the test substance is administered p. o. 60 minutes after administration, the balloon is filled with 1.2 ml of water and the number of abdominal contractions is counted for 10 minutes.
  • Rats 10 rats are studied per group. The test is performed blind. The test substance will be evaluated at 3 doses, and compared with the vehicle group. Rats will be euthanized at the end of the experiments by exposure to a mixture of O 2 /CO 2 (20%/80%) followed by CO2. Data will be analyzed by comparing treated groups with vehicle control using Mann Whitney U tests.
  • L5 spinal nerve ligation model a Surgery and post-operative care
  • spinal nerve ligation (SNL) procedure male Sprague Dawley rats (100-200 g; Harlan) are anesthetized using isoflurane (1-5%; inhalation).
  • a dorsal midline incision is made from approximately spinal nerve L3 to S2.
  • a combination of sharp and blunt dissection is used to expose the L6/S1 posterior interarticular process.
  • the L6 transverse process is visualized and removed, and the L4 and L5 spinal nerves are exposed distal to their emergence from the intervertebral foramina.
  • the L5 nerve is then tightly Iigated with 6-0 silk suture.
  • the muscle is closed with 4-0 absorbable suture and the skin is closed with wound clips.
  • Postoperative monitoring is carried out to assure that animals are exposed to the least amount of pain as possible, Animals are housed in pairs on bedding and are monitored (2x) daily for three days post-operatively by Laboratory Animal Resource staff and then daily by investigator for any signs of possible distress.
  • Behavioral testing Prior to surgery, rats are tested for pre-surgery mechanical hind paw withdrawal thresholds by applying a series of calibrated von Frey filaments (0.25 - 15 g) to the left hind paw and determining the median withdrawal threshold using the Dixon "up-down" method (Chaplan et al., J Neurosci Meth 53:55, 1994).
  • Rats are placed in individual plastic chambers on an elevated mesh galvanized steel platform and allowed to acclimate for 60 min. Pre-surgery mechanical hind paw withdrawal thresholds are determined, and rats having a threshold ⁇ 15 g are excluded from the study. Following determination of pre-surgery withdrawal thresholds, rats undergo the SNL procedure described above. Between 28-35 days following the surgical procedure, rats are tested for post-surgery thresholds using the procedure described above, and animals displaying a hind paw withdrawal threshold ⁇ 4.0 g are considered allodynic (i.e. mechanical hypersensitivity).
  • CFA Complete Freunds adjuvant
  • the mechanical stimulus is applied to each hind paw 2 times, and the average post-CFA mechanical hind paw withdrawal thresholds are determined for both the left and right hind paw.
  • rats receive test compound, vehicle, or the positive comparator naproxen (30 mg/kg, p.o.), and effects of compounds on withdrawal thresholds for the inflamed (CFA) hind paw are determined.
  • Efficacy in the CFA model is evaluated by determining the % reversal of mechanical hypersensitivity using the formula:
  • mice Female Sprague-Dawley rats weighed 250-350 g were housed in a temperature- and light (12-h light/dark cycle)-controlled room, and were allowed access to food and water ad libitum. The animals were anesthetized with urethane (1.0 g/kg, Lp.). Supplemental urethane was given if necessarily. A lower abdominal midline incision was made to expose the bladder, and a polyethylene catheter (PE-50) was inserted into the bladder dome for recording the intravesical pressure and intravesical infusion of physiological saline at the rate of 0.05 ml/min.
  • PE-50 polyethylene catheter
  • the intravesical pressure was measured using a pressure transducer, and signal was recorded using a multiple channel data acquisition system (Power lab, AD Instruments, Biopac systems, Colorado Springs, CO) at a sampling rate of 10 Hz.
  • the drugs were administered intravenously (0.25 ml/kg), ⁇ ntermicturition interval (functional bladder capacity) and micturition pressure (maximum intravesical pressure) were obtained from micturitions prior to dosing (baseline) and between 5 to 30 min after dosing using Chart program (v5,5.4, AD Instruments), and calculated the ratio to baseline.
  • Human P2X 3 receptor cDNA (Accession number NM 002559) was subcloned as a 5'XhoI and 3 ⁇ indIII fragment into the expression vector pcDNA5/FRT (Invitrogen).
  • Human P2X 2 receptor cDNA (Accession number NM_174873) was subcloned as a 5'EcoRI and 3'NotI fragment into the expression vector pIRESneo2 (BD Biosciences Ciontech).
  • the human P2X 3 expression construct was transfected using Lipofectamine 2000 (Invitrogen) into Flp-in - 293 cells (Invitrogen) according to the manufacturer's directions.
  • the stable human P2X 3 cell line was co-transfected with the human P2X 2 expression construct using Lipofectamine 2000 as above and co-transfected cells selected using 100 mg/ml hygromycin and 1 mg/ml G418.
  • the stable P2X 3 cell line was propagated in DMEM 5 10% FBS, 100 ⁇ g/m! hygromycin, and 100 units/ml penicillin and 100 ⁇ g/ml streptomycin, and maintained at 37° and 95% humidity.
  • the stable P2X 2/3 cell line was propagated as above with the addition of 500 ⁇ g/ml G418,
  • Intracellular Calcium Measurement to Assess Antagonist Affinity - A fluorescent imaging plate reader (FLIPR; Molecular Devices) was used to monitor intracellular calcium levels using the calcium-chelating dye Fluo-4 (Molecular Probes). The excitation and emission wavelengths used to monitor fluorescence were 488 nm and 530 nm, respectively. Cells expressing either human P2X 3 or human P2X 2/3 were plated at a density of 20,000 cells/well (20 ⁇ l/well) in 384-well black-wailed plates approximately 20 hours before beginning the assay.
  • Electrophysiological Assay Cells expressing human P2X 3 receptors were grown to a confluence of 65-85% 20 to 32 hours prior to assay. The cells were dissociated with trypsin, centrifuged, and resuspended in bath solution at a cell density of IxIO 6 cells/ml and loaded onto PatchXpress.
  • the bath solution contained 150 mM NaCl, 4 mM KCl, 2 mM CaCl 3 , 1,2 mM MgCl 2 , 10 mM HEPES, and 11.1 mM glucose, at pH 7.2.
  • Agonist stock solutions were prepared in HjO and diluted in bath solution prior to use. All antagonists were prepared as 10 mM stock solutions in DMSO and diluted in bath solution prior to use. All experiments were performed on cells under the whole-cell patch clamp configuration at room temperature. Up to 16 individual cells could be patch clamped simultaneously on the PatchXpress instrument.
  • % inhibition Of P2X3 100*(Ip2X3-(conSrol)-Ip2X3-(drug)yip2X3-(contro1)
  • concentration of an antagonist was tested on at least two independent ceils.
  • concentration of drug required to inhibit P2X 3 current by 50% was determined by fitting of the Hill equation to the averaged % inhibition data at each concentration:

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.

Description

TITLE OF THE INVENTION
P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN FIELD OF THE INVENTION The invention relates generally to compounds which act as modulators, e.g., antagonists of the P2X3 receptor, compositions and therapeutic uses thereof.
BACKGROUND OF THE INVENTION
Purines, acting via an extracellular purinoreceptor, have been implicated as having a variety of physiological and pathological roles. (See, Burnstock (1993) Drug Dev. Res. 28:195-206.) Purinoreceptors (P2) have been generally categorized as either metabotropic nucleotide receptors or ionotropic receptors for extracellular nucleotides. Metabotropic nucleotide receptors (usually designated P2Y or P2Y(n), where "n" is a subscript integer indicating subtype) are believed to differ from ionotropic receptors (usually designated P2X or P2X(n) in that they are based on a different fundamental means of transmembrane signal transduction: P2Y receptors operate through a G protein-coupled system, while P2X receptors are Hgand-gated ion channels.
At least seven P2X receptors, and the cDNA sequences encoding them, have been identified to date. P2Xi cDNA was cloned from the smooth muscle of the rat vas deferens (Valera et al. (1994) Nature 371 :516-519) and P2X2 cDNA was cloned from PC12 cells (Brake et al. (1994) Nature 371 :519-523). Five other P2X receptors have been found in cDNA libraries by virtue of their sequence similarity to P2Xj and P2X2 - P2X3 : Lewis et al. (1995) Nature 377:432-435, Chen et al. (1995) Nature 377:428-431; P2X4 : Buell et al. (1996) EMBO J. 15:55- 62, Seguela et al. (1996) J. Neurosci. 16:448-455, Bo et al. (1995) FEBS Lett. 375:129-133, Soto et al. (1996) Proc. Natl. Acad. Sci. USA 93 :3684-36889 Wang et al. (1996) Biochem. Biophys. Res. Commun.220: 196-202; P2X5 : CoUo et al. (1996) J. Neurosci. 16:2495-2507, Garcia- Guzman et al. (1996) FEBS Lett. 388: 123-127; P2X6 : Collo et al. (1996), supra, Soto et al. (1996) Biochem. Biophys. Res. Commun. 223:456-460; P2X7 : Surprenant et al. (1996) Science 272:735-738). For a comparison of the amino acid sequences of rat P2X receptor see Buell et al. (1996) Eur. J. Neurosci. 8:2221-2228.
Purinergic receptors, in particular, P2X receptors, are known to function as homomultimeric cation-permeable ion channels and, in some cases, as heteromeric channels consisting of two different P2X receptor subtypes (Lewis et al., Nature 377:432-435 (1995); Le et al., J. Neurosci. 18:7152-7159 (1998); Torres et al., MoI. Pharmacol. 54:989-993 (1998)). The P2X2 and P2X3 subunits form functional channels when expressed alone, and can also form a functional heteromultimeric channel that has properties similar to currents seen in native sensory channels when co-expressed. At least one pair of P2X receptor subtypes, P2X2 and P2X3s functions as a heteromeric channel in rat nodose ganglion neurons where it exhibits distinct pharmacological and electrophysiological properties (Lewis et al, supra (1995)).
Native P2X receptors are known to form rapidly activated, nonselective cationic channels upon activation by ATP. The channels formed by P2X receptors generally have high Ca2+ permeability (P(Ca) /P(Na) )• With respect to individual receptors, the P2X3 purinergic receptor is a ligand-gated cation channel that is selectively permeable to small cations. Known Hgands for P2X receptors include natural nucleotides, for example, ATP, UTP, UDP, or synthetic nucleotides, for example 2-methylthioATP. ATP5 in addition to its function as an intracellular energy donor, is now recognized as an important neurotransmitter or cotransmitter, in both the central and peripheral nervous system (Ralevic, V., et al., Pharmacol. Rev., 50:413-492 (1998)). It is released from a variety of cell types, including nerve fibers, upon stimulation and produces diverse effects on many tissues by activation of specific membrane receptors including purinoreceptors (P2 receptor) (See Burnstock, G., Pharmacol. Rev., 24:509-581 (1972); Burnstock, G., Cell Membrane Receptor for Drugs and Hormones: A Multidisciplinary
Approach, edited by R. W. Straub and L. Bolid. New York: Raven, 1978, p.107-118). With respect to the P2X purinergic receptor, data suggest that ATP is capable of activating P2X3 homomeric receptors and P2X2 /P2X3 heteromeric receptors where it functions as an excitatory neurotransmitter in the spinal cord dorsal horn and in primary afferents from sensory ganglia, In vitro, co-expression of P2X2 and P2X3 receptor subunits is necessary to produce ATP-gated currents with the properties seen in some sensory neurons. See, Lewis, et al. (1995) Nature 377:432-435.
ATP, and to a lesser extent, adenosine, can stimulate sensory nerve endings resulting in intense pain and a pronounced increase in sensory nerve discharge. According to available data, ATP released from damaged cells can evoke pain by activating P2X3 homomeric receptors, or P2X2/P2X3 heteromeric receptors expressed on nociceptive nerve endings of sensory nerves. This is consistent with reports of the induction of pain by intradermally applied ATP in the human blister-base model; the identification of P2X3 containing receptor on nociceptive neurons in the tooth pulp; and with reports that P2X antagonists are analgesic in animal models. To date, research data suggests that the mechanism whereby ATP-induced activation of the P2X purinergic receptors on dorsal root ganglion nerve terminals in the spinal cord and on neurons in the brain results in pain sensation is by the stimulation of the release of glutamate, a key neurotransmitter involved in nociceptive signaling.
It has also been recently demonstrated that P2X3 receptor gene disruption results in a diminished sensitivity to noxious chemical stimuli and reduced pain. The nociceptive effects of exogenously administered ATP and P2X containing receptor agonists have also been demonstrated in laboratory animals. See Bland- Ward et al., Dr. J. Pharmacol. 122:366-371 (1997); Hamilton et al., Br. J. PhamacoL 126:326- 332 (1999). The peripheral nociceptive actions of P2X activation and stimulation of spinal P2X containing receptor also contribute to nociception as indicated by the ability of intrathecally (i.t.) administered P2 receptor agonists to increase sensitivity to acute and persistent noxious stimuli in rodents. See Driessen et al., Brain Res. 666:182-188 (1994); Tsuda et al., Br. J. Pharmacol. 127:449-4S6 (1999); Tsuda et al., Br. J. Pharmacol. 128:1497- 1504 (1999). A selective P2 receptor-mediated increase in ectopic neuronal excitability that is localized to damaged sensory afferents has also been recently reported in rats following chronic constriction nerve injury. See Chen et al., NeuroReport
10:2779-2782 (1999). This role in pain transmission is consistent with the observation that the rat P2X3 receptor expression is found primarily in a subset of neurons of the sensory ganglia, which are involved in pain transmission. See Chen et al., Nature 377:428-430 (1995); Vulchanova et al., Neuropharmacol. 36:1229-1242 (1997). See also US20080004442, US200700409609, WO2007041087, WO20061 19504, WO200112627, WO2007001973 and WO2007010553.
Taken together, the functional and immunohistochemical localization of P2X3 containing receptors (P2X3 and/or ?2Xm) on sensory nerves indicates that these P2X receptors may have a primary role in mediating the nociceptive effects of ATP. Thus, compounds which block or inhibit activation of P2X3 receptors serve to block the pain stimulus. More, receptor antagonists to compounds which normally activate the P2X3 receptor and/or P2X2/P2X3 heteromeric channels, such as ATP, could successfully block the transmission of pain. Indeed, modulators of P2X receptors, e.g., P2X3 receptor may find use as analgesics.
Additionally, compounds that block or inhibit activation of P2X3 receptors also serve to treat genitourinary, gastrointestinal and respiratory diseases, conditions and disorders or receptor antagonists to compounds which normally activate the P2X3 receptor and/or P2X2/P2X3 heteromeric channels, such as ATP are useful for treatment of genitourinary, gastrointestinal and respiratory diseases, conditions and disorders.
Burnstock (1999) J. Anatomy 194:335-342; and Ferguson et al. (1997) J. Physiol 505:503-51 1 disclose that P2X receptor subunits have been found on afferents in rodent and human bladder urothelium. There data suggests that ATP may be released from epithelial/endothelial cells of the urinary bladder or other hollow organs as a result of distention. ATP released in this manner may serve a role in conveying information to sensory neurons located in subepithelial components, e.g., suburothelial lamina propria (Namasibayam, et al. (1999) BJU Intl. 84:854-860). P2X receptors have been studied in a number of neurons including sensory, sympathetic, parasympathetic, mesenteric, and central neurons (Zhong, et al. (1998) Br. J Pharmacol. 125:771-781). These studies indicate that purinergic receptors play a role in affterent neurotransmission from the bladder, and that modulators of P2X receptors are potentially useful in the treatment of bladder disorders such as urinary incontinence and other genitourinary diseases or conditions.
P2X3 receptors have been shown to be expressed in human colon, and are expressed at higher levels in inflamed colon, than in normal colon (Y. Yiangou et al, Neurokastroenterol Mot (2001) 13:365-69). P2X3 receptors have also been implicated in detection of distension or intraluminal pressure in the intestine and initiation of reflex contractions (X. Bian et al. J. Physiol (2003) 551.1 :309-22), and have linked this to coilitis (G. Wynn et al., Am J Physiol Gastrointest Liver Physiol (2004) 287:G647-57).
P2X3 receptors also have been shown to be expressed in pulmonary neuroepithelial bodies (NEBs), implicating the receptor in pain transmission in the lung (Inge
Brouns et al., Am J. Respir Cell MoI Biol (2000) 23:52061). Additionally, P2X2 and P2X3 receptors have been implicated in pθ2 detection in pulmonary NEBs (W. Rong et al., J Neurosci
(2003) 23(36):1 1315-21).
However, the utility of available purinergic ligands to evaluate the role of individual P2 receptor subtypes in mammalian physiology has been complicated by the susceptibility of P2 receptor agonists to undergo enzymatic degradation. As well, the study of the role of an individual P2X receptor is hampered by the lack of receptor subtype-specific agonists and antagonists.
Consequently, the state of the art begs an inquiry into methods and/or compounds which will provide the ability to regulate or control the P2X receptors, for example, P2X3, because control of such receptors will provide the ability to minimize pain in patients in need of such treatment. In addition, for both research and therapeutic purposes there is a need in the art for specific agonists and antagonists for each P2X receptor subtype and, in particular, agents that will be effective in vivo, as well as for methods for identifying purinoreceptor-specific agonist and antagonist compounds.
See WO9824780, US6420385, US6096753, US6410729, US6649604, US6436972, US6544986, US6977266, and US6610698 for the state of the art regarding compound structures.
The present invention aims to overcome some of the aforementioned drawbacks by providing novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator. SUMMARY OF THE INVENTION
The present invention relates to a novel P2X3 type receptor antagonists of structural formula I:
Figure imgf000006_0001
or pharmaceutically acceptable salts and individual enantiomers and diaslereomers thereof wherein: A represents pyridinyi, pyrimidinyl, or pyridinonyl;
W and Z independently are absent or represent C(R2)2, -O-, NR2, CO, or SθQ-2;
R2 represents H, Q -6 alkyl, CF3, OH, CHF2, or CH2F;
R3 represents CR2R4R5, (CH2)nC3-10 cycloalkyl, (CH2)nC6-10 aiyl, (CH2)nC5-io heterocycle,said cycloalkyl, and heterocyclyl optionally substituted with 1 to 3 groups of Ra;
or R2 and R3 can be combined with the nitrogen to which they are attached to form a C5-10 heterocyclyl optionally substituted with 1 to 3 groups of Ra;
R4 and R5 independently represent H, (CH2)nOR2, CHF2, (CH2)nCF3, (CH2)nC5-10 heterocyclyl, (CH2)nC6-10 aryl C3.10 cycloalkyl, Ci-6 alkoxy, C2-6 alkenyl, C(O)i-2R2, or C 1-6 alkyl; said alkyl, cycloalkyl, heterocyclyl and aryl optionally substituted with 1 to 3 groups of Ra;
R6 represents hydrogen, OR2, -O",CF3, C(R2)2θR2, CJ.6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-IO cycloalkyl, (CH2)nC6-10 aryl, (CH2)nC5-10 heterocyclyl, said alkyl, cycloalkyl, aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra;
R7 represents C\.β alkyl, C3-10 cycloalkyl, (CH2)nC5-10 heterocyclyl, or (CH2)nC6-10 aryl, said alkyl, cycloalkyl, heterocyclyl and aryl optionally substituted with 1 to 3 groups of Ra; Ra represents C 1-6 alkyl, halogen, hydroxy., OR2 (CH2)nCF3, -O-} C3.6 cycloalkyl, NR2C(O)R2? C(O)N(R2)2, C(R2)2OR2, C(O)R2, NO2, CN, N(R2)2J C(O)OR2, SO2R2, OR2, (CH2)nC5-10 heterocyclyl, or (CH2)nC6-10 aryl, said heterocyclyl and aryl optionally substituted with 1 to 3 groups of C 1-6 alkyl, halogen, hydroxyl, (CH2)nCF3,or CN; and
n represents 0 to 4, provided that when A is pyrimidinyl WZR6 is not OH and when A is pyridinonyl WZR6 is not hydrogen. This invention also relates to compositions and methods for using the compounds disclosed herein. These and other embodiments of the present invention will readily occur to those of ordinary skill in the art in view of the disclosure herein.
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a novel P2X3 type receptor antagonists of structural formula I that are useful in treating pain and diseases associated with pain.
An embodiment of the invention of formula I is realized when R? is Ci_6 alkyl optionally substituted with 1 to 3 groups of Ra and all other variables are as previously described. Another embodiment of the invention of formula I is realized when R? is C3-10 cycloalkyl optionally substituted with 1 to 3 groups of Ra and all other variables are as previously described. A sub-embodiment of this invention is realized when the cycloalkyl is cyclopropyl.
Another embodiment of the present invention is realized when R? is (CH2)nC6- 10 aryl optionally substituted with 1 to 3 groups of Ra and all other variables are as previously described. A sub-embodiment of this invention is realized when the aryl is phenyl. Another sub- embodiment of this invention is realized when n is 0.
Another embodiment of the present invention is realized when R? is optionally substituted (CH2)nC5-10 heterocyclyl and all other variables are as previously described. A sub- embodiment of this invention is realized when the heterocyclyl is pyridinyl, morpholinyl, pyrimidinyl, imidazolyl, or oxazolyl optionally substituted with 1 to 3 groups of Ra. Another sub-embodiment of this invention is realized when n is 0.
Still another embodiment of the present invention is realized when R? is represented by structural formula Ia:
Figure imgf000008_0001
wherein X is N or CH; and Rl represents H, Cl-6 alkyl, halogen, (CH2)nCF3, C3-10 cycloalkyl, C(R2)2θH, -O-, CN, (CH2)nOR2, (CH2)nC5-10 heterocyclyl, (CH2)nC6-10 aryl, or Cl-6 alkoxy; said alkyl, cycloalkyl, heterocyclyl and aryl optionally substituted with 1 to 3 groups of Cl-6 alkyl, halogen, hydroxyl, (CH2)nCF3,or CN. A sub-embodiment of the present invention is realized when X of formula Ia is N and all other variables are as previously described. Another sub-embodiment of the present invention is realized when X of formula Ia is CH and all other variables are as previously described. Another embodiment of the present invention is realized when formula Ia is linked to a carbon atom on A and all other variables are as previously described.
Yet another embodiment of the present invention is realized when formula Ia is linked to a nitrogen atom on A and all other variables are as previously described.
Another embodiment of the present invention is realized when A is pyridyl and all other variables are as previously described. A subembodiment of this invention is realized when -C(O)NR2R3 and -WZRό are independently attached to carbon atoms on A.
Another embodiment of the present invention is realized when A is pyridyl, - C(O)NR2R3 is attached to a carbon atom on A and -WZR6 is attached to a nitrogen atom on A.
Another embodiment of the present invention is realized when A is pyrimidinyl and all other variables are as previously described. A subembodiment of this invention is realized when -C(O)NR2R3 and -WZR6 are independently attached to carbon atoms on A.
Another embodiment of the present invention is realized when A is pyridinonyl and all other variables are as previously described. A subembodiment of this invention is realized when — C(O)NR2R3 and -WZR^ are independently attached to carbon atoms on A. Another subembodiment of this invention is realized when -WZRό is attached to the nitrogen atom on A and -C(O)NR2R3 is attached to a carbon atom on A. Yet another embodiment of this invention is realized when formula Ia is attached to a carbon atom on A. Still another embodiment of this invention is realized when foruma Ia is attached to the nitrogen atom on A. Yet another embodiment of this invention is realized when the =0 of the pyridinonyl is ortho to the bond linking A to formula Ia.
Another embodiment of the present invention is realized when W and Z both are absent. Still another embodiment of this invention is realized when R6 is hydrogen, OR2, Cl -6 alkyl, C340 cycloalkyl, (CH2)nC6-10 aryl, (CH2)nC5-10 heterocyclyl, said alkyl, cycloalkyl, aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra. A subembodiment of this invention is realized when R6 is hydrogen, Cl -6 alkyl, OR2, (CH2)nmorpholinyl, (CH2)nPyπdyl, (CH2)npiperidinyl, (CH2)πoxazolyl, (CH2)nisoxazolyl, (CH2)nphenyl, (CH2)nimidazolyls (CH2)npyrimidinyl, cyclopropyl, cyclobutyl, preferably hydrogen,
(CH2)nPyridyl (CH2)nniorpholinyl, (CH2)nphenyl, Cμg alkyl, cyclopropyl, all optionally substituted with 1 to 3 groups of Ra. A further sub-embodiment of this invention is realized when R6 is is hydrogen, C 1-6 alkyl, OR2, (CH2)nmorpholinyl,, (CH2)npyridyl, , (CH2)nphenyl5 or (CH2)npyrimidinyl. Another embodiment of the present invention is realized when W and Z both are absent, and R6 is an -O- linked to a nitrogren on the ring.
Still another embodiment of this invention is realized when one of W and Z is absent and the other is -O-, or NR2. Still another embodiment of this invention is realized when Rό is hydrogen, OR2, Cl -6 alkyl, C3.10 cycloalkyl, (CH2)nC6-10 aryl, (CH2)nC5-10 heterocyclyl, said alkyl, cycloalkyl, aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra. A subembodiment of this invention is realized when R6 is hydrogen, Cl -6 alkyl, OR2, (CH2)nniorpholinyl, (CH2)nPyridyl, (CH2)npiperidmyl, (CH2)n<>xazoryl, (CH2)nisoxazolyl, (CH2)nphenyl> (CH2)nimiclazolyl> (CH2)npynmidinyls cyclopropyl, cyclobutyl, preferably hydrogen, (CH2)nPvrMyl, (CH2)nmorpholinyl, (CH2)nphenyl, Cl -6 alkyl, cyclopropyl, all optionally substituted with 1 to 3 groups of Ra.
Another embodiment of the present invention is realized when R2 is hydrogen and all other variables are as previously described.
Still another embodiment of the present invention is realized when R3 is (CH2)nC3-10 cycloalkyl and all other variables are as previously described. Still another embodiment of the present invention is realized when R3 is
CR2R4R5 and all other variables as previously described. A subembodiment of this invention is realized when R^ of CR2R4R5 1S hydrogen. A subembodiment of this invention is realized when one of R4 and Rβ is C 1-6 alkyl or hydrogen and the other is (CH2)nC6-10 aryl, or (CH2)nC6-10 heterocyclyl, said alkyl, aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra, A further subembodiment of this invention is realized when said aryl and heterocyclyl is (CH2)nphenyl, (CH2)nPyridyl, (CH2)npyπmidinyl, (CH2)ntriazolyl, pyrazinyl, or (CH2)nθxadiazoly 1.
Another subembodiment of this invention is realized when R3 is CR2R4R5} which is an alkyl optionally substituted with 1 to 3 groups of Ra and all other variables are as previously described. A subembodiment of this invention is realized when R2 of CR2R4R5 is hydrogen, and one of R4 and R5 is Cχ-6 alkyl or hydrogen and the other is (CH2)nC6-10 aryl, or (CH2)nC6-10 heterocyclyl, said alkyl, aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra. Another subembodiment of this invention is realized when R2 of CR2R4R5 js hydrogen, and one of R4 and R5 is Ci_g alkyl or hydrogen and the other is (CH2)nphenyl, (CH2)nPyridyl, (CH2)nPyriniidinyl, (CH2)ntriazolyl, pyrazinyl, or (CH2)noxadiazolyl, said phenyl, pyridyl, pyrimidinyl, triazolyl, pyrazinyl and oxadiazolyl optionally substituted with 1 to 3 groups of R^. Still another subembodiment of this invention is realized when R2 of CR2R4R5 is hydrogen, and one of R4 and R5 is Cl -6 alkyl or hydrogen and the other is (CH2)npyridyϊ» or (CH2)noxadiazolyl, said oxadiazolyl optionally substituted with 1 to 3 groups of Ra. Another embodiment of the present invention is realized when R3 is (CH2)nC6-
10 aryl, optionally substituted with 1 to 3 groups of Ra. A subembodiment of mis invention is realized when said aryl is optionally substituted phenyl.
Another embodiment of the present invention is realized when R3 is (CH2)nC5- 10 heterocyclyl optionally substituted with 1 to 3 groups of Ra. A subembodiment of this invention is realized when said heterocyclyl is optionally substituted (CH2)nPyridyl,
(CH2)npyήmidinyl, (CH2)ntriazolyl, (CH2)nθxadiazolyl, or pyrazinyl. Another subembodiment of this invention is realized when the heterocyclyl is optionally substituted (CH2)nPyridyI, or (CH2)nθxadiazolyl.
Still another embodiment of the present invention is realized when Ra is Ci-6 alkyl, halogen (preferably chloro or fluoro), -O-, OR2, CN, CF3, (CH2)nC5-10 heterocyclyl, or (CH2)nC6-10 aryl, said heterocyclyl and aryl optionally substituted with 1 to 3 groups of Ci-6 alkyl, halogen, hydroxy., (CH2)nCF3,or CN
Still another embodiment of this invention is realized by structural formula II:
Figure imgf000010_0001
Wherein R3, R6, R?, W and Z are as previously described. A subembodiment of formula II is realized when W and Z are absent, R? is (CH2)nC6-10 aryl, or (CH2)nC6-10 heterocyclyl optionally substituted with 1 to 3 groups of Ra, R6 is hydrogen, Ci-6 alkyϊ, OR2, (CH2)nπiorpholinyl, (CH2)nPyπdyl> (CH2)npiperidmyl, (CH2)noxazolyl, (CH2)nisoxazolyl, (CH2)nphenyl, (CH2)nPiperidinyl, (CH2)nύnidazolyl, (CH2)npyrimidinyl, cyclopropyl, cyclobutyl, all optionally substituted with 1 to 3 groups of Ra, and R3 is CR2R4RS wherein R2 of CR2R4R5 is hydrogen, and one of R4 and R5 is Ci-6 alkyl or hydrogen and the other is (CH2)nC6-10 aryl, or (CH2)nC6-10 heterocyclyl, said alkyl, aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra. Another subembodiment of formula II is realized when R7 is phenyl, pyridinyl, morpholinyl, pyrimidinyl, imidazolyl, or oxazolyl optionally substituted with 1 to 3 groups of Ra.
Still another subembodiment of the compound of formula II is realized by structural formula Ha:
Figure imgf000011_0001
wherein Rl, R3, R65 X, W and Z are as previously described. A subembodiment of formula Ha is realized when W and Z are absent, Rβ is Ci- 6 alkyl, optionally substituted with 1 to 3 groups of Ra X is CH, Rl is H, Ci -6 alkyl, halogen, or (CH2)nCF3, and R3 is CR2R4R5 wherein R2 of CR2R4R5 is hydrogen, and one of R4 and R5 is Cl -6 alkyl or hydrogen and the other is (CH2)nC6-10 aryl, or (CH2)nC6-10 heterocyclyl, said alkyl, aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra.
Yet another embodiment of this invention is realized by structural formula HI:
Figure imgf000011_0002
Wherein R3, R6; R7; W and Z are as previously described. A subembodiment of formula III is realized when W and Z are absent, R? is (CH2)nC6-10 aryl, or (CH2)nC6-10 heterocyclyl optionally substituted with 1 to 3 groups of Ra, R6 is hydrogen, Ci- 6 alkyl, OR2, (CH2)nmorpholinyl, (CH2)nPyπdyl, (CH2)npiperidinyl, (CH2)noxazolyl, (CH2)nisoxazolyl, (CH2)nPhenyl, (CH2)npiperidinyl, (CH2)nimidazolyl, (CH2)npyrimidinyl, cyclopropyl, cyclobutyl, all optionally substituted with 1 to 3 groups of Ra, and R3 is CR2R4R5 wherein R2 of CR2R4R5 is hydrogen, and one of R4 and R5 is CI_6 alkyl or hydrogen and the other is (CH2)nC6-10 aryl, or (CH2)nC6-10 heterocyclyl, said alkyl, aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra. Another subembodiment of formula III is realized when R7 is phenyl, pyridinyl, morpholinyl, pyrimidinyl, imidazolyl, or oxazolyl optionally substituted with 1 to 3 groups of Ra.
Another embodiment of this invention is realized by structural formula IV:
Figure imgf000012_0001
Wherein R3, R6S R7, W and Z are as previously described. A subembodiment of formula IV is realized when W and Z are absent, R7 is (CH2)nC6-10 aryl, or (CH2)nC6-10 heterocyclyl optionally substituted with 1 to 3 groups of Ra, R6 is hydrogen, Cl -6 alkyl, OR2, (CH2)nmorphoIinyl, (CH2)npyήdyl, (CH2)npiperidinyl, (CH2)noxazolyl, (CH2)nisoxazolyl, (CH2)nphenyl, (CH2)npipeπdmyl» (CH2)nimidazolyl, (CH2)nPyrimidinyl, cyclopropyl, cyclobutyl, all optionally substituted with 1 to 3 groups of Ra, and R3 is CR2R4R5 wherein R2 of CR2R4R5 is hydrogen, and one of R4 and R5 is Ci-6 alkyl or hydrogen and the other is (CH2)nC6-10 aryl, or (CH2)nC6-10 heterocyclyl, said alkyl, aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra. Another subembodiment of formula IV is realized when R7 is phenyl, pyridinyl, morpholinyl, pyrimidinyl, imidazolyl, or oxazolyl optionally substituted with l to 3 groups of Ra.
Another embodiment of this invention is realized by structural formula V:
Figure imgf000012_0002
wherein R3, R<5, R7, W and Z are as previously described and the "+" charge on the ring is balanced by a counter balancing ion group of W, Z or R6. A subembodiment of formula V is realized when W and Z are absent, R7 is (CH2)nC6-10 aryl, or (CH2)nC6-10 heterocyclyl optionally substituted with 1 to 3 groups of Ra, R6 is -O-, and R3 is CR2R4R5 wherein R2 of CR2R4R5 is hydrogen, and one of R4 and R5 is Ci -6 alkyl or hydrogen and the other is (CH2)nC6-10 8^ or (CH2)nQ»-10 heterocyclyl, said alkyl, aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra. A subembodiment of formula V is realized when R7 is phenyl, pyridinyl, morpholinyl, pyrimidinyl, imidazolyl, or oxazolyl optionally substituted with 1 to 3 groups of Ra.
Another embodiment of this invention is realized by structural formula YI:
Figure imgf000013_0001
Wherein R3, Re, R7, W and Z are as previously described. A subembodiment of formula VI is realized when W and Z are absent, R7 is (CH2)nC6-10 aryl, or (CH2)nC6-10 heterocyclyl optionally substituted with 1 to 3 groups of Ra, Rβ is hydrogen, Cl -6 alky], OR2, (CH2)nmorpholinyl, (CH2)npyridyl, (CH2)npipeπdmyl,. (CH2)noxazolyl, (CH2)nisoxazolyl, (CH2)nPhenyl> (CH2)npiperidinyl, (CH2)n∞ύda2θlyl, (CH2)npyrimidinyl, cyclopropyl, cyclobutyl, any of which is optionally substituted with 1 to 3 groups of Ra, and R3 is CR2R4R5 wherein R2 of CR2R4R5 is hydrogen, and one of R4 and R5 is Ci -6 alkyl or hydrogen and the other is (CH2)nC6-10 81Y^ ot (CH2)nC6-10 heterocyclyl, said alkyl, aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra. A subembodiment of formula VI is realized . when R? is phenyl, pyridinyl, morpholinyl, pyrimidinyl, imidazolyl, or oxazolyl any one of which is optionally substituted with 1 to 3 groups of Ra, R2 of CR2R4R5 in R is hydrogen, and one of R4 and R5 of CR2R4R5 is C 1-6 alkyl or hydrogen and the other is (CH2)nphenyl, (CH2)npyήdyl, (CH2)nPyriniid!nyl, (CH2)ntπazolyl, pyrazinyl, or (CH2)nθxadiazolyl, said phenyl, pyridyl, pyrimidinyl, triazolyl, pyrazinyl and oxadiazolyl optionally substituted with 1 to 3 groups of Ra. Another subembodiment of formula VI is realized when R2 of CR2R4R5 in R3 is hydrogen, and one of R4 and R5 of CR2R4RS is Cl -6 alkyl or hydrogen and the other is (CH2)noxadiazolyl, said oxadiazolyl optionally substituted with 1 to 3 groups of Ra
Table 1
Figure imgf000014_0001
Figure imgf000014_0002
Figure imgf000015_0001
Figure imgf000016_0001
Figure imgf000017_0001
Figure imgf000018_0001
Figure imgf000019_0001
Figure imgf000020_0001
Figure imgf000021_0001
Figure imgf000022_0001
Figure imgf000023_0001
Figure imgf000024_0001
Figure imgf000025_0001
Figure imgf000026_0001
Figure imgf000027_0001
Figure imgf000028_0001
Figure imgf000029_0001
Figure imgf000030_0001
Figure imgf000031_0001
Figure imgf000032_0003
Table 2
Figure imgf000032_0001
Figure imgf000032_0002
Figure imgf000033_0001
Figure imgf000034_0003
Table 3
Figure imgf000034_0001
Figure imgf000034_0002
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001
Figure imgf000039_0003
Table 4
Figure imgf000039_0001
Figure imgf000039_0002
Figure imgf000040_0001
Figure imgf000040_0002
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
Figure imgf000051_0001
Figure imgf000052_0001
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
Figure imgf000057_0001
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0001
Figure imgf000061_0001
Figure imgf000062_0001
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof. When any variable (e.g. aryl, heterocycle, Rl, R^ etc.) occurs more than one time in any constituent, its definition on each occurrence is independent at every other occurrence. Also, combinations of substituents/or variables are permissible only if such combinations result in stable compounds.
When Ra or Rό is -O- and attached to a carbon it is referred to as a carbonyl group and when it is attached to a nitrogen (e.g., nitrogen atom on a pyridyl group) or sulfur atom it is referred to a N-oxide and sulfoxide group, respectively. As used herein, "alkyl" encompasses groups having the prefix "alk" such as, for example, alkoxy, alkanoyl, alkenyl, and alkynyl and means carbon chains which may be linear or branched or combinations thereof. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, and heptyl. "Alkenyl" refers to a hydrocarbon radical straight, branched or cyclic containing from 2 to 10 carbon atoms and at least one carbon to carbon double bond. Preferred alkenyl groups include ethenyl, propenyl, butenyl and cyclohexenyl. Preferably, alkenyl is C2-Cg alkenyl. Preferred alkynyls are C2-C6 alkynyl.
"Alkenyl," "alkynyl" and other like terms include carbon chains containing at least one unsaturated C-C bond.
As used herein, "fluoroalkyl" refers to an alkyl substituent as described herin containing at least one flurine substituent. The term "cycloalkyl" refers to a saturated hydrocarbon containing one ring having a specified number of carbon atoms. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
The term "Ci _6" includes alkyls containing 6, 5, 4, 3, 2, or 1 carbon atoms The term "alkoxy" as used herein, alone or in combination, includes an alkyl group connected to the oxy connecting atom. The term "alkoxy" also includes alkyl ether groups, where the term 'alkyl' is defined above, and 'ether' means two alkyl groups with an oxygen atom between them. Examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, methoxymethane (also referred to as 'dimethyl ether'), and methoxyethane (also referred to as 'ethyl methy! ether').
As used herein, "aryl" is intended to mean any stable monocyclic or bicycHc carbon ring of up to 7 members in each ring, wherein at least one ring is aromatic. Examples of such aryl elements include phenyl, napthyl, tetrahydronapthyl, indanyl, or biphenyl.
The term heterocycle, heterocyclyl, or heterocyclic, as used herein, represents a stable 5- to 7-membered monocyclic or stable 8- to 1 1-membered bicyclic heterocyclic ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O, and S, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. The term heterocycle or heterocyclic includes heteroaryl moieties. Examples of such heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, 1,3-dioxolanyl, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazoHdinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, 2-oxopiperazinyl, 2-oxopiperdinyl, 2-oxopyrrolidinyl, piperidyl, piperazinyl, pyridyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrahydrofuryϊ, tetrahydroisoquinolinyl, tetrahydroquinolinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiazolyl, thiazolinyl, thienofuryl, thienothienyl, and thienyl. An embodiment of the examples of such heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzϊsoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, 2-oxopiperazinyl, 2-oxopiperdinyl, 2-oxopyrrolidinyl, piperidyl, piperazinyl, pyridyl, 2- pyridinonyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, quinazolinyl, qmnolinyl, quinoxalinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, thiamorpholinyl, thiamorpholϊnyl sulfoxide, thiazolyl, thiazolinyl, thienofuryl, thienothienyl, thienyl and triazolyl.
In certain embodiments, the heterocyclic group is a heteroaryl group. As used herein, the term "heteroaryl" refers to groups having 5 to 14 ring atoms, preferably 5, 6, 9, or 10 ring atoms; having 6, 10, or 14 π electrons shared in a cyclic array; and having, in addition to carbon atoms, between one and about three heteroatoms selected from the group consisting of N, 0, and S. heteroaryl groups include, without limitation, thienyl, benzothienyl, furyl, benzofuryl, dibenzofuryl, pyrrolyl, imidazolyl, pyrazoiyl, pyridyl, pyrazinyl, pyrimidinyl, indolyl, quinolyl, isoquinolyl, quinoxalinyl, tetrazolyl, oxazolyl, thiazolyl, and isoxazolyϊ.
In certain other embodiments, the heterocyclic group is fused to an aryl or heteroaryl group. Examples of such fused heterocycles include, without limitation, tetrahydroquinolinyl and dihydrobenzofuranyl.
The term "heteroaryl", as used herein except where noted, represents a stable 5- to 7- membered monocyclic- or stable 9- to 10-membered fused bicyclic heterocyclic ring system which contains an aromatic ring, any ring of which may be saturated, such as piperidinyl, partially saturated, or unsaturated, such as pyridinyl, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. Examples of such heteroaryl groups include, but are not limited to, benzimidazole, benzisothiazole, benzisoxazole, benzofuran, benzothiazole, benzothiophene, benzotriazole, benzoxazole, carboline, cinnoline, furan, furazan, imidazole, indazole, indole, indolizine, isoquinoline, ϊsothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, quinazoline, quinoline, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazine, triazole, and N-oxides thereof.
Examples of heterocycloalkyls include azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, imidazolinyl, pyrolidin-2-one, piperidin-2-one, and thiomorpholinyl. The term "heteroatom" means O, S or N, selected on an independent basis. A moiety that is substituted is one in which one or more hydrogens have been independently replaced with another chemical substituent. As a non-limiting example, substituted phenyls include 2- flurophenyl, 3,4-dichlorophenyl, 3-chloro-4-fluoro-phenyl, 2,4fluor-3~propylphenyl. As another non- limiting example, substituted n-octyls include 2,4 dimethyl-5-ethyl-octyl and 3-cyclopentyloctyl. Included within this definition are methylenes (-CH2-) substituted with oxygen to form carbonyl (-CO-).
Unless otherwise stated, as employed herein, when a moiety (e.g., cycloalkyl, hydrocarbyl, aryl, alkyl, heteroaryl, heterocyclic, urea, etc.) is described as "optionally substituted" it is meant that the group optionally has from one to four, preferably from one to three, more preferably one or two, non-hydrogen substituents. Suitable substituents include, without limitation, halo, hydroxy, oxo (e.g., an annular -CH- substituted with oxo is -C(O)-), nitro, halohydrocarbyl, hydrocarbyl, aryl, aralkyl, alkoxy, aryloxy, amino, acylamino, alkylcarbamoyl, arylcarbamoyl, aminoalkyl, acyl, carboxy, hydroxyalkyl, , alkanesulfonyl, arenesulfonyl, alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl, acyloxy, cyano, and ureido groups. Preferred substituents, which are themselves not further substituted (unless expressly stated otherwise) are:
(a) halo, cyano, oxo, carboxy, formyl, nitro, amino, amidino, guanidino, and (b) Cl -C6 alkyi or alkenyl or arylalkyl imino, carbamoyl, azido, carboxamido, mercapto, hydroxy, hydroxyalkyl, alkylaryl, arylalkyl, C1-C8 alkyl, SO2CF3, CF3, Sθ2Me, Q-C8 alkenyl, Q-C8 alkoxy, Cl -Cg alkoxycarbonyl, aryloxycarbonyl, C2-C8 acyl, C2-C8 acylamino, C1-C8 aikylthio, arylalkylthio, arylthio, Cl-C8alkylsulfinyl, arylalkylsulfnyl, arylsulfnyl, Q-C8 alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, C0-C6 N-alkylcarbamoyl, C2-C15 N,N dialkylcarbamoyl, C3-C7 cycloalkyl, aroyl, aryloxy, arylalkyl ether, aryl, aryl fused to a cycloalkyl or heterocycle or another aryl ring, C3-C7 heterocycle, or any of these rings fused or spϊro-fused to a cycloalkyl, heterocyclyl, or aryl, wherein each of the foregoing is further optionally substituted with one more moieties listed in (a), above.
"Halogen" refers to fluorine, chlorine,, bromine and iodine. The term "mammal" "mammalian" or "mammals" includes humans, as well as animals, such as dogs, cats, horses, pigs and cattle.
All patents, patent applications and publications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety and are deemed representative of the prevailing state of the art. As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural references unless the content clearly dictates otherwise. Thus, for example, reference to "a primer" includes two or more such primers, reference to "an amino acid" includes more than one such amino acid, and the like.
The phrases "effective amount" or "therapeutically effective amount" mean a concentration of P2X receptor complex modulator sufficient to inhibit or enhance the effect of the P2X receptor complex. "Pain" means the more or less localized sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings. There are many types of pain, including, but not limited to, lightning pains, phantom pains, shooting pains, acute pain, inflammatory pain, neuropathic pain, complex regional pain, neuralgia, neuropathy, tissue injury pain, and the like (Dorland's Illustrated Medical Dictionary, 28th Edition, W. B. Saunders
Company, Philadelphia, Pa.). The goal of treatment of pain is to reduce the degree or severity of pain perceived by a treatment subject.
"Treating" or "treatment of* a disease state includes: 1) preventing the disease state, i.e. causing the clinical symptoms of the disease state not to develop in a subject that may be exposed to or predisposed to the disease state, but does not yet experience or display symptoms of the disease state; 2) inhibiting the disease state, i.e., arresting the development of the disease state or its clinical symptoms; 3) or relieving the disease state, i.e., causing temporary or permanent regression of the disease state or its clinical symptoms.
Compounds described herein may contain one or more double bonds and may thus give rise to cis/trans isomers as well as other conformational isomers. The present invention includes all such possible isomers as well as mixtures of such isomers unless specifically stated otherwise.
The compounds of the present invention may contain one or more asymmetric centers and may thus occur as racemates, racemic mixtures, single enantiomers, diastereomeric mixtures, and individual diastereomers. In the compounds of generic Formula I, the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present invention is meant to include all suitable isotopic variations of the compounds of generic Formula I. For example, different isotopic forms of hydrogen (H) include protium (1H) and deuterium (^H). Protium is the predominant hydrogen isotope found in nature.
Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples. Isotopically-enriched compounds within generic Formula I can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically- enriched reagents and/or intermediates.
It will be understood that, as used herein, references to the compounds of structural formula I are meant to also include the pharmaceutically acceptable salts, and also salts that are not pharmaceutically acceptable when they are used as precursors to the free compounds or in other synthetic manipulations. The compounds of the present invention may be administered in the form of a pharmaceutically acceptable salt. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids. When the compound of the present invention is acidic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases. Salts derived from such inorganic bases include aluminum, ammonium, calcium, copper (ic and ous), ferric, ferrous, lithium, magnesium, manganese (ic and ous), potassium, sodium, zinc and the like salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, as well as cyclic amines and substituted amines such as naturally occurring and synthesized substituted amines. Other pharmaceutically acceptable organic non-toxic bases from which salts can be formed include ion exchange resins such as, for example, arginine, betaine, caffeine, choline, N, N - dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methyl glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, and tromethamine.
When the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like.
The pharmaceutical compositions of the present invention comprise compounds of the invention (or pharmaceutically acceptable salts thereof) as an active ingredient, a pharmaceutically acceptable carrier, and optionally one or more additional therapeutic agents or adjuvants. Such additional therapeutic agents can include, for example, i) opiate agonists or antagonists, ii) calcium channel antagonists, iii) 5HT receptor agonists or antagonists, iv) sodium channel antagonists, v) NMDA receptor agonists or antagonists, vi) COX-2 selective inhibitors, vii) NKl antagonists, viii) non-steroidal anti-inflammatory drugs ("NSAID"), ix) selective serotonin reuptake inhibitors ("SSRl") and/or selective serotonin and norepinephrine reuptake inhibitors ("SSNRI"), x) tricyclic antidepressant drugs, xi) norepinephrine modulators, xii) lithium, xiii) valproate, xiv) neurontin (gabapentin), xv) pregabalin, xvi) sodium channel blockers and xvii) calcitonin gene-related peptide (CGRP) antagonists such as BIBN4096BS (olcegepant), MK-0974 (telcagepant), and CGRP8-.37 and beta-3 adrenergic receptor agaonists
(β3AR) such as CL316243. The instant compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. The pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
The present compounds and compositions are useful for the treatment of chronic, visceral, inflammatory and neuropathic pain syndromes. They are useful for the treatment of pain resulting from traumatic nerve injury, nerve compression or entrapment, postherpetic neuralgia, trigeminal neuralgia, small fiber neuropathy, and diabetic neuropathy. The present compounds and compositions are also useful for the treatment of chronic lower back pain, phantom limb pain, chronic pelvic pain, neuroma pain, complex regional pain syndrome, migraines, chronic arthritic pain and related neuralgias, and pain associated with cancer, chemotherapy, HIV and HIV treatment-induced neuropathy. Compounds of this invention may also be utilized as local anesthetics. Compounds of this invention are useful for the treatment of irritable bowel syndrome and related disorders, as well as Crohn's disease.
The instant compounds have clinical uses for the treatment of epilepsy and partial and generalized tonic seizures. They are also useful for neuroprotection under ischaemic conditions caused by stroke or neural trauma and for treating multiple sclerosis. The present compounds are useful for the treatment of tachy-arrhythmias. Additionally, the instant compounds are useful for the treatment of neuropsychiatric disorders, including mood disorders, such as depression or more particularly depressive disorders, for example, single episodic or recurrent major depressive disorders and dysthymic disorders, or bipolar disorders, for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder; anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, for example, specific animal phobias, social phobias, obsessive-compulsive disorder, stress disorders including post-traumatic stress disorder and acute stress disorder, and generalised anxiety disorders. Thus, another aspect of this invention is the use of the compounds of formula I in the manufacture of a medicament to treat pain and other diseases associated with pain.
Compounds of Formula I also may be used alone or in combination with other drugs in the treatment/prevention/suppression or amelioration of the diseases, conditions, or disorders such as overactive bladder, urinary incontinence, urge urinary incontinence, and urinary urgency.
In addition to primates, such as humans, a variety of other mammals can be treated according to the method of the present invention. For instance, mammals including, but not limited to, cows, sheep, goats, horses, dogs, cats guinea pigs, or other bovine, ovine, equine, canine, feline, rodent such as mouse, species can be treated. However, the method can also be practiced in other species, such as avian species (e.g., chickens).
It will be appreciated that for the treatment of depression or anxiety, a compound of the present invention may be used in conjunction with other anti-depressant or anti-anxiety agents, such as norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOΪs), reversible inhibitors of monoamine oxidase (RJMAs), serotonin and noradrenaline reuptake inhibitors (SNRJs), α-adrenoreceptor antagonists, atypical anti-depressants, benzodiazepines, 5-HTIA agonists or antagonists, especially 5-HTIA partial agonists, neurokinin- 1 receptor antagonists, corticotropin releasing factor (CRF) antagonists, and pharmaceutically acceptable salts thereof.
Further, it is understood that compounds of this invention can be administered at prophylactically effective dosage levels to prevent the above-recited conditions and disorders, as well as to prevent other conditions and disorders associated with calcium channel activity. Creams, ointments, jellies, solutions, or suspensions containing the instant compounds can be employed for topical use. Mouth washes and gargles are included within the scope of topical use for the purposes of this invention.
Dosage levels from about 0.01 mg/kg to about 140 mg/kg of body weight per day are useful in the treatment of inflammatory and neuropathic pain, or alternatively about 0.5 mg to about 7 g per patient per day. For example, inflammatory pain may be effectively treated by the administration of from about O.Olmg to about 75 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day. Neuropathic pain may be effectively treated by the administration of from about 0.01 mg to about 125 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 5.5 g per patient per day.
The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration to humans may conveniently contain from about 0.5 mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may ary from about 5 to about 95 percent of the total composition. Unit dosage forms will generally contain between from about 1 mg to about 1000 mg of the active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg or 1000 mg.
It is understood, however, that the specific dose level for any particular patient will depend upon a variety of factors. Such patient-related factors include the age, body weight, general health, sex, and diet of the patient. Other factors include the time and route of administration, rate of excretion, drug combination, and the severity of the particular disease undergoing therapy.
In practice, the compounds of the invention, or pharmaceutically acceptable salts thereof, can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). Thus, the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient. Further, the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion or as a water-in-oil liquid emulsion. In addition to the common dosage forms set out above, the compounds of the invention, or pharmaceutically acceptable salts thereof, may also be administered by controlled release means and/or delivery devices. The compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.
Thus, the pharmaceutical compositions of this invention may include a pharmaceutically acceptable carrier and a compound or a pharmaceutically acceptable salt. The compounds of the invention, or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more therapeutically active compounds. The pharmaceutical carrier employed can be, for example, a solid, liquid, or gas.
Examples of solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples of liquid carriers are sugar syrup, peanut oil, olive oil, and water. Examples of gaseous carriers include carbon dioxide and nitrogen. As described previously, in preparing the compositions for oral dosage form, any of the usual pharmaceutical media can be employed. For example, in the case of oral liquid preparations such as suspensions, elixirs and solutions, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used; or in the case of oral solid preparations such as powders, capsules and tablets, carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be included. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form in which solid pharmaceutical carriers are employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques. In addition to the common dosage forms set out above, controlled release means and/or delivery devices may also be used in administering the instant compounds and compositions. In preparing the compositions for oral dosage form, any convenient pharmaceutical media may be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents can be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are advantageous oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets may be coated by standard aqueous or nonaqueous techniques A tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Each tablet advantageously contains from about 0.1 mg to about 500 mg of the active ingredient and each cachet or capsule advantageously containing from about 0.1 mg to about 500 mg of the active ingredient. Thus, a tablet, cachet, or capsule conveniently contains 0.1 mg, 1 mg, 5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, or 500 mg of the active ingredient taken one or two tablets, cachets, or capsules, once, twice, or three times daily.
Pharmaceutical compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water. A suitable surfactant can be included such as, for example, hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
Pharmaceutical compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions. Furthermore, the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In all cases, the final injectable form must be sterile and must be effectively fluid for easy syringability. The pharmaceutical compositions must be stable under the conditions of manufacture and storage, and thus should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof. Pharmaceutical compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, and dusting powder. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound represented of the invention, or pharmaceutically acceptable salts thereof, via conventional processing methods. As an example, a cream or ointment is prepared by mixing hydrophilic material and water, together with about 5 wt% to about 10 wt% of the compound, to produce a cream or ointment having a desired consistency.
Pharmaceutical compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid, such as, for example, where the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in moulds.
In addition to the aforementioned carrier ingredients, the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, and preservatives (including anti-oxidants). Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient. Compositions containing a compound of the invention, or pharmaceutically acceptable salts thereof, can also be prepared in powder or liquid concentrate form.
Further, as described above, the instant compounds can be utilized in combination with one or more therapeutically active compounds. In particular, the inventive compounds can be advantageously used in combination with i) opiate agonists or antagonists, ii) other calcium channel antagonists, iii) 5HT receptor agonists or antagonists, including 5-HTjΛ agonists or antagonists, and 5-HTJA partial agonists, iv) sodium channel antagonists, v) N-methyl-D- aspartate (NMDA) receptor agonists or antagonists, vi) COX-2 selective inhibitors, vii) neurokinin receptor 1 (NKl) antagonists, viii) non-steroidal anti-inflammatory drugs (NSAID), ix) selective serotonin reuptake inhibitors (SSRJ) and/or selective serotonin and norepinephrine reuptake inhibitors (SSNRI), x) tricyclic antidepressant drugs, xi) norepinephrine modulators, xii) lithium, xui) valproate, xiv) norepinephrine reuptake inhibitors, xv) monoamine oxidase inhibitors (MAOIs), xvi) reversible inhibitors of monoamine oxidase (RJMAs), xvii)alpha- adrenoreceptor antagonists, xviii) atypical anti-depressants, xix) benzodiazepines, xx) corticotropin releasing factor (CRF) antagonists, xxi) neurontin (gabapentin) and xxii) pregabalin. The abbreviations used herein have the following meanings (abbreviations not shown here have their meanings as commonly used unless specifically stated otherwise): Ac (acetyl), Bn (benzyl), Boc (tertiary-butoxy carbonyl), Bop reagent (benzotriazol-1- yloxy)tris(dimethylamino)phosonium hexafluorophosphate, CAMP (cyclic adenosine-3',5'- monophosphate), DAST ((diethylamino)sulfur trifluoride), DBU (l,8-diazabicyclo[5.4.0]undec- 7-ene), DIBAL (diisobutylaluminum hydride), DIEA (diisopropylethyl amine), DMAP (4- (dimethylamino)pyridine), DMF (N,N-dimethylformamide), DPPF (l,l'-bisdiphenylphosphino ferrocene), EDC (l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride), Et3N (triethylamine), GST (glutathione transferase), HOBt (1-hydroxybenzotriazole), LAH (lithium aluminum hydride), Ms (methanesulfonyl; mesyl; or SO2Me), MsO (methanesulfonate or mesylate), MCPBA (meta-chloτo perbenzoic acid), NaHMDS (sodium hexamethyldisilazane), NBS (N-bromosuccinimide)j NCS (N-chlorosuccinimide), NSAID (non-steroidal antiinflammatory drug), PDE (Phosphodiesterase), Ph (Phenyl), r.t. or RT (room temperature), Rac (Racemic), SAM (aminosulfonyl; sulfonamide or SO2NH2), SPA (scintillation proximity assay), Th (2- or 3-thienyl), TFA (trifluoroacetic acid), THF (Tetrahydrofuran), Thi (Thiophenediyl), TLC (thin layer chromatography), TMEDA (N,N,N',N'-tetramethylethylenediamine), TMSI (trimethylsilyl iodide), Tr or trityl (N-triphenylmethyl), C3H5 (Allyl), Me (methyl), Et (ethyl), n- Pr (normal propyl), i-Pr (isopropyl), n-Bu (normal butyl), i-Butyl (isobutyl), s-Bu (secondary butyl), t-Bu (tertiary butyl), c-Pr (cyclopropyϊ), c-Bu (cyclobutyl), c-Pen (cyclopentyl), c-Hex (cyclohexyl).
The present compounds can be prepared according to the procedures provided in the Examples. The following Examples further describe, but do not limit, the scope of the invention.
Unless specifically stated otherwise, the experimental procedures were performed under the following conditions: All operations were carried out at room or ambient temperature; that is, at a temperature in the range of 18-25 0C. Inert gas protection was used when reagents or intermediates were air and moisture sensitive. Evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000pascals: 4.5-30 mm Hg) with a bath temperature of up to 60 0C. The course of reactions was followed by thin layer chromatography (TLC) or by high-pressure liquid chromatography-mass spectrometry (HPLC-MS), and reaction times are given for illustration only. The structure and purity of all final products were assured by at least one of the following techniques: TLC, mass spectrometry, nuclear magnetic resonance (NMR) spectrometry or microanalytical data. When given, yields are for illustration only. When given, NMR data is in the form of delta (δ) values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as internal standard, determined at 300 MHz, 400 MHz or 500 MHz using the indicated solvent. Conventional abbreviations used for signal shape are: s, singlet; d. doublet; t. triplet; m. multiplet; br. Broad; etc. In addition, "Ar" signifies an aromatic signal. Chemical symbols have their usual meanings; the following abbreviations are used: v (volume), w (weight), b.p. (boiling point), m.p, (melting point), L (liter(s)), mL (milliliters), g (gram(s)), mg (milligrams^)), mol (moles), mmol (millimoles), eq (equivalent(s)). The procedures described herein for synthesizing the compounds may include one or more steps of protecting group manipulations and of purification, such as, re-crystallization, distillation, column chromatography, flash chromatography, thin-layer chromatography (TLC), radial chromatography and high-pressure chromatography (HPLC). The products can be characterized using various techniques well known in the chemical arts, including proton and carbon-13 nuclear magnetic resonance (1H and 13C NMR), infrared and ultraviolet spectroscopy (IR and UV), X-ray crystallography, elemental analysis and HPLC and mass spectrometry (HPLC-MS). Methods of protecting group manipulation, purification, structure identification and quantification are well known to one skilled in the art of chemical synthesis.
Appropriate solvents are those which will at least partially dissolve one or all of the reactants and will not adversely interact with either the reactants or the product. Suitable solvents are aromatic hydrocarbons (e.g, toluene, xylenes), halogenated solvents (e.g, methylene chloride, chloroform, carbontetrachloride, chlorobenzenes), ethers (e.g, diethyl ether, diisopropylether, tert-butyl methyl ether, diglyme, tetrahydrofuran, dioxane, anisole), nitriles (e.g, acetonitrile, propionitrile), ketones (e.g, 2-butanone, dithyl ketone, tert-butyl methyl ketone), alcohols (e.g, methanol, ethanol, n-propanol, iso-propanol, n-butanol, t-butanol), N,N-dimethyl formamide (DMF), dimethylsulfoxide (DMSO) and water. Mixtures of two or more solvents can also be used. Suitable bases are, generally, alkali metal hydroxides, alkaline earth metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, barium hydroxide, and calcium hydroxide; alkali metal hydrides and alkaline earth metal hydrides such as lithium hydride, sodium hydride, potassium hydride and calcium hydride; alkali metal amides such as lithium amide, sodium amide and potassium amide; alkali metal carbonates and alkaline earth metal carbonates such as lithium carbonate, sodium carbonate, cesium carbonate, sodium hydrogen carbonate, and cesium hydrogen carbonate; alkali metal alkoxides and alkaline earth metal alkoxides such as sodium methoxide, sodium ethoxide, potassium tert-butoxide and magnesium ethoxide; alkali metal alkyls such as methyllithium, n-butyllithium, sec-butyllithium, t-bultyllithium, phenyllithium, alkyl magnaesium halides, organic bases such as trimethylamine, triethylamine, triisopropylamine, N,N-diisopropylethyl amine, piperidine, N-methyl piperidine, morpholine, N-methyl morphoHne, pyridine, collidines, lutidines, and 4-dimethylarninopyridine; and bicyclic amines such as DBU and DABCO. It is understood that the functional groups present in compounds described in the examples below can be further manipulated, when appropriate, using the standard functional group transformation techniques available to those skilled in the art, to provide desired compounds described in this invention.
It is also understood that compounds of this invention contain one or more stereocenters that may be prepared as single enantiomers or diastereomers, or as mixtures containing two or more enantiomers or diastereomers in any proportion.
Other variations or modifications, which will be obvious to those skilled in the art, are within the scope and teachings of this invention. This invention is not to be limited except as set forth in the following claims.
Several methods for preparing the compounds of this invention are illustrated in the following Schemes and Examples. Starting materials are made according to procedures known in the art or as illustrated herein.
REACTION SCHEMES
The compounds of the present invention can be prepared readily according to the following Schemes and specific examples, or modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in this art but are not mentioned in greater detail. The general procedures for making the compounds claimed in this invention can be readily understood and appreciated by one skilled in the art from viewing the following Schemes.
Scheme 1
Figure imgf000081_0001
Figure imgf000081_0002
The synthesis of 2-amino pyridine analogs is shown in Scheme 1. Dichloropyridine U. can be cross-coupled under palladium catalysis with either aryl or heteroaryl boronic acids or esters to give mono-coupled products L2, N-aryiation of substituted piperidines, moφholines, and piperazines yields amino pyridines U_. Ester hydrolysis and amide bond formation using EDC gives final targets 1.4.
Scheme 2
heat
Figure imgf000082_0001
Figure imgf000082_0002
Biaryl substituted pyridines are prepared according to Scheme 2. Palladium-catalyzed cross couplings can be performed on pyridine carboxylic acid 2.1. A second cross coupling is next carried out on various aryl or heteroaryl boronic acids or esters to give triaryl intermediates 23. Amide bond formation then yields the final targets 2Λ.
Scheme 3
Figure imgf000083_0001
Figure imgf000083_0002
Tertiary hydroxyl analogs are prepared as shown in Scheme 3. Suzuki coupling of dichloropyridine 3JL with isopropenyl boronate ester followed by sequential addition of a substituted aryl or heteroaryl boron ic acid or ester yields the disubstituted pyridine 32_. Oxidation with catalytic cobalt tetraphenyl porphorin affords the tertiary alcohol derivative which is then hydro lyzed to acid 3J.. Amide bond formation gives final targets 3A
Scheme 4
Figure imgf000083_0003
Figure imgf000083_0004
Pyridine N-oxides can be prepared according to Scheme 4, Bromopyridine 4J. can undergo palladium-catalyzed Suzuki cross coupling to a variety of aryl or heteroaryl boronic acids or esters. Subsequent hydrolysis furnishes acid 42,. Oxidation with MCPBA affords the corresponding pyridine N-oxides 4J, and amide bond formation using EDC provides amides 4.4.
Scheme 5
Figure imgf000084_0001
Figure imgf000084_0002
Substituted pyridinones are prepared according to Scheme 5. Bromopyridinone 5J, can undergo Suzuki coupling with a variety of ary] or heteroaryl boronic acids or esters to afford intermediate 5.2. N-alkylation can be accomplished using cesium carbonate and an appropriate alkyl halide or tosylate. In some cases a significant amount of o-alkylation is observed. N-arylation is effected using copper(I) iodide with a trans 1,2-cyclohexyl diamine ligand. Hydrolysis and amide bond formation yields final targets 5Λ.
Figure imgf000085_0001
Scheme 6 depicts the general synthetic route to prepare compounds of type 6J5. Dichloropyridine 6J, is protected using Boc2O and subsequent vinyllation gives intermediate 62. Oxidation, incorporation of trifluoromethyl group and Suzuki cross-coupling gives intermediates of type 6.4. Ester deprotection and final amide coupling gives examples of type 6Ji.-
Figure imgf000085_0002
Amine intermediates of type TJi can be prepared from one of several intermediates as shown in Scheme 7. This method utilizes diastereoselective EIlman sulfinimine addition chemistry to generate a pair of diastereomeric sulfinamides. The diastereomers are separated by silica chromatography prior to HCl deprotection to give 2Ji. Depending on the substrate either the R or S EIlman reagent is utilized to favor the desired alpha methyl amino compound with the preferred stereo configuration shown.
INTERMEDIATES AND EXAMPLES
The following examples are provided so that the invention might be more fully understood. These examples are illustrative only and should not be construed as limiting the invention in any way.
INTERMEDIATE 1
Figure imgf000086_0001
( 1 S)- 1 -(AH- 1.2.4-Tr iazo 1-3 -vDethanamine
Step A: Benzyl [π£V2~amino-l-methyl-2-thioxoethyl] carbamate To a solution of [(15)-2-amino-l-methyI-2-oxoethyl]carbamate (15.0 g, 67.5 mmol) in dichloromethane (337 mL) was added 2,4-bis-(4-methoxyphenyl)-l,3-dithia-2,4-diphosphetane 2,4- disulfide (15.01 g. 37.1 mmol) and the mixture was heated to 55 °C. After 1.5 h, the reaction was allowed to cool to ambient temperature and concentrated. Recrystallization from dichloromethane gave the title compound (13.4 g). MS 239.1 (M+l).
Step B: Benzyl [(lS)-l-(4H-l,2,4ι.rtriazol-3-yπethyl]carbamate
To a solution of benzyl [(1 S)-2-arnino-l-methyl-2-thioxoethyl] carbamate (13.4 g, 56.2 mmol) in ethanol (1.125 L) was added formic acid hydrazide (20.26 g, 337 mmol) and mercury(II) chloride (19.85 g, 73.1 mmol). After 1 h the reaction was filtered and concentrated. Saturated aqueous sodium carbonate and ethyl acetate were added. The organic layer was isolated and the aqueous layer was extracted with ethyl acetate (2x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered, and concentrated. A solution of the resulting residue in ethanol (1.125 L) was heated to 80 °C. After 16 h, the reaction was concentrated. Purification by silica gel chromatography (100% dichloromethane → 90% dichloromethane / methanol with 1% ammonium hydroxide) gave the title compound (8.7 g). MS 247.1 (M+ 1).
Step C: (iy>-l-(4H-L2.4-Triazol-3-vnethanamme To a solution of benzyl [(I S)- 1-(4H-1 ,2,4-triazol-3-yl)ethyl] carbamate (8.6 g, 34.9 mmol) in ethanol (140 mL) was added 4 M hydrochloric acid in 1,4-dioxane (43.7 mL, 175 mmol) and 10% palladium on carbon (1,858 g, 1.746 mmol) and the mixture was pressurized to 47 psi under hydrogen. After 4 h, the reaction was depressurized and filtered. Concentration gave the title compound as a hydrochloride salt (6,6 g). MS 113.0 (M+l). Η NMR (500 MHz, CD3OD): δ 8.82 (s, 1 H); 4.67 (q, J = 6.9 Hz, 1 H); 1.70 (dd, J= 6.9, 1.0 Hz, 3 H).
INTERMEDIATE 2
Figure imgf000087_0001
(IR)-I -f 6-(Trifluoromethyl)pγπdin~3-yl1etanamine
Step A: 2-methylTN-{(l£r)-j'6-(trif}uoroniethyl)-3-pyridinyl1methylene>-2-propanesulfinamide
To a solution of 6-(trifluoromethyl)nicotraaldehyde (45.0 g, 257 mmol) in dichloroethane (640 mL) were added (5)-(-)-2-methyl-2-propanesulfinamide (34.3 g, 283 mmol) and anhydrous copper(II) sulfate (82 g, 514 mmol). The mixture was stirred at 50 0C. After 48 h, the mixture cooled to ambient temperature. The reaction mixture was filtered through Celite. The filtered cake was washed with dichloromethane and the filtrate was concentrated to give the title compound (76.8g). MS 223.1 (U'tert-butyl +1)
Step B : 2-Methyl-N- 1 (IR)-I 46-(IT ifluoromethvi)- 3 -pyridiny llethyl ) -2-propanesulfinamide
To a solution of 2-methyl-N-{(lJ5)-[6-(trifluoromethyl)-3-pyridinyl]methylene}- 2-propanesulfinamide (76.8 g, 276 mmol) in dichloromethane (920 mL) at -45 0C was added methylmagnesium bromide (3.0 M in THF; 184 mL, 552 mmol). The mixture was stirred at -45 0C for 4 h. The reaction mixture was warmed to -200C. Additional methylmagnesium bromide (3.0 M in THF; 276 mL, 828 mmol) was added at -20 0C. The reaction mixture was warmed to 0 0C and was quenched with saturated aqueous ammonium chloride (300 mL). The mixture was allowed to warm to ambient temperature. The organic layer was separated and the aqueous layer was extracted with dichloromethane (3x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated. The concentrate was recrystallized using ethyl alcohol (500 mL). Then white solid was filtered and dried under reduced pressure (41.6 g). MS 295.0 (M+ 1).
Step C: (lJ?Vl-[6-(Trifluoromethyl)-3-pyridinyl1ethanamine To a solution of 2-methyl-N-{(l-β)-l-[6-(trifluoromethyl)-3-ρyridinyl]ethyl}-2- propanesulfinamide (41.6 g, 141 mmol) in methyl alcohol (470 mL) at 0 0C was added hydrogen chloride (4.0 M in dioxane; 106 mL, 424 mmol). After 30 min, the mixture was concentrated to dryness. The residue was recrystallized using ethyl alcohol (15 mL) and ether (40 mL). The white solid was filtered and dried under reduced pressure to give the hydrochloride salt of the title compound (26.3 g). MS 191.2 (M+l). 1H ΝMR (500 MHz, CD3 OD): δ 8.83 (d, J = 2.2 Hz, 1 H); 8.17 (d, J = 8.2 Hz1 1 H); 7.93 (d, J = 8.2 Hz, 1 H); 4.69 (q, J = 6.9 Hz, 1 H); 1.70 (d, J = 6.9 Hz, 3 H).
INTERMEDIATE 3
Figure imgf000088_0001
( 1 RY 1 -f 1 -Oxido-6-(trifluoromethv I)-3 -pyridinyliethanarnine
Step A: tert-Butyl K li?)-l-[6-(trifluoromethyl)-3-pyridinyl]ethvπ carbamate
To a solution of (lR)-l-[6-(trifIuoromethyl)pyridin-3~yl]ethanamine hydrochloride salt (0.554 g, 0.21 mmol) in dichloromethane (7.0 mL) were added d\-tert-buty\ dicarbonate (0.506g, 2.32 mmol) and triethylamine (0.969 mL, 6.95 mmol). The reaction mixture was stirred at ambient temperature for 4 h. Saturated aqueous ammonium chloride was added. The mixture was extracted with dichloromethane (3x). The combined organics extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated to give the title compound which was used directly in Step B (0.626 g).
Step B: tert-Butyl ((I J?)-l-π-oxido-6-(trifluoromethyl)-3-pyridinyl]ethyl) carbamate
To a solution of tert-bυtyl {(li?)-l-[6-(trifluoromethyl)-3-pyridinyl]ethyl}carbamate (0.626 g, 2.157 mmol) in chloroform (10.0 mL) were added 2,6-di-tørt-butyl-4-methylphenol (24 mg, 0.108 mmol) and 3-chloroperbenzoic acid (0.665 g, 2,70 mmol). The reaction mixture was stirred at 50 0C for 48 h. The reaction mixture was cooled to ambient temperature. Saturated aqueous sodium thiosulfate and saturated aqueous sodium bicarbonate were added. The mixture was extracted with dichloromethane (3x). The combined organics extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated. Purification by silica gel chromatography (75% hexanes/ ethyl acetate → 100% ethyl acetate) gave the title compound ( 140 mg). MS 307.0 (M+ 1 ).
Step C: (lJ?Vl-[l-Oxido-6-(trifluρromethyπ-3-pyridinyl'|ethanamine hydrochloride To a solution of tert-butyl {(lϋ)-l-[l-oxido-6-(trifluoromethyI)-3- pyridinyl]ethyl}carbamate (140 mg, 0.457 mmol) in dioxane (2 niL) was added hydrogen chloride (4.0 M in dioxane; 0.343 mL, 1,371 mmol). The reaction mixture was stirred for 4 h. The reaction mixture was concentrated to dryness to give the hydrochloride salt of the title compound (118 mg). MS 207.1 (M+ 1).
INTERMEDIATE 4
Figure imgf000089_0001
( 1 R)- 1 -(3 -Methyl- 1.2.4-oxadiazol-5-yl)ethanamine
Step A: tert-Butyl faRyi-f3~methyl-L2.4-oxadiazol-5-yl)ethyl")carbamate
To a solution of N-(/er/-butoxycarbonyl)-D-aianine (20 g, 106 mmol), acetamide oxime (17.3 g, 234 mmol) in 120 mL of 1,4-dbxane and 30 mL of N, N-dimethylformamide were added EDC (44,8 g, 234 mmol). The mixture was heated at 60 °C for 4 h then at 100 °C for 16 h. After cooling to ambient temperature, 300 mL of ethyl acetate was added. The mixture was washed with aqueous saturated sodium bicarbonate (2x). The combined organic extracts were dried over magnesium sulfate, filtered and concentrated. The residue was purified by silica gel chromatography (100% dichloromethane —* 90% dichloromethane/ methanol) to give pure tert-baty\ [( IR)-I -(3-methyl- 1,2,4- oxadiazoi-5-yl)ethyl]carbamate (6.0 g). MS 172.1 ((M-r-butyl+H)+l).
Step B: πR)-l-(3-Methyt-L2,4-oxadiazol~5-yl)ethanamine
To a solution of tert-butyl [(lR)-l-(3-methyl-l,2,4-oxadiazol-5-yl)ethyl]carbamate (6.0 g, 26.4 mmol) in dioxane (40 mL) was added 4 M hydrochloric acid in dioxane (30 mL). The reaction mixture was stirred for 16 h. The solution was concentrated and dried by vacuum to give hydrochloride salt of (IR)-I -(3 -methyl- lf2,4-oxadiazol-5-yl)ethanamine (5.1 g). 'H ΝMR (500 MHz, CD3OD): 5 4.90- 4.83 (m, 1 H); 2.41 (s, 3 H); 1.72 (d, J= 7.0 Hz, 3 H). MS 128.2 (M+l). INTERMEDIATE 5
Figure imgf000090_0001
(li?)-l-(S-Fluoropyridin-2-yl)ethanamine
Step A: Ethyl 5-fluoropyridine-2-carboxylate
To a degassed solution of ethyl alcohol (400 niL) in a Parr steel bomb was added sodium acetate (43.3 g, 528 mmol), 2-bromo-5-fluoropyridine (20 g, 114 mmol), 1,1'- bis(diphenylphosphino)ferrocene (2.27 g, 4,09 mmol) and palladium acetate (204 mg, 0.91 mmol). The vessel was put under nitrogen and sealed with Parr top. The atmosphere was displaced with carbon monoxide gas and the pressure was adjusted to 300 psi. The mixture was heated to 90 C. After 3 h, the pressure dropped to below 100 psi. The vessel was cooled to ambient temperature and the reaction was repressurized with carbon monoxide to 300 psi. The vessel was heated to 90 °C for an additional 4 h.
The vessel was cooled to ambient temperature and the remaining carbon monoxide was vented. The mixture was concentrated to half of the volume. Ethyl acetate (500 mL) and water (300 mL) were added.
The organic layer was isolated and the aqueous layer was extracted with ethyl acetate (2x). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated.
Purification by silica gel chromatography (100% hexanes —> 70% hexanes/ ethyl acetate) gave the title compound. MS 170.0 (M+ 1),
Step B: 5-Fluoropyridine-2-carbaldehvde
To a solution of ethyl 5-fluoropyridine-2-carboxylate (25 g, 148 mmol) in tetrahydrofuran (250 mL) at -78 °C was added dropwise diisobutylaluminum hydride (1.0 M in hexanes;
296 mL, 296 mmol). After 1 h, the reaction was quenched with ethyl alcohol (10 mL). Saturated aqueous sodium potassium tartrate tetrahydrate ( 1.3 L) was added and the aqueous layer was extracted with ethyl acetate (2x). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered. The solution mixture (1.4 L) was carried onto the next step without concentration. MS
125.9 (M+l).
Step C : JV-[C 1 ip-(5-Fluoropyridin-2-y Dmethyletie] -2-methy lpropane-2-sulfinamide
To a solution of 5-fluoropyridine-2-carbaldehyde (18.49 g, 148 mmol) in ethyl acetate (850 mL), THF (250 mL) and hexanes (300 mL) were added (iϊ)-(+)-2-methyl-2- propanesulfinamide (19.71 g, 163 mmol) and anhydrous copper(II) sulfate (59.0 g, 370 mmol). The mixture was stirred at ambient temperature. After 18 h, the mixture was filtered through Celite. The filtered cake was washed with ethyl acetate and the filtrate was concentrated. Purification by silica gel chromatography (100% dichloromethane → 98% dichloromethane/ methanol) gave the title compound.
Step D: N-\(\R)- 1 -r5-Fluoropyridin-2-vl)ethvl1-2-methylpropane-2-sulfinamide To a solution of N-[(l£)'(5-fluoropyridin-2-yI)methylene]-2-methylpropane-2- sulfmamide (52.12 g, 228 mmol) in dichioromethane (1000 mL) at -78 °C was added methylmagtiesium bromide (3.0 M in THF; 198 mL, 594 mmol). The mixture was allowed to warm to ambient temperature. After 30 min, the mixture was cooled down to -78 °C and was quenched with saturated aqueous ammonium chloride (100 mL). The mixture was allowed to warm to ambient temperature. The organic layer was separated and the aqueous layer was extracted with dichloromethane (3x). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% ethyl acetate) gave the title compound. MS 245 (M+ 1).
Step E: πRyi-(5-FIuoropyridin-2-yl)ethanamine To a solution of N-[( 1 R)- 1 -(5-fluoropyridin-2-yl)ethyl]-2-methylpropane-2- suJfinamide (34.3 g, 140 mmol) in methyl alcohol (700 mL) at 0 °C was added hydrogen chloride (4.0 M in dioxane; 105 mL, 421 mmol). After 30 min, the mixture was concentrated to dryness. The residue was recrytalized using ethyl alcohol (15 mL) and ether (40 mL). The white solid was filtered and dried under reduced pressure to give the hydrochloride salt of the title compound. MS 141.1 (M+l).
INTERMEDIATE 6
Figure imgf000091_0001
( 1 R)- 1 -(5 -F luoro- 1 -oxidopyrindm-2-y Dethanam be
Step A: tert-Bntyl fπ/?H-(5-fluoropvridin-2-vDethyr|carbamate
To a solution of the toluene sulfonic acid salt of ( IiJ)-I -(5-fluoropyridm-2-yl)ethanamine
(7.5 g, 24.0 mmol) in dichloromethane (96 mL) at 0 C was added triethylamine (7.03 mL, 50.0 mmol) and di-tert-buty\ dicarbonate (6.13 mL, 26.4 mraol). The mixture was allowed to warm to ambient temperature. After 16 hours, saturated aqueous sodium bicarbonate was added. The organic layer was isolated and the aqueous layer was extracted with dichloromethane (2x). The combined organic extracts were washed with brine, dried over magnesium sulfate, and filtered. Concentration gave the title compound (7.72 g). MS 241.1 (M+ 1).
Step B: tert-Butyl [(lJ?Vl-(5-fluoro-l-oxidopyridin-2-yπethyllcarbamate To a solution of tert-butyl [(lJΪ)-l-(5-fluoropyridin-2-yl)ethyl]carbamate (5.77 g, 24.0 mmol) in dichloromethane (96 niL) was added 3-chloroperbenzoic acid (6.51 g, 26.4 mraol). After 4.5 h, excess 3-chloroperbenzoic acid (0.59 g, 2.6 mmol) was added. After 72 h, saturated aqueous sodium sulfite was added. After 1 h, saturated aqueous sodium bicarbonate was added. The organic layer was isolated and the aqueous layer was extracted with dichloromethane (2x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered> and concentrated. Purification by silica gel chromatography (100% dichloromethane → 90% dichloromethane / methanol with 1% ammonium hydroxide) gave the title compound (5.45 g). MS 257.1 (M+ 1).
Step C: ( IR)- 1 -f5-Fluoro-l~oxidoργrmdin-2-yl)ethanamine To a solution of tert-butyl [(li?)-l-(5-fluoro-l-oxidopyridin-2-yl)ethyl]carbamate (1,47 g,
5,74 mmol) in dichloromethane (28,7 mL) was added 4 M hydrochloric acid in 1,4-dioxane (43.0 mL, 172 mmol). After 2 h, concentration gave the title compound as a hydrochloride salt (1.396 g). MS 157.1 (M+ 1). 1H NMR (500 MHz, CD3OD): δ 8.55 (dd, J= 4.3, 2.4 Hz, 1 H); 7.70 (dd, J = 9.0, 6.7 Hz, I H); 7.52 (ddd, J = 9.1, 7.1, 2.4 Hz, I H); 4.80 (q, J= 7.0 Hz5 1 H); 1.74 (d, J= 7.0 Hz, 3 H).
INTERMEDIATE 7
Figure imgf000092_0001
( 1 R)- 1 -(5-Methyl- 1.2.4-oxadiazol-3 -vDethanamine
Step A: Benzyl [(lR)-l-cyanoethyllcarbamate
To a solution of benzyl [(li?)-2-amino-l-methyl-2-oxoethyl]carbamate (10 g, 45 mmol) in 50 mL of N, N-dimethylformamide was added 2,4,6-trichloro-l,3,5-triazine (4.15 g, 22.5 mmol). After
2 h, 100 mL of water was added and the mixture was filtered. The solids were washed with 100 mL aqueous sodium bicarbonate (2x) and dried under vacuum to give pure benzyl [(I R)-I- cyanoethyl]carbamate (7.2 g), MS 205.2 ((M+ 1). Step B: Benzyl ffUt 2Z)-2-amino-2-f hydroxy imino)-l-methyiethyl] carbamate
To a solution of benzyi [(lφ-l-cyanoethyljcarbamate (2.52 g, 12,3 mmol) in ethanol (30 ml) was added hydroxylamine hydrochloride salt ( 0.90 g, 13.0 mmol) and triethylamine (3.43 ml, 24.6 mmol) and the mixture heated to 75 0C. After 16 h, the solution was concentrated and the residue was dissolved in 200 mL of dichloromethane. The mixture was washed with 100 mL of saturated aquous sodium bicarbonate (2x) and brine (100 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated to give benzyl [(IR, 2Z)-2-amino-2-(hydroxyimino)-l- methylethyl]carbamate (2.9 g). MS 238.2 (M+l).
Step C: Benzyl [αift-H5-methyl-1.2.4-oxadiazol~3-vnethγllcarbarnate
To a solution of benzyl [(Ii?, 2Z)-2-amino-2-(hydroxyimino)-l-methylethyl] carbamate (2.25 g, 9.48 mmol) in dioxane (80 ml) was added 1-acetyl-lH-imidazole (3.13 g, 28.5 mmol) and the mixture heated to 90 0C. After 16 h, the solution was concentrated and the residue was dissolved in 200 mL of dichloromethane. The mixture was washed with 100 mL of aquous saturated sodium bicarbonate (2x) and brine (100 mL). The organic layer was dried over sodium sulfate, filtered and concentrated. The residue was purified by silica gel chromatography ( 100% dichloromethane → 95% dichloromethane/ methanol) to give the title compound (1.1 g). MS 262.1 (M+l).
Step D: (1 R)- 1 -( 5 -Methyl- K2.4-oxadiazol-3-yl)ethanamine To a solution of benzyl [(lΛ)-l-(5-methyI-l,2,4-oxadiazol-3-yl)ethyl]carbamate (1.10 g,
4.21 mmol) in dichloromethane (40 mL) was added 1 M boron trichloride solution in dichloromethane (21.1 mL, 2Ll mmol) at 0 0C. The reaction mixture was allowed to warm from 0 0C to 20 0C over 4 h. The solution was quenched by 5 ml of methanol at 0 0C. After warming to ambient temperature, the mixture was concentrated and the residue was washed with 100 mL of diethyl ether (2x) to give the hydrochloride salt of ( 1 R)-I -(5-methyl-l ,2,4-oxadiazol-3-yl)ethanamine was obtained as solid (0.84 g). 1H NMR (500 MHz, CD3OD): δ 4.70-4.61 (m, 1 H); 2.63 (s, 3 H); 1.67 (d, /= 6.9 Hz, 3 H).
INTERMEDIATE 8
Figure imgf000093_0001
( Ii?)- 1 -f2-(Trifluoromethyl)pyrimidin-5-yllethanamine Step A: Ethyl 2-(trifluorornethyl)pyrimidme-5-carboxytate To a solution of ethyl 4-chloro-2-(trifluoromethyl)pyrimidine-5-carboxylate
(30.2 g, 119.0 mmol) in ethanol (594 mL) under nitrogen were added palladium (10% on carbon, 50% water wet; 2.58g, 1.21 mmol) and diisopropylethylamine (50.0 mL, 286.0 mmol). The mixture stirred under hydrogen (1 atm). After 6 h, the mixture was filtered with Celite. The filtrate was concentrated and ethyl acetate was added. The mixture was washed with sat. NaHCθ3 (2x), brine, dried over Na2SO4, filtered and concentrated to give the title compound (25.6 g). MS 221,1 (M+ 1).
Step B: 2-(Trifluoromethyl)pyrirnidine-5-carbaldehyde
To a solution of ethyl 2-(trifluoromethyl)pyrimidine-5-carboxylate (25.5 g, 116.0 mmol) in dichloromethane (580 mL) at -78 0C was slowly added DBAL-H (1.0 M; 130.0 mL, 130.0 mmol). The mixture was stirred at -78 0C. After 2 h, the mixture was quenched via slow addition of HCl
(2.0 M in water). The mixture was allowed to warm to ambient temperature. The mixture was extracted with diethyl ether (3x). The combined organic extracts was dried over Na2SO4, filtered and concentrated to give the title compound (28.2 g).
Step C: 2-Methyl-N-{(lZ)-[2-(trifluoromethyl)pyrimidin-5-yl1methylene}propane-2-sulfinamide
To a solution of 2-(trifluoromethyl)pyrimidine-5-carbaIdehyde (27,2 g, 99 mmol) in dichloroethane (250 mL) was added (R)-(+)-2-methyl-2-propanesulfinamide (13.3 g, 109.0 mmol) and copper(ΪI) sulfate (31.5 g, 197.0 mmol). The mixture was heated to 500C. After 18 h, the mixture was cooled to ambient temperature and filtered through a pad of silica gel. The filtered cake was washed with dichloromethane and the filtrate was concentrated to give the title compound (27.3 g). MS 224
[(M+O-56].
Step D: 2-Methyl-N-{(l./?)- 1 -[2-(tnfluoromethyl)pyrimidin-5-yl]ethyUpropane-2-sulfmamide
To a solution of 2-methyl-N-{(lZ)-[2-(trifluoromethyl)pyrimidin-5- yl] methylene }propane-2-sulfϊnamide (14.3 g, 51.2 mmol) in toluene (260 mL) at -70 0C was added methyllithium (1.6 M; 35.0 mL, 56.0 mmol). The mixture was stirred at -70 0C for 15 min. The mixture was quenched with sat. NH4Cl and the reaction was allowed to warm to ambient temperature. The mixture was extracted with dichloromethane (3x). The combined organic extracts was dried over
Na2SO4, filtered and concentrated. Purification by silica gel chromatography (100% hexanes — » 35% hexanes / ethyl acetate then 100 % ethyl acetate → 94% ethyl acetate / methanol) gave the title compound (7.23 g). MS 240.0 [(M+l)-56],
Step E: (1 RM-β^TrifluoromethyDpyrimidin-S-yllethanamine To a solution of 2-methyl-N-{(lϋ)-l-[2-(trifluoromethyl)pyrimidin-5- yl]ethyl}propane-2-sulfinamide (7.23 g, 24.5 mmol) in methanol (100 mL) was added HCl (4,0 M in dioxane; 18.5 mL, 74.0 mmol). The mixture was stirred at ambient temperature. After 1 h, the mixture was concentrated to give the title compound (4.6 g).
EXAMPLE 1.32
Figure imgf000095_0001
2-r2-Flυoro-4-methylphenyπ-6-morpholin-4-yl-N-[f l'Sf)-l-(4H-l,ι2,4-triazol-3-yl)ethyl]isonicotinamide Step A: Methyl 2-chloro-6-(2-fluoro-4-methylphenyl)ispnicgtinate
To a solution of methyl 2,6-dichioroisonicotinate (3.34 g, 16.2 mmol) in toluene (100 mL) were added (2-fluoro-4-methylphenyl)boronic acid (1.4 g, 9.09 mmol), (tetrakistriphenylphosphine)palladium (0) (0.94 g, 0.81 mmol) and sodium carbonate (2.0 M in water; 8.1 g, 16.2 mmol). The mixture was degassed with nitrogen (3x) and heated to 80 0C. After 42 h, the mixture was cooled to ambient temperature and saturated ΝaΗCC>3 was added. The mixture was extracted with ethyl acetate (3x). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. Purification by reverse phase chromatography (C-18, 85% water / acetonitrile -→ 5% water / acetonitrile with 0.1% trifluoroacetic acid) gave the title compound (1.07 g). MS 280.0 (M+ 1).
Step B: Methyl 2-(2-fluoro-4-methyiphenyl)-6-morpholin-4-ylisonicotinate
To a solution of methyl 2-chloro-6-(2-fluoro-4-methylphenyl)isonicotinate (0.26 g, 0.94 mmol) in DMA (4 mL) were added morpholine (0.10 mL, 1.17 mmol), tris(dibenzylideneacetone)dipalladium(0) (21.4 mg, 0.02 mmol), 2-dicyclohexyIphosphmo-2',4',6'- triisopropylbiphenyl (33.5 mg, 0.07 mmol) and cesium carbonate (0.46g, 1.41 mmol). The mixture was heated to 80 0C. After 18 h, the mixture was filtered. The filtered cake was washed with methanol. The filtrate was concentrated to remove methanol. The solution in DMA was carried onto the next step.
Step C; 2-(2-Fluoro-4-methylphenyi)-6-moφholin-4-ylisonicotinic acid To a solution of methyl 2-(2-fluoro-4-methylphenyl)-6-morpholin-4- ylisonicotinate (0.31 g, 0.94 mmol) in DMA (4 mL) was added sodium hydroxide (1.0 M solution in water; 1.87 niL, 1.87 rnmol). The mixture was stirred at ambient temperature. After 1 h, HCl (1.0 M in water; 1 ,87 niL, 1.87 mmol) was added and the mixture was concentrated. Methanol was added and the mixture was filtered and the filtrate was concentrated. The mixture was purified by reverse phase chromatography (C- 18, 95% water / acetonitrile → 25% water / acetonϊtrile with 0.1% trifluoroacetic acid). HCl (1.0 M) was added and fractions were concentrated to give the hydrochloride salt of the title compound (129 mg). MS 317.0 (M+l).
Step D: 2-r2-Fluoro-4-methylphenvn-6-morpholm-4-yl-N-rd5>-i-(4H-L2.4-triazol-3- yl)ethyl]isonicotinamide
To a solution of the hydrochloride salt of 2-(2~fluoro-4-methylphenyl)-6- morpholin-4-ylisonicotinic acid (50 mg, 0.14 mmol) in DMF (1.5 mL) were added hydrochloride sait of (lS>l-(4H-l,2,4-triazol-3-yl)ethanamine (31.5 mg, 0.17 mmol), EDC (35.3 mg, 0.18 mmol), ΗOBT (21.7 mg, 0.14 mmol) and diisopropylethylamine (99.0 μL, 0.57 mmol). The mixture was stirred at ambient temperature. After 72 h, the mixture was filtered and the filtrate was purified by reverse phase chromatography (C-18, 95% water / acetonitrile — > 25% water / acetonitrile with 0.1% trifluoroacetic acid). The product was treated with HCl (2.0 M in ether) to give the hydrochloride salt of the title compound (69 mg). ΗRMS 411.1936 (M+l). 1H ΝMR δ (ppm)(CH3 OH-d4 ): 9.32 (s, IH), 7.74 (t, J= 7.96 Hz, IH), 7.63 (s, IH), 7.50 (s, IH), 7.21 (d, J= 7.95 Hz, IH), 7.16 (d, J= 12.16 Hz, IH), 5.52-5.46 (m, IH), 3.87 (t, J= 4.72 Hz, 4H), 3.77 (t, J= 4.67 Hz, 4H), 2.44 (s, 3H), 1.78 (d, J- 7.05 Hz, 3H).
EXAMPLE 1.62
Figure imgf000096_0001
2-(2,4-Difluorophenyl)-6-(l-hydroxy-l-methylethylVN-((lig)-l-[l-oxido-6-(trifl«oromethyl)pyridin-3- yliethyUisonicotinamide
Step A: Methyl 2-(2.4-difluoropheny0-6~isopropenylisonicotinate
To a degassed solution of methyl 236-dichloroisonicotinate (0.1 g, 0.49 mmol), tripotassium phosphate (0.16 g, 0.73 mmol), palladium(Il) acetate (8.72 mg, 0.04 mmol) and tris(2- methoxypheny!)phosphine (27.4 mg, 0.08 mmol) in THF (1 mL) and water (0.25 mL) was added 2- isopropenyl-4,4,5,5-tetrametliyl-l,3,2-dioxaborolane (0.1 1 mL, 0.61 mmol) ) The mixture was heated to 65 0C. After 4 h, a solution of (2,4-difluorophenyl)boromc acid (0.12 g, 0.73 mmol) in THF (0.5 mL) was added. The mixture was continued to stir at 65 0C. After 18 h5 the mixture was cooled to ambient temperature. Saturated aqueous NaHCO3 was added the mixture was extracted with ethyl acetate (3x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% hexanes → 90% hexanes / ethyl acetate) gave the title compound (144 mg, 80% pure). MS 290.1 (M+ 1).
Step B: 2-(2,4-Difluorophenyi)-6-(l -hydroxy- 1 -methylethypisonicotinic acid To a solution of methyl 2-(2,4-difluorophenyl)-6-isopropenylisonicotinate (0,29 g, 1.01 mmol) in methanol (5.1 mL) and DME (5.1 mL) was added cobalt(II)mesotetraphenylporphine (6.8 mg, 10.1 umol). The mixture was stirred at ambient temperature. After 18 h, tetraethylammonium borohydride (73.5 mg, 0.51 mmol) was added. After 15 min, additional tetraethylammonium borohydride (0.14 g, 1.01 mmol) was added. After 1,5 h, sodium hydroxide (1.0 M in water; 2.03 mL, 2.03 mmol) was added. The mixture was heated to 50 0C, After 1 h, HCl (0.17 mL, 2.03 mmol) was added and the mixture was concentrated. Purification by reverse phase chromatography (C-18, 95% water / acetonitrile → 25% water / acetonitrile with 0.1% trifluoroacetic acid) gave the title compound (0.22 g). MS 294.1 (M+1).
Step C : 2-(2,4-Difluorophenyl)-6-f 1 -hydroxy- 1 -methylethy H-N- (( 1 R)- 1 - \ 1 -oxido-6- (trifluoromethyDpyridin-3-yl]ethyl)isonicotinamide
To a solution of 2-(2,4-difluorophenyl)-6-(l -hydroxy- l-methylethyl)isonicotinic acid (19.5 mg, 0.07 mmol) in DMF (0.67 mL) were added hydrochloride salt of (U?)-l-[l-oxido-6- (trifluoromethyl)pyridin-3-yl]ethanamine (24.2 mg, 0.10 mmol), HATU (0.5 M in DMA; 0.2 mL, 0.10 mmol) and diisopropylethylamine (46.5 uL, 0.27 mmol). The mixture was stirred at ambient temperature. After 30 min, small amount of water and trifluoroacetic acid were added and the mixture was purified by reverse phase chromatography (C-18, 95% water / acetonitriie → 5% water / acetonitrile with 0.1% trifluoroacetic acid) gave the title compound (28 mg). HRMS 482.1462 (M+l). Η NMR (400 MHz, CDCl3 ): δ 8.38 (s, IH); 8.09-8.01 (m, IH); 7.94 (s, IH); 7.73 (s, IH); 7.67 (d, J= 8.3 Hz, IH); 7.38 (d, J= 8.3 Hz, IH); 7.07-6.98 (m, IH); 6.99-6.90 (m, IH); 6.74 (d, J = 6.9 Hz, IH); 5.32- 5.25 (m, IH); 4.38 (s, IH); 1.67 (d, J= 7.1 Hz, 3H); 1.62 (s? 6H).
EXAMPLE 1.63
Figure imgf000098_0001
2-r2-Hvdroxyproρan-2-yπ-6-f4-methyiphenyl)-N-[(l;y)-l-f4H-L2.4-triazol-3-vπethyllpvridine-4- carboxamide Step A: Methyl 2-f4-methylphenyJ)-6-(prop-l-en-2-yDpyridine-4-carboxylate
To a degassed solution of palladium(II) acetate (21.8 mg, 0.10 mmol) and tris(2- methoxyphenyl)phosphine (68.4 mg, 0.19 mmol) in THF (1 niL) was added a degassed mixture of methyl 2,6-dichloroisonIcotinate (250 mg, 1.21 mmol), tripotassium phosphate (386 mg, 1,82 mmol), and 2- isopropenyl-4!4,5,5-tetramethyl-l,3,2-dioxaborolane (0.285 mL, 1.52 mmol) in THF (1.5 mL) and water (0.625 mL). The mixture was heated to 63 0C. After 4 h, a degassed solution of 4-methytphenylboronic acid (247 mg, 1.82 mmol) in THF (1.25 mL) was added. The resulting mixture was heated to 63 0C. After 18 h, 4-methylphenylboronic acid (247 mg, 1.82 mmol), patladium(II) acetate (21.8 mg, 0.10 mmol), and tris(2-methoxyphenyl)phosphine (68.4 mg, 0.19 mmol) were added. The resulting mixture was heated to 63 0C. After 18 h, the mixture was cooled to ambient temperature. Saturated aqueous NaHCO3 was added and the mixture was extracted with ethyl acetate (3x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated. Purification by reverse phase chromatography (C- 18, 80% water / acetonitrile → 5% water / acetonitrile with 0.1% trifluoroacetic acid) gave the title compound (191 mg). MS 268.1 (M+ 1).
Step B: Methyl 2-(2-hydroxypropan-2~yl>6-f4-methylphenyi)pyridine-4-carboxylate
To a solution of methyl 2-(4-methyIphenyl)-6-(prop-l-en-2-yl)pyridine-4- carboxylate (191 mg, 0.71 mmol) in methanol (3.6 mL) and DME (3.6 mL) was added cobait(II)mesotetraphenylporphine (2.4 mg, 3.6 μmol). After 30 min} tetraethyl ammonium borohydride (170 mg, 1.17 mmol) was added in 3 portions over 1 h. Saturated aqueous NaHCO3 was added. The mixture was diluted with water and extracted with ethyl acetate (3x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated. Purification by reverse phase chromatography (C-18, 90% water / acetonitrile -÷ 5% water / acetonitrile with 0.1% trifluoroacetic acid) gave the title compound (165 mg). MS 286.1 (M+l).
Step C: 2-(2-Hvdroxypropan-2-yl)-6-(4-methvbhenvDρyridine-4-carboxylic acid To a solution of methyl 2-(2-hydroxypropan-2-yl)-6-(4-methylphenyl)pyridine-4- carboxylate (165 mg, 0.58 mmol) in methyl alcohol (5.8 niL) was added sodium hydroxide (1 M; 1 ,16 mL, L16 mmol). The resulting mixture was heated to 60 0C. After 30 min, the mixture was cooled to ambient temperature. Hydrogen chloride (96 μL, 1.16 mmol) was added. The resulting mixture was concentrated, giving the sodium chloride salt of the title compound. MS 272.1 (M+l).
Step D: 2-f2-Hvdroxvpropan-2-vlV6-(4-methyIphenylVN-[π5)-l-(4H-1.2.4-triazol-3-vnethyllpyridine-4- carbpxarnide
To a solution of the sodium chloride salt of 2-(2-hydroxypropan-2-yl)-6-(4- methylphenyl)pyridine-4-carboxylic acid (224 mg, 0,58 mmol) in DMF (2.3 mL) was added the hydrochloride salt of (15)-l-(4H-l,2,4-triazol-3-yl)ethanamme (160 mg, 0.87 mmol), HOBT (89 mg, 0.58 mmol), triethylamine (322 μL, 2.31 mmol), and EDC (139 mg, 0.72 mmol). The resulting mixture was heated to 60 0C, After 30 min, the mixture was cooled to ambient temperature. A small amount of water was added and the mixture was purified by reverse phase chromatography (C- 18, 95% water / acetonitrile ■→ 5% water / acetonitrile with 0.1% trifluoroacetic acid). Treatment with 2 M hydrogen chloride in diethyl ether gave the title compound as the hydrochloride salt. (230 mg). HRMS 366.1920 (M+l). 1H ΝMR (399 MHz, DMSO): δ 9.28 (d, J= 7.9 Hz, 1 H); 8.38 (s, 1 H); 8.18 (s, 1 H); 8.07 (d, J= 8.0 Hz, 2 H); 8.02 (d, J= 1.3 Hz, 1 H); 7.33 (d, J= 7.9 Hz, 2 H); 5.37 (t, J= 7.3 Hz, 1 H); 2.38 (s, 3 H); 1.59 (d, J= 7.0 Hz, 3 H); 1.52 (s, 6 H).
EXAMPLE 1.68
Figure imgf000099_0001
2-(2,4-Difluorophenyl)-6-(2-methylpyrimidin-5-yl')-N-{(li?)-l-[l-oxido-6-(trifluoromethyDpyridin-3- yl") ethyl lisonicotinamide
Step A: 2-Chloro-6~(2,4-difIuorophenyDisonicotinic acid
To a solution of 2,6-dichloroisonicotinic acid (2.43 g, 12.67 mmol) in DMF (38 mL) and water (12.7 mL) were added (2,4-difluorophenyl)boronic acid (2.0 g, 12.67 mmol), tri(m- sulfophenyl)phosphine sodium salt (0.54 g, 0.95 mmol), palladium(II) acetate (71.0 mg, 0.32 mmoi) and diisopropylamine (6.3 mL, 44.3 mmol). The mixture was heated 500C. After 2.5 h, the mixture was cooled to ambient temperature and stirred for 18 h. HCl (1.0 M in water) was added and the mixture was was extracted with ethyl acetate (3x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated, Purification by reverse phase chromatography (C- 18, 85% water / acetonitrile → 5% water / acetonitrile with 0.1% trifluoroacetic acid) gave the title compound (1.24 g). MS 270.0 (M+l).
Step B: 2-(2.4-Difluorophenyl)-6-(2-rnethylpyrimidin-5-yl)isonicotinic acid
To a solution of 2-chIoro-6-(2,4-difluorophenyl)isonicotinic acid (0.10 g, 0.37 mmol) in DMF (1.9 mL) and water (0.6 mL) were added (2-methylpyrimidin-5-yl)boronic acid (0.31 g, 2.23 mmol), palladium(II)acetate (12.5 mg, 0.06 mmol), 3,3',3"-phosphinidynetris(benzenesulfonic acid) trisodium salt (95.0 mg, 0.17 mmol) and diisopropylamine (0.19 mL, 1.30 mmol). The mixture was heated to 80 0C. After 2 h, the mixture was filtered and the filtrate was purified by reverse phase chromatography (C-18, 95% water / acetonitrile — > 25% water / acetonitrile with 0, 1% trifluoroacetic acid). To the product fractions was added HCl (2.0 M in ether) and the mixture was concentrated to give the hydrochloride salt of the title compound. MS 328.1 (M+l).
Step C: 2-(2,4-Difluorophenyl)-6--(2-methylpyrimidin:5ι-yl)-N:((lJKVl-[l-oxido-6-- (triflυoromethyl)ρyridin~3-yl]ethyl}isonicotinamide To a solution of 2-(2,4-difluorophenyl)-6-(2-methyrpyπmidin-5-yl)isonicotinic acid (21.3 mg, 0.05 mmol) in DMF (0.5 mL) were added hydrochloride salt of (l.R)-l-[l-oxido-6- (tπfluoromethyI)pyridin-3-yI]ethanamine (27.0 mg, 0.07 mmol), HATU (0.5 M in DMF; 0.16 mL, 0.08 mmol) and diisopropylethylamine (65 μL, 0.37 mmol). The mixture was stirred at ambient temperature. After 25 min, the mixture was purified by reverse phase chromatography (C-18, 95% water / acetonitrile — * 25% water / acetonitrile with 0.1% trifluoroacetic acid) gave the title compound, which was converted to hydrochloride salt using 2.0 M HCl in ether (31 mg). HRMS 516.1453 (M+l). 1H ΝMR (400 MHz1 CDCh ): δ 9.34 (s, 2H), 8.42 (s, IH), 8.24-8.15 (m, IH), 8.09 (s, IH), 8.06 (s, IH), 7.68 (d, J= 8.3 Hz, IH), 7.40 (d, J- 8.4Hz, IH), 7.11-7.04 (m, IH), 6.97 (t, J- 9.8 Hz, IH), 6.85 (d, J- 7.0 Hz, IH), 5.37- 5.30 (m, IH), 2.83 (s, 3H)5 1.69 (d, J- 7.1 Hz, 3H).
EXAMPLE 1.79
Figure imgf000101_0001
N- ((I R )- 1 -f 6-( L 1 -DifluoroethylV I -oxidopyr idin-3 -yj] ethyl } -2-f2.4-difluoropheny lV6-f 2.2.2-tr ifluoro- 1 - hydroxyethypisonicotinamide
Step A: tert-Butyl 2,6-dich!oroisonicotinate
To a solution of 2,6-dichloroisonicotinic acid (10.0 g, 52.1 mmol) in THF (200 mL) were added di-ter/-butyl dϊcarbonate (12.5 g, 57.3 mmol) and DMAP (1.9 g, 15.6 mmol). The mixture was stirred at ambient temperature. After 72 h, water was added and the mixture was extracted with ethyl acetate (3x). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated.
Step B: ter t-Buty\ 2-chloro-6-vinylisonicotiπate
To a solution of tert-batyl 2,6-dichloroisonicotinate (11.0 g, 44.3 mmol) in THF (200 mL) were added potassium vinyltrifluoroborate (7.1 g, 53.2 mmol), dichloro[l,l'- bis(diphenylphosphϊno)ferrocene] palladium(II) dichlororaethane adduct (0.97 g, 1.33 mmol) and triethylamine (9.3 mL, 66.5 mmol). The mixture was heated to 65 0C. After 1 h, saturated aqueous sodium bicarbonate was added and and the mixture was extracted with ethyl acetate (3x). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% hexanes — > 90% hexanes / ethy! acetate) gave no separation of desired product. The mixture was carried onto next step.
Step C: tert-Butyl 2-chlprp:6-fρrrnyiis^nicotinate
To a solution of tert-butyl 2-chloro-6-vinylisonicotinate (9.6 g, 40.1 mmol) in
THF (100 mL) and water (100 mL) were added osmium tetroxide (4% in water; 6.3 mL, 0.80 mmol) and sodium periodate (25.7 g> 120.0 mmol). The mixture was stirred at ambient temperature. After 30 min, saturated aqueous sodium bicarbonate was added and and the mixture was extracted with ethyl acetate (3x). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated.
Step D: tert-Butyl 2-ch1oro-6-(2,2,2-trifiuoro-l-hydroxyethyl)isonicotinate To a solution of tert-butyl 2-chloro-6-formylisonicotinate (1.5 g, 6.2 mmol) in THF (40 mL) were added (trifluoromethyl)trimethylsilane (1.49 mL, 4.31 mmol) and ground 4A° molecular sieves. The mixture was cooled to 0 0C and TBAP (1.0 M in THF; 1.86 mL, 1.86 mmol) was added dropwise. The mixture was warmed to ambient temperature. After 30 min, additional (trifluoromethyl)trimethylsilane (0.5 mL, 1.44 mmol), TBAP (1.0 M in THF; 0.62 mL, 0.62 mmol) and ground 4A° molecular sieves were added. After 30 min, the mixture was filtered with Celite. Aqueous 1 N HCl was added to the filtrate and the filtrate was extracted with ethyl acetate (3x). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% hexanes — * 95% hexanes / ethyl acetate) gave the title compound (1.4 g). MS 312.2 (M+l),
Step E: fert-Butyl 2-(2,4-difluorophenyl)-6-(2.2,2-trifluoro-l-hydroxyethyl)isonicotinate
To a solution of tert-butyl 2-chloro-6-(2,2,2-trifluoro-l- hydroxyethyl)isonicotinate (0.5 g, 1.6 mmol) in toluene (15 mL) were added (2,4-difluorophenyl)boronic acid (0,38 g, 2.41 mmol), palladium(Il) acatate (36.0 mg, 0.16 mmol), 2-dicyclohexy!phosphino-2',4',6I- triisopropylbiphenyl (76.0 mg, 0.16 mmol) and potassium phosphate tribasic (1.02 g, 4.81 mmol). The mixture was degassed and heated to 100 0C. After 1 h, saturated aqueous sodium bicarbonate was added and and the mixture was extracted with ethyl acetate (3x). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% hexanes → 80% hexanes / ethyl acetate) gave the title compound (0.56 g). MS 390.3 (M+l).
Step F: 2-(2.4-Difluorophenyl)-6-(2,2,2-trifluoro-l-hydroxyethyl)isonicotinic acid
To a solution of tert-butyl 2~(2,4-difluorophenyl)-6-(2,2,2-trifluoro-l- hydroxyethyl)ϊsonicotinate (0.56 g, 1.44 mmol) in dichloromethane (3 mL) was added trifluoroacetic acid (3 mL). The mixture was stirred at ambient temperature. After 18 h, additional trifluoroacetic acid (1 mL) was added and the mixture was stirred at ambient for 1 h. The mixture was concentrated to dryness to give the title compound (0.43 g). MS 334.2 (M+l).
Step G: N-(dRVl-F6-nj-Difluoroethvn-l-oxidopyridin-3-yl]ethyli-2-r2.4-difluorophenvlV6-f2.2.2- trifluoro- 1 -hydroxyethy Disonicotinamide
To a solution of 2-(2,4-difluorophenyl)-6-(252,2-trifiuoro-l- hydroxyethyl)isonicotinic acid (0.15 g, 0.45 mmol) in DMF (2.5 mL) were added hydrochloride salt of
(li?)-l-[l-oxido-6-(trifluoromethyl)pyridin-3-yl]ethanamine (0.16 g, 0.59 mmol), EDC (0.17 g, 0.90 mmol), HOAT (61.3 mg, 0.45 mmol) and triethyiamine (0.38 mL, 2.7 mmol). The mixture was stirred at
60 0C, After Ih5 the mixture was cooled to ambient temperature and saturated aqueous ΝaHCθ3 was added. The mixture was extracted with ethyl acetate (3x). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. The mixture was suspended in dichloromethane and the solid was filtered. The solid cake was washed with cold dichlorom ethane and dried under hi-vac. The product was treated with HCl (2.0 M in ether) to give the hydrochloride salt of the title compound (0.18 g). HRMS 522.1063 (M+l). 1H NMR (400 MHz, CDs OD): δ 8.48 (s, IH); 8.17 (s, IH); 8.09-7.99 (m, 2H); 7.89 (d, J= 8.4 Hz, IH); 7.65 (d, J= 8.4 Hz, IH); 7.10 (t, J= 9.1 Hz, 2H); 5.28-5.18 (m, 2H); 1.62 (d, J- 7.2 Hz, 3H).
EXAMPLE 1.87
Figure imgf000103_0001
6-Isopropyl-5'-methvl-N- { ( IJt)- 1 -[2-(trifluoromethv1)pyrimldm-5-yllethyl} -2,2'-bipyridine-4- carboxamide
Step A: Methyl 2-chloro-6-isopropenylisonicotinate To a solution of 2-chloro-6-isopropenylisonicotinic acid (0.25 g, 1.27 mmol) in dichloromethane (4.7 mL) and methanol (1.6 mL) was added (diazomethyl)(trimethyl)silane (0.63 mL, 1.27 mmol). After the addition, the mixture was concentrated and carried onto the next step. MS 212.0 (M+l).
Step B: Methyl 6-isopropenyl-5'-methyl-2,2'-bipyridine-4-carboxyiate
To a solution of methyl 2-chloro-6-isopropenylisonicotinate (0.5 g, 2.36 mmol) in DMF (12 mL) were added 5-methyl-2-(4,4J5,5-tetramethyl-l,3,2-dioxaborolan-2-yI)pyridine (1.3 g, 5.9 mmol), palladium(II)acetate (26.5 mg, 0.12 mmol), cesium carbonate (1.54 g, 4.72 rnmol), dichloro[l,r- bis(diphenylphosphino)ferrocene]palladjum(ll) dichloromethane adduct (0.13 g, 0.24 mmol) and copper(I) chloride (0.23 g, 2.36 mmol). The mixture was purged with argon and heated to 100 0C. After 45 min, saturated aqueous NaHCO3 was added. The mixture was extracted with ethyl acetate (3x). The combined organic extracts were washed with water (3x), brine, dried over sodium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% hexanes → 75% hexanes / ethyl acetate) gave the title compound (0.55 g). MS 269.1 (M+l).
Step C: Methyl 6-isopropyl-5'-methyl-2.2'-bipyridine-4-carboxylate To a solution of methyl 6-isopropenyl-5'-methyl-2,2'-bipyridine-4-carboxyIate (0.25 g, 0.93 mmol) in ethanol (9.3 mL) was palladium (10% on carbon; 49.6 mg, 0.047 mmol). The mixture was purged with hydrogen (3x) and stirred under hydrogen (1 atm). After 35 min, the mixture was filtered with Celite and the filtrate was concentrated. MS 271.2 (M+ 1).
Step D: 6~Isopropyl-5'-methyl-2,2'-bipyridine-4-carboxylic acid
To a solution of methyl 6-isopropyl-51-methyl-2,2'-bipyridine-4-carboxylate (275 rag, 1.02 mmol) in methanol (10 mL) was added sodium hydroxide (1.0 M in water; 2.03 mL, 2.03 mmol). The mixture was heated to 50 C. After 45 min, HCl (1.0 M in water; 2.03 mL; 2.03 mmol) was added and the mixture was concentrated to give the sodium chloride salt of the title compound (0.32 g). MS 257.1 (M+l).
Step E: 6-Isopropyl-5'-methvi-N-((lif)-l-[2-(trifiuoromethyl)pyrimidin-5-yllethyl}-2.2'-bipyridine-4- carboxarnide To a solution of 6-isopropyl-5'-methyl-2,2'-bipyridine-4-carboxy!ic acid (25.0 mg, 0.07 mmol) in DMF (0.3 mL) were added hydrochloride salt of (lR)-l-[2- (trifluoromethyl)pyrimidin-5-yl]ethanamine (22.1 mg, 0.08 mmol), HATU (38.2 mg, 0.10 mmol) and diisopropylethylamine (58.5 μL, 0.34 mmol). The mixture was stirred at ambient temperature. After 20 min, the mixture was purified by reverse phase chromatography (C-18, 95% water / acetonitriie — * 25% water / acetonitriie with 0.1 % trifluoroacetic acid) gave the title compound (24 mg). HRMS 430.1850 (M+l). 1H NMR (400 MHz, CDCh ): δ 8.96 (s, 2H), 8.48 (s, IH), 8.43 (d, J- 8.1 Hz, IH), 8.37 (s,lH), 7.67 (d, /= 8.2 Hz, IH), 7.63 (s, IH)1 6.96 (d, J= 6.7 Hz, IH), 5,44-5.35 (m, IH), 3.24-3.14 (m, IH), 2.42 (s, 3H), 1.74 (d, J= 7.2 Hz, 3H), 1.37 (d, J- 6.9 Hz, 6H).
EXAMPLE 2.3
Figure imgf000104_0001
N-[Y 1 R)- 1 -(3 -Methyl- 1 ,2,4-oxadiazol-5-yBethyl1-2,6-bis(4-methylphenvI)pyrimidine-4-carboxamide Step A: Methyl 2,6-bis(4-methylphenyl)pyrimidine-4-carboxyiate To a solution of methyl 2,6-dichloropyrimidine-4-carboxylate (0.39 g; 1.87 mmol) in DMF (15 mL) were added (4-methyIphenyl)boronic acid (0.84 g, 6.17 mmol), potassium phosphate tribasic (0.79 g, 3.74 mmol) and dichloro[l,r-bis(diphenylphosphino)ferrocene]palladiura(π) dichloromethane adduct (0.15 g, 0.19 mmol). The mixture was heated to 800C. After 16 h, the mixture was cooled to ambient temperature. Saturated aqueous sodium bicarbonate was added and and the mixture was extracted with ethyl acetate (3x), The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% hexanes -→ 70% hexanes / ethyl acetate) gave the title compound (0.31 g). MS 319.2 (M+ 1).
Step B: 2,6-Bis(4-methylphenvDpyrimidine-4-carboxylic acid
To a solution of methyl 2,6-bis(4-methylphenyl)pyrimidine-4-carboxylate (0.31 g, 0.98 mmol) in THF (10 mL) and water (10 mL) were added sodium hydroxide (1.0 M in water; 2.05 mL, 2.05 mmol). The mixture was stirred at ambient temperature. After 18 h, HCl (1.0 M in water) was added and the mixture was extracted with dichloromethane (3x). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. MS 305.1 (M+l).
Step C: N-[riJ?)-l-(3-Methyl-1.2.4-oxadiazol-5-vnethvn-2.6-bis(4-methylphenyl)pyrimidine-4- carboxamide
To a solution of 2,6-bis(4-methylphenyl)pyrimidine-4-carboxylic acid (15.0 mg, 0.05 mmol) in DMF (1 mL) were added hydrochloride salt of (lΛ)-l-(3-methyl-l,2,4-oxadiazol-5- yl)ethanamine (14.7 mg, 0.07 mmol), EDC (23.8 mg, 0.15 mmol), HOBT (22.6 mg, 0.15 mmol) and diisopropylethylamine (34.4 μL, 0.20 mmol). The mixture was stirred at ambient temperature. After 18 h, the mixture was purified by reverse chromatography (C- 18, 95% water / acetonitrile → 5% water / acetonitrile with 0.1% trifluoroacetic acid) to give the trifluoroacetate salt of the title compound (33 mg). HRMS 414.1924 (M+l). 1H ΝMR (499 MHz, DMSO): δ 9.80 (d, J= 8.3 Hz, IH); 8.66 (d, J= 8.0 Hz, 2H); 8.37-8.29 (m, 3H); 7.42 (t, J = 9.1 Hz, 4H); 5.55-5.47 (m, IH); 2.43 (d, J = 3.4 Hz, 6H); 2.35 (s, 3H); 1.73 (d, J= 7.1 Hz, 3H).
EXAMPLE 3.13
Figure imgf000105_0001
5-f2.4-Difluorophenyl')-N-f (1 R)- 1-f l-oxido-6-(trifluoromethyDpyridin-3-yl]ethyUnicotinamide Step A: 5~(2,4-Difluorophenyl)nicotinic acid
To a solution of 5-bromonicotinic acid (0.5 g, 2.48 mmol) in DMF (7.4 niL) and water (2.5 mL) were added (2,4-difluorophenyl)boronic acid (0.43 g, 2.72 mmol), palladium acetate
(27.8 mg, 0.12 mmol), 3,3',3"-phosphinidynetris (benzensulfonic acid) trisodium salt (0.21 g, 0.37 mmol) and diisopropylamine (1.23 mL, 8.66 mmol). The mixture was heated to 800C. After 1.5 h, the mixture was cooled to ambient temperature and filtered. The filtrate was purified by reverse chromatography (C- 18, 95% water / acetonitrile → 5% water / acetonitri Ie with 0.1% trifluoroacetic acid). The product was converted to hydrochloride salt by adding HCl (2.0 M in ether) and concentrated to give the hydrochloride salt of the title compound (0.65 g). MS 236.0 (M+ 1).
Step B: 5-(2,4-Difluorophenvπ-N-{(lJ?)-l-[l-oxido-6-(trifluoromethyl)pyridin-3-yllethyU nicotinamide To a solution of 5-(2,4-difluorophenyl)nicotinic acid (40.0 mg, 0.15 mmol) in DMF (0.7 mL) were added hydrochloride salt of (lR)-l~[l-oxido-6-(trifluoromethyl)pyridin-3- yl)ethanamine (49.3 mg, 0.18 mmol), EDC (33 ,9 mg, 0.18 mmol), HOBT (22.6 mg, 0.15 mmol) and triethylamine (0.10 mL, 0.74 mmol). The mixture was stirred at ambient temperature for 18 h. Purification by reverse chromatography (C-18, 95% water / acetonitrile → 25% water / acetonitrile with 0.1% trifluoroacetic acid) gave the title product, which was converted to hydrochloride salt using 2.0 M HCl in ether (47 mg). HRMS 424.1086. 1H ΝMR (400 MHz, CD3 OD): δ 9.22 (s, IH); 9.15 (s, IH); 9.00 (s, IH); 8.52 (s, IH); 7.92 (d, J= 8,4 Hz, IH); 7.83-7.73 (m, IH); 7.70 (d, J= 8.4 Hz, IH); 7.31- 7.21 (m, 2H); 5.33-5.25 (m, IH); 1.67 (ά, J= 7.1 Hz, 3H).
Figure imgf000106_0001
5-(4-FIuorophenyl)-6-isopropoxy-N-[( IR)-I -(3-methyl- 1 ,2 t4~oxadiazol-5-vDethyl1 nicotinamide (example 3.24) and 5-(4-fluorophenylVl-isopropyl-N-[(lRVl-G-methvl-l,2.4-oxadiazol-5-yl)ethvll-6-oxo-1.6- dihydropyridine-3-carboxamide (example 5.61) Step A: Methyl 5-(4-fluorophenyl)-6-oxo-L6-dthvdropyridine-3-carboxylate To a solution of methy! 5-bromo-6-oxo-l,6-dihydropyridine-3-carboxylate (0.50 g, 2,16 mmol) in DMF (8.1 mL) and water 2.7 mL) were added (4-fluorophenyl)boronic acid (0.38 g, 2,69 mmoϊ), palladium(II) acetate (36.3 rag, 0.16 mmol), tris(3-sulfonatophenyl)phosphine hydrate sodium salt (0.31 g, 0.49 mmol) and dϋsopropylamine (1.54 mL, 10.8 mmol). The mixture was heated in the microwave reactor at 125 0C for 15 min. The mixture was filtered and water was added to the filtrate, The mixture was extracted with ethyl acetate and the organic layer was washed with water (3x), brine, dried over sodium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% dichloromethane → 70% dichloromethane / ethyl acetate) gave the title compound (0.35 g). MS 248.1 (M+ 1).
Step B: Methyl 5-(4-fluorophenyl)-6-isopropoxynicotinate and methyl 5-(4-fluorophenyl)-l-isopropyl-6- OXO- 1 ,6-dihydropyridine-3 -carboxy late
To a solution of methyl 5-(4-fiuorophenyl)-6-oxo-l,6-dihydropyridine-3- carboxylate (0.18 g, 0.72 mmol) in DMF (3 mL) were added 2-iodopropane (0.61 g, 3,58 mmol) and cesium carbonate (0.35 g, 1.07 mmol). The mixture was stirred at ambient temperature. After 2 h, the mixture was filtered and washed with methanol. The filtrate was concentrated to remove methanol. The DMF solution was carried onto the next step.
Step C: 5~(4-Fluorophenyl)-6-isopropoxynicotinic acid and 5-(4-fluorophenyl)-l-isopropyl-6-oxo-l,,6- dihydropyridine-3-carboxylic acid
To a solution of methyl 5-(4-fluorophenyI)-6-isopropoxynicotinate and methyl 5- (4-fluorophenyl)-l-isopropyl-6-oxo-l,6-dihydropyridine-3 -carboxy late in DMF (5 mL) and water (2 mL) were added sodium hydroxide (1.0 M in water; 1.43 mL, 1.43 mmol). The mixture was stirred at 50 0C. After 1 h, additional sodium hydroxide (1.0 M in water; 1.43 mL, 1.43 mmol) was added. After 2 h, HCl (1.0 M in water) was added and the mixture was extracted with dichloromethane (3x). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. The desired products were still in the DMF layer. The DMF solution was carried onto the next step.
Step D: 5-(4-Fluoropheiiyl)-6-isopropoxy-N-[(li?)-l-(3-methyl-l,2,4-oxadiazol-5-yl)ethyπnicotinamide (example 3.24) and 5-(4-fluorophenyl)-l-isopropyt-N-[dR)-l-(3-methyl-l,2.4-oxadiazol-5-yl)ethyl1-6- oxo-l,6-dihydropyridine-3-carboxamide (example 5.61)
To a solution of 5-(4-fluorophenyl)-6-isopropoxynicotinic acid and 5-(4- fluorophenyl)-l-isopropyl-6-oxo-l,6-dihydropyridine-3-carboxylic acid (50 mg, 0.09 mmol) in DMF (0.5 mL) were added hydrochloride salt of (lφ-l-tS-methyl-l^^-oxadiazol-S-ylJethanamine (21.8 mg, 0.11 mmol), HATU (0.5 M in DMF; 0.27 mL, 0.14 mmol) and diisopropylethylamine (63 μL, 0.36 mmol).
The mixture was stirred at ambient temperature. After 10 min, HCl (1.0 M) was added and the mixture was purified by reverse chromatography (C-18, 95% water / acetonitrile → 5% water / acetonitrile with 0.1% trifluoroacetic acid) to give the N-alkylated product, 5-(4-fluoropheny I)-I- isopropyl-N-[( IiJ)-I -(3 - methyl-l^^-oxadiazol-S-y^ethyll-δ-oxo-l^-dmydropyridine-S-carboxamide (example 5.61) (20.9 mg). HRMS 385.1685. 1H NMR (^O MHz1 CDCh ): δ 8.21 (d, J = 2.5 Hz5 IH); 7.69-7.63 (m, 3H); 7.12 (t, J= 8.5 Hz, 2H); 6.52 (d, J= 7.7 Hz, IH); 5.60-5.51 (m, IH); 5.37-5.27 (m, IH); 2.41 (s, 3H); 1.70 (d, J= 7.1 Hz, 3H); 1.45 (dd, J= 6.8, 2.2 Hz, 6H). The o-alkylated product was repurified by reverse chromatography (C-18, 95% water / acetonitrile — * 5% water / acetonitrile with 0,05% ammonium hydroxide) to give 5-(4-fluorophenyl)-64sopropoxy-N-[(lR)-l-(3-methyi-l,2,4-oxadiazol-5- yl)ethyl]nicotinamide (example 3.24) (16.1 mg). HRMS 385.1679. 1H NMR (400 MHz, CDCb ): δ 8.59 (s, IH); 8.01 (d, J- 2.3 Hz, IH); 7.55 (dd, J = 8.3, 5.4 Hz, 2H); 7.16-7.08 (m, 2H); 6.63 (d, J= 7.7 Hz5 IH); 5.63-5.55 (m, IH); 5.51-5.43 (m, IH); 2.40 (s, 3H); 1.71 (d, J= 7.1 Hz, 3H); 1.35 (d, J = 6.2 Hz1 6H).
EXAMPLE 4.1
Figure imgf000108_0001
5-(2-Fiuoro-4-methylphenyl)-N-Kl^):,l-(3:methyl-1.2.4-oxadiazol-5-yl)ethyllnicotinamide 1-oxide Step A: Ethyl 5-(2-fluoro-4-methylpιhenyl)nicotinate To a solution of ethyl 5-bromonicotinate (0.58 g, 2.53 mmol) in acetonitrile (15 mL) and water (5 mL) were added (2-fluoro-4-methylphenyl)boronic acid (0.47 g, 3.04 mmol), 3,3',3"- phosphinidynetris(benzenesulfonic acid) trisodium salt (0.22 g, 0.38 mmol), palladium(II)acetate (28.4 mg, 0.13 mmol) and dϋsopropylamine (0.90 mL, 6.32 mmol). The mixture was heated to 800C. After 1 h, the mixture was cooled to ambient temperature and saturated aqueous ΝaHCC>3 was added. The mixture was extracted with ethyl acetate (3x). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% hexanes → 70% hexanes / ethyl acetate) gave the title compound (0.67 g). MS 260.1 (M+l).
Step B: 5-(2-Fluoro-4-methyiphenyDnicotinic acid To a solution of ethyl 5-(2-fluoro-4-methylphenyI)nicotinate (0.67 g, 2.58 mmol) in methanol (10 mL), THF (10 mL) and water (5 mL) were added sodium hydroxide (1.0 M in water; 5.17 mL, 5.17 mmol). The mixture was stirred at ambient temperature. After 40 min, HCl (1.0 M in water; 5.17 mL, 5.17 mmol) was added and the mixture was concentrated to give the sodium chloride salt of the title compound (0.87 g). MS 232.1 (M+l).
Step C: 5-(2-Fluoro-4-methylphenyl)nicotinic acid I -oxide
To a solution of 5-(2-fluoro-4-methylphenyl)nicotinic acid (0.15 g, 0.43 mmol) in dichloromethane (5 mL) and methanol (3 mL) was added 3-chloroperbenzoic acid (70%; 0.16 g, 0.65 mmol). The mixture was stirred at ambient temperature. After 18 h, additional 3-chloroperbenzoic acid (70%; 0.19 g, 0.86 mmol) was added. The mixture was continued to stir at ambient temperature. After 24 h, additional 3-chloroperbenzoic acid (70%; 0.19 g, 0.86 mmol) was added. After 18 h, the mixture was concentrated. Purification by reverse chromatography (C- 18, 95% water / acetonitrile → 25% water / acetonitrile with 0.1% trifluoroacetic acid) gave the title compound (70 mg). MS 248.0 (M+l).
Step D: 5-f2-Fluoro-4-methylphenylVN-rfli?Vl-f3-methvI-L2,4-oxadiazol-5-vDethyllnicotinamide 1- oxide
To a solution of 5-(2-fluoro-4-methylphenyl)nicotinic acid 1-oxide (22.6 mg, 0.09 mmol) in DMF (0.5 mL) were added hydrochloride salt of (lR)-l-(3-methyl-l,2,4-oxadiazol-5- yl)ethanamine (23.8 mg, 0.12 mmol), EDC (26.3 mg, 0.14 mmol), HOBT (15.4 mg, 0.10 mmol) and diisopropylethylamine (64 μL, 0.37 mmol). The mixture was stirred at ambient temperature. After 72 h, the mixture was purified by reverse chromatography (C-18, 95% water / acetonitrile → 25% water / acetonitrile with 0.1% trifluoroacetic acid) to give the title compound (18.4 mg). FIRMS 357.1367 (M+l). 1H NMR (400 MHz, CDCl 3 ): δ 9.02 (s, IH); 8.73 (d, J= 7.6 Hz, IH); 8.53 (s, 1 H); 7.98 (s, IH); 7.32 (t, J = 8.0 Hz, IH); 7.08 (d, J= 8.0 Hz, IH); 7.02 (d, J= 11.8 Hz, IH); 5.60-5.51 (m, IH); 2.42 (s, 3H); 2.29 (s, 3H); 1.80 (d, J= 7.1 Hz, 3H).
EXAMPLE 5.88
Figure imgf000109_0001
3-(4-Fluorophenvn-N-rdJ?Vl-f3-methyl-L2.4-oxadiazol-5-vl)ethvl1-2-oxo-2H-1.2'-bipyridine-5- carboxamide
Step A: Methyl 5-(4-1IuOrOPhBnVlVo-OXO- l,6-dihydropyridine-3-carboxvlate To a solution of methyl 5-bromo-6-oxo-l56-dihydropyridine-3-carboxylate (0.5 g, 2.16 mmol) in DMF (8.1 mL) and water (2.7 mL) were added (4-fluorophenyl)boronic acid (0.38 g, 2.69 rnmof), paliadium(II)acetate (36.3 mg, 0.16 mmol), tris(3-sulfonatophenyl)phosphine hydrate sodium salt (0.31 g, 0.49 mmol) and diisopropylamine (1.54 mL, 10.77 mmol). The mixture was heated in the microwave reactor for 15 min at 125 0C. The mixture was filtered and water was added to the filtrate. The mixture was extracted with ethyl acetate (3x). The combined organic extracts were washed with water (3x), brine, dried over sodium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% dichlroomethane → 70% dichloromethane / ethyl acetate) gave the title compound (0.35 g). MS 248.1 (M+l).
Step B: Methyl 3-f4~fluorophenyI)-2-oxo-2H-l,2'-bipyridine-5-carboxylate
To a solution of methyl 5-(4-fluorophenyl)-6-oxo-l,6-dihydropyridine-3- carboxylate (77.0 mg, 0.31 mmol) in dioxane (2.1 mL) were added 2-bromopyridine (0.15 g, 0.92 mmol), trans-(lR,2R)-N,N'-bismethyl-ls2-cyclohexanediamine (17.7 mg, 0.13 mmol) and potassium carbonate (86.0 mg, 0.62 mmol). The mixture was heated in the microwave reactor at 120 0C for 1 h then heated in an oil bath at 80 0C for 8 h. The mixture was cooled to ambient temperature and dichloromethane was added. The mixture was washed with water, sat. NaHCO3, brine and dried with sodium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% dichlroomethane → 75% dichloromethane / ethyl acetate) gave the title compound (94 mg). MS 325.1 (M+l).
Step C: 3-(4-FluorophenylV2-oxo-2H-1.2'-bipyridine-5-carboxylic acid
To a solution of methyl 3-(4-fluorophenyl)-2-oxo-2H-l,2'-bipyπdme-5- carboxylate (93.0 mg, 0.29 mmol) in dioxane (5 mL) and water (2 mL) was added NaOH (1.0 M in water; 0.36 mLP 0.36 mmol). The mixture was stirred at 60 C. After 1,25 h, the mixture was cooled to ambient temperature and HCl (1 ,0 M in water; 0.36 mL, 0.36 mmol) was added. The sample was put under the lyophilizer to give the sodium chloride salt of the title compound (1 11 mg). MS 31 1.1 (M+l).
Step D: 3-f4-Fluorophenvn-N-rf li;Vl-G-methyl-1.2,4-oxadiazol-5-vnethvn-2-oxo-2H-1.2'-bipyridine-5- carboxamide To a solution of 3-(4-fIuorophenyl)-2-oxo-2H- 1 ,2'-bipyridine-5-carboxylic acid
(20.0 mg, 0.05 mmol) in DMF (0.5 mL) were added hydrochloride salt of (l£)-l-(3-methyI~ 1,2,4- oxadiazol-5-yl)ethanamine (13.6 mg, 0.07 mmol), ΗATU (0.5 M in DMF; 0.16 mL, 0.08 mml) and diisopropylethylamine (36 μL, 0.21 mmol). The mixture was stirred at ambient temperature. After 30 min, the mixture was purified by reverse chromatography (C- 18, 95% water / acetonitrile → 25% water / acetonitrile with 0.1% trifluoroacetic acid) to give the title compound (20 mg). ΗRMS 420.1470 (M+l). Η ΝMR (400 MHZ, CDCh ): 6 8.62 (d, J= 4.8 Hz, IH); 8.53 (d, J= 2.5 Hz, IH); 7.94-7.83 (m, 3H); 7.70 (dd, J= 8.3, 5.4 Hz, 2H); 7.41 (t, J= 5.8 Hz, IH); 7.12 (t, J= 8.5 Hz, 2H); 6.66 (d, J- 7.7 Hz5 IH); 5.60-5.51 (m, IH); 2.40 (s, 3H); 1.69 (d, J= 7.1 Hz, 3H).
Figure imgf000111_0001
5-f4-FluofophenylVl-f3-hvdroxy-3-methylbutan-2-vn-N-rClR)-l-('3-methvl-L2.4-oχadiazol-5-vl)ethvll- 6-oxo- 1 ,6-dihydropyridine-3-carboxamide Step A: Methyl 5-bromo~6-oxo-l-(3-oxobutan-2~viπ,6-dihydropyridine-3-carboxylate
To a solution of methyi-S-bromo-δ-oxo-l^-dihydropyridine-θ-carboxylate (10.0 g, 43.1 mmol) and cesium carbonate (16.9 g, 51.7 mmol) in N,N-dimethylformamide (144 mL) was added 3-bromo-2-butanone (7.8 g, 51.7 mmol). The reaction mixture was stirred at ambient temperature. After 20 min, saturated aqueous sodium bicarbonate and water were added. The mixture was extracted with ethyl acetate (3x). The combined organic extracts were washed with water (3x), brine, dried over magnesium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% dichloromethane — * 50% dichloromethane/ ethyl acetate) gave the title compound. MS 302.1 (M).
Step B: Methyl 5-f4-fluorophenyl)-6-oxo-l-(3-oxobutan-2-yl)-L6-dihvdropyridine-3-carboxylate To a solution of methyl 5-bromo-6-oxo- 1 -(3-oxobutan-2-yl)- 1 ,6-dihydropyridine-
3-carboxylate (11.3 g, 37.4 mmol) in N,N-dimethylformamide (112 mL) and water (37 mL) were added 4-fluorophenylboronic acid (6.28 g, 44.9 mmol), palladium acetate (0.17 g, 0.75 mmol), 3,3 \3"- phosphinidynetris(benzenesulfonic acid) trisodium salt (1.28 g, 2.24 mmol) and diisopropylamine (13.3 mL, 94.0 mmol). The reaction mixture was heated to 80 0C. After 30 mm, the mixture was cooled to ambient temperature. Saturated aqueous sodium bicarbonate and water were added. The mixture was extracted with ethyl acetate (3x). The combined organic extracts were washed with water (3x), brine, dried over magnesium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% dichloromethane → 80% dichloromethane/ ethyl acetate) gave the title compound. MS 318.2 (M+l). Step C: Methyl 5-f4-fluorophenyl')-l-(3-hydroxyM-3-methylbutaii-2-yl)-6-oxo-l,6-dihydropyridine-3- carboxyiate
To a solution of methyl 5-(4-fluorophenyl)-6-oxo-l-(3-oxobutan-2-yl)-l,6- dihydropyridine-3-carboxylate (1 1.1 g, 35.0 mmol) in tetrahydrofuran (175 mL) at 0 0C was added methylmagnesium bromide (3,0 M in JHF; 14.0 mL, 42.0 mmol). After 20 min, the mixture was quenched with saturated aqueous sodium bicarbonate. The mixture was cooled to ambient temperature and extracted with ethyl acetate (3x). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated. Purification by silica gel chromatography (100% dichloromethane — *■ 80% dichloromethane/ ethyl acetate) gave the title compound. MS 334.2 (M+l).
Step D: 5-(4-Flυorophenyl)-l:(3-hvdroxy-3-methylbutan-2-yπ-6-oxo-l,6-dihydropyridiRe-3-carboxylic acid
To a solution of methyl 5-(4-fluorophenyl)-l-(3-hydroxy-3-methylbutan-2-yl)-6- oxo-l,6-dihydropyridine-3-carboxylate (400 mg, 1.20 mmol) in tetrahydrofuran (6 mL) and water (2 mL) was added sodium hydroxide (55 mg, 1.38 mmol). The resulting mixture was heated to 50 °C. After 140 min, the mixture was cooled to ambient temperature. Hydrogen chloride (0.113 mL, 1.38 mmol) was added and the mixture was concentrated to give the sodium chloride salt of the title compound. MS
342,2 (M+Na).
Step E: 5-(4-Fluorophenvn-l-(3-hvdroxy-3-methylbutan-2-yl)-N-r(lRVl-(3-methvl-l,2,4-oxadiazol-5- yl)ethyl]-6-oxo-1.6-dihydropyridine-3-carboxamide
To a solution of the sodium chloride salt of 5-(4-fluorophenyl)-l-(3-hydroxy-3- methylbutan-2-y l)-6-oxo- l,6-dihydropyrϊdine-3-carboxylic acid (177 mg, 0.46 mmol) in JV9JV- dimethylformamide (2 mL) were added (li?)-l-(3-methyl-l,2,4-oxadiazol-5-yl)ethanamine hydrochloride salt (110 mg, 0.55 mmol), EDC (105 mg, 0.55 mmol), l-hydroxy-7-azabenzotriazole (6 mg, 0.05 mmol) and N-methylmorpholine (0.121 mL, 1.10 mmol). The reaction mixture was stirred at ambient temperature. After 18 h, water was added. Purification by reverse phase HPLC (C- 18, 95% water/ acetonitrile -→ 15% water/ acetonitrile with 0.1% trifluoroacetic acid) gave the title compound. HRMS 429.1973 (M+l).
Examples 5.135 and 5.136
Figure imgf000113_0001
5^4-FIuorophenylVl-rf2RV3-hvdroxy-3-metfavibutan-2-vn-N-rflRVl-f3-methyl-1.2.4-oxadiazol-5- yl)ethyI]-6-oxo-l .6-dihydropyridine-3~carboxamide and 5-(4-Fluorophenyl)-l -|"(2S)-3~hydroxy-3- methylbvitan-2-yll-N-rαRVl-f3-methyl-1.2.4-oxadiazol-5-vDethvl]-6-oxo-1.6-dihvdropyridine-3- carboxamide
Purification of the two dtastereomers by chiral chromatography (Whelk-Ol, 2.1 cm x 25 cm, 60% heptane and 40% isopropanol, 28 raL/ rain) gave the title compounds, EXAMPLE 5.135: HRMS 429.1928 (M+l). 1H NMR (400 MHz, DMSO): δ 9.05 (d, J= 7.4 Hz, 1 H); 8.46 (s, 1 H); 8.13 (s, 1 H); 7.76 (t, J= 6.9 Hz, 2 H); 7.25 (t, J- 8.7 Hz, 2 H); 5.76 (s, 1 H); 5.35 (t, J= 7.2 Hz, 1 H); 5.15 (d, J= 8.1 Hz, I H); 4.95 (s, 1 H); 2.33 (s, 3 H); 1.59 (d, J= 7.2 Hz, 3 H); 1.39 (d, J= 7.1 Hz, 3 H); 1.25 (s, 3 H); 0.91 (s, 3 H). Example 5.136: HRMS 429.1931 (M+l). 1H NMR (400 MHz, DMSO): δ 9.03 (d, J= 12 Hz, 1 H); 8.47 (s, 1 H); 8.14 (s, 1 H); 7.76 (t, J- 6.8 Hz, 2 H); 7.25 (t, J= 8.7 Hz, 2 H); 5.35 (t, J- 7.2 Hz, 1 H); 5,15 (d, J= 8.1 Hz, 1 H); 4.94 (s, 1 H); 2.33 (s, 3 H); 1.59 (d, J = 7.1 Hz, 3 H); 1.39 (d, J= 7.1 Hz, 3 H); 1.25 (s, 3 H); 0.91 (s, 3 H).
Assay
In vivo rat visceral pain model
Male Sprague-Dawley rats, weighing 150 - 180 g (max. range per experiment = 40 g) at the beginning of the experiments. Animals will be delivered to the laboratory at least 5 days before the experiments during which time they are acclimatized to laboratory conditions. Rats will be housed in groups of 4, 5 or 6 in macrolon cages (41 x 25 x 14 cm or 44 x 28 x 19 cm) on wood with free access to food and water until tested (or as indicated otherwise). The animal house will be maintained under artificial lighting (12 hours) between 7.00 and 19.00 in a controlled ambient temperature of 21 ± 3°C, and relative humidity maintained at 40-70%. Information related to any clinical signs and mortality will be archived with the study materials. After overnight food-deprivation, male Sprague-Dawley rats are slightly anesthetized (isoflurane) and injected with 1% acetic acid into the colon (1.5 ml) using a cannula of 5 cm in length. After a recovery period of 75 minutes, rats are again slightly anesthetized (isoflurane) and a latex balloon of 1.5 cm in length tightly attached to a catheter is inserted via the anus into the descending colon and rectum. Anesthesia is then immediately discontinued, 15 minutes later, the test substance is administered p. o. 60 minutes after administration, the balloon is filled with 1.2 ml of water and the number of abdominal contractions is counted for 10 minutes.
10 rats are studied per group. The test is performed blind. The test substance will be evaluated at 3 doses, and compared with the vehicle group. Rats will be euthanized at the end of the experiments by exposure to a mixture of O2/CO2 (20%/80%) followed by CO2. Data will be analyzed by comparing treated groups with vehicle control using Mann Whitney U tests.
In vivo L5 spinal nerve ligation model a. Surgery and post-operative care For the spinal nerve ligation (SNL) procedure, male Sprague Dawley rats (100-200 g; Harlan) are anesthetized using isoflurane (1-5%; inhalation). Using aseptic technique, a dorsal midline incision is made from approximately spinal nerve L3 to S2. A combination of sharp and blunt dissection is used to expose the L6/S1 posterior interarticular process. The L6 transverse process is visualized and removed, and the L4 and L5 spinal nerves are exposed distal to their emergence from the intervertebral foramina. The L5 nerve is then tightly Iigated with 6-0 silk suture. The muscle is closed with 4-0 absorbable suture and the skin is closed with wound clips. Postoperative monitoring is carried out to assure that animals are exposed to the least amount of pain as possible, Animals are housed in pairs on bedding and are monitored (2x) daily for three days post-operatively by Laboratory Animal Resource staff and then daily by investigator for any signs of possible distress. b. Behavioral testing Prior to surgery, rats are tested for pre-surgery mechanical hind paw withdrawal thresholds by applying a series of calibrated von Frey filaments (0.25 - 15 g) to the left hind paw and determining the median withdrawal threshold using the Dixon "up-down" method (Chaplan et al., J Neurosci Meth 53:55, 1994). Rats are placed in individual plastic chambers on an elevated mesh galvanized steel platform and allowed to acclimate for 60 min. Pre-surgery mechanical hind paw withdrawal thresholds are determined, and rats having a threshold <15 g are excluded from the study. Following determination of pre-surgery withdrawal thresholds, rats undergo the SNL procedure described above. Between 28-35 days following the surgical procedure, rats are tested for post-surgery thresholds using the procedure described above, and animals displaying a hind paw withdrawal threshold <4.0 g are considered allodynic (i.e. mechanical hypersensitivity). Effects of test compounds on SNL-induced mechanical hypersensitivity are determined by dosing the compound along with a vehicle control group and a group receiving the positive comparator pregabalin (20 mg/kg, p.o.). Efficacy in the SNL model is evaluated by determining the % reversal of mechanical hypersensitivity using the formula:
Figure imgf000115_0001
At the conclusion of the study, all rats are euthanized using CO2 and plasma and brain tissue are collected for bioanalytical analysis of drug exposures.
In vivo Complete Freunds adjuvant (CFA) model Male Sprague Dawley rats (300-400 g; Charles River) receive an intradermal injection of CFA
(200 ul, 0.5 mg/ml) into the plantar aspect of the left hind paw and are subsequently returned to their cages where they are maintained on soft bedding. 72 hrs following CFA injection rats are tested for post- CFA mechanical hind paw withdrawal thresholds by wrapping the rat in a towel and placing the hind paw (either left or right) in a modified Randall-Sellito paw pinch apparatus (Stoelting, Wood Dale, IL). A plastic bar attached to a lever is placed on the dorsum of the hind paw, and an increasing force is applied to the hind paw until the rat vocalizes or pulls its hind paw away from the bar. The rat's hind paw withdrawal threshold is recorded at that point. The mechanical stimulus is applied to each hind paw 2 times, and the average post-CFA mechanical hind paw withdrawal thresholds are determined for both the left and right hind paw. Following determination of post-CFA withdrawal thresholds, rats receive test compound, vehicle, or the positive comparator naproxen (30 mg/kg, p.o.), and effects of compounds on withdrawal thresholds for the inflamed (CFA) hind paw are determined. Efficacy in the CFA model is evaluated by determining the % reversal of mechanical hypersensitivity using the formula:
(post-drug threshold m]M m - post-CFA threshold ιefthmdpaw)
Figure imgf000116_0001
At the conclusion of the study, all rats are euthanized using CO2 and plasma and brain tissue are collected for bioanaiytical analysis of drug exposures. Cystometry in normal healthy rats
Female Sprague-Dawley rats weighed 250-350 g were housed in a temperature- and light (12-h light/dark cycle)-controlled room, and were allowed access to food and water ad libitum. The animals were anesthetized with urethane (1.0 g/kg, Lp.). Supplemental urethane was given if necessarily. A lower abdominal midline incision was made to expose the bladder, and a polyethylene catheter (PE-50) was inserted into the bladder dome for recording the intravesical pressure and intravesical infusion of physiological saline at the rate of 0.05 ml/min. The intravesical pressure was measured using a pressure transducer, and signal was recorded using a multiple channel data acquisition system (Power lab, AD Instruments, Biopac systems, Colorado Springs, CO) at a sampling rate of 10 Hz. After confirming stable inter-micturtion interval and micturition pressure by intravesical infusion of saline, the drugs were administered intravenously (0.25 ml/kg), ϊntermicturition interval (functional bladder capacity) and micturition pressure (maximum intravesical pressure) were obtained from micturitions prior to dosing (baseline) and between 5 to 30 min after dosing using Chart program (v5,5.4, AD Instruments), and calculated the ratio to baseline.
Cystometry in rat acetic acid-induced hyper-reflexia model Female Sprague-Dawley rats weighed 250-35O g were housed in a temperature- and light
(12-h light/dark cycle)-controlled room, and were allowed access to food and water ad libitum. The animals were anesthetized with urethane (1.0 g/kg, i.p.). Supplemental urethane was given if necessarily. A lower abdominal midline incision was made to expose the bladder, and a polyethylene catheter (PE-50) was inserted into the bladder dome for recording the intravesical pressure and intravesical infusion at the rate of 0.05 ml/min. The intravesical pressure was measured using a pressure transducer, and signal was recorded using a multiple channel data acquisition system (Power lab, AD Instruments, Biopac systems, Colorado Springs, CO) at a sampling rate of 10 Hz. After confirming stable inter-micturtion interval and micturition pressure by intravesical infusion of saline, 0.25% of acetic acid-saline solution was infused at the same infusion rate. After 30-60 mm, drugs were intravenously infused using infusion pumps at a rate of 10 μl/min. Intermicturition interval (functional bladder capacity) and micturition pressure (maximum intravesical pressure) were obtained from micturitions prior to dosing (baseline) and between 30 to 45 min after starting drug infusion using Chart program (v5.5,4, AD Instruments), and calculated the ratio to baseline. Generation of a Human P2Xi andP2X2/3 Stable Cell Line ~ Human P2X3 receptor cDNA (Accession number NM 002559) was subcloned as a 5'XhoI and 3ΗindIII fragment into the expression vector pcDNA5/FRT (Invitrogen). Human P2X2 receptor cDNA (Accession number NM_174873) was subcloned as a 5'EcoRI and 3'NotI fragment into the expression vector pIRESneo2 (BD Biosciences Ciontech). The human P2X3 expression construct was transfected using Lipofectamine 2000 (Invitrogen) into Flp-in - 293 cells (Invitrogen) according to the manufacturer's directions. Cells positive for flp-mediated recombination of rhesus P2X3 were selected using 150 μg/ml hygromycin. The stable human P2X3 cell line was co-transfected with the human P2X2 expression construct using Lipofectamine 2000 as above and co-transfected cells selected using 100 mg/ml hygromycin and 1 mg/ml G418. The stable P2X3 cell line was propagated in DMEM5 10% FBS, 100 μg/m! hygromycin, and 100 units/ml penicillin and 100 μg/ml streptomycin, and maintained at 37° and 95% humidity. The stable P2X2/3 cell line was propagated as above with the addition of 500 μg/ml G418,
Intracellular Calcium Measurement to Assess Antagonist Affinity - A fluorescent imaging plate reader (FLIPR; Molecular Devices) was used to monitor intracellular calcium levels using the calcium-chelating dye Fluo-4 (Molecular Probes). The excitation and emission wavelengths used to monitor fluorescence were 488 nm and 530 nm, respectively. Cells expressing either human P2X3 or human P2X2/3 were plated at a density of 20,000 cells/well (20 μl/well) in 384-well black-wailed plates approximately 20 hours before beginning the assay. On the day of the assay 20 μl of loading buffer (Hank's balanced salt solution, 2.5 mM CaCl2, 20 mM HEPES, 0.1% BSA, 2.5 mM probenecid, TR-40, Fluo-4, and 138 mM NMDG substituted for NaCl) is added and cells dye-loaded for 60 min in the dark at room temperature. Ten minutes prior to adding agonist, the antagonist was added in a volume of 10 μl and allowed to incubate at room temperature. During this period fluorescence data is collected at 3 sec intervals followed by 10 sec intervals. The agonist, α,β-meATP, is added at a 6x concentration ([αjβ-meATP]^! = EC50). Following agonist addition fluorescence was measured at 5 sec intervals and analyzed based on the increase in peak relative fluorescence units (RFU) compared to the basal fluorescence. Peak fluorescence was used to determine the inhibitory effect at each concentration of antagonist by the following equation:
% Inhibition = 100 * (1 - ((RFU(drag) - RFU(coπtro))) / (RFU^Msooniy) - RFU(C01ltr0D)))
In vitro Electrophysiological Assay - Cells expressing human P2X3 receptors were grown to a confluence of 65-85% 20 to 32 hours prior to assay. The cells were dissociated with trypsin, centrifuged, and resuspended in bath solution at a cell density of IxIO6 cells/ml and loaded onto PatchXpress. The bath solution contained 150 mM NaCl, 4 mM KCl, 2 mM CaCl3, 1,2 mM MgCl2, 10 mM HEPES, and 11.1 mM glucose, at pH 7.2. The intracellular solution contained either 140 mM K-aspartate, 20 mM NaCl, 5 mM HEPES, 10 mM EGTA, at pH 7.2 or 30 mM CsCl, 5 mM HEPES, 10 mM EGTA, 120 mM CsF, 5 mM NaF, 2 mM MgC12, pH=7.3 with CsOH. Agonist stock solutions were prepared in HjO and diluted in bath solution prior to use. All antagonists were prepared as 10 mM stock solutions in DMSO and diluted in bath solution prior to use. All experiments were performed on cells under the whole-cell patch clamp configuration at room temperature. Up to 16 individual cells could be patch clamped simultaneously on the PatchXpress instrument. A baseline response was established by repeated CTP (100 μM; for 2 sec.) followed by antagonist incubation for 2 min. in the absence of CTP. After antagonist preincubation 100 μM CTP and antagonist were co-administered to determine the inhibitory effect of the antagonist. These steps were then repeated on the same cell with a range of concentrations of the antagonist. A maximum of five concentrations of antagonist were tested on any individual cell. The control P2X3 current amplitude (ImH∞πtroi)) was taken as an average of the peak current amplitude from the last two agonist additions prior to incubation with an antagonist. The peak P2X3 current amplitude in the presence of an antagonist (Ip2χ3-(dr_g)) was used to calculate the inhibitory effect at each concentration of the antagonist according to the following equation:
% inhibition Of P2X3 =100*(Ip2X3-(conSrol)-Ip2X3-(drug)yip2X3-(contro1)
Each concentration of an antagonist was tested on at least two independent ceils. The concentration of drug required to inhibit P2X3 current by 50% (IC50) was determined by fitting of the Hill equation to the averaged % inhibition data at each concentration:
% of Control =100 • (1 + ([Drug]/IC50)/!χ1
In vitro Electrophysiological Assay for P2X2/3- ?2X2β was assayed as above with two protocol modifications: 1) 30 μM αfβ-meATP used as agonist; and 2) current amplitude was measured at the end of 2-second agonist application. Using the assays described herein the compounds of this invention were found to be active for the P2X3 receptor. The compounds of formula I have an IC50 activity of 100 μM or less for the P2X3 receptor. Many of the compounds of formula I disclosed herein were found to have an IC50 of less than 200 nM. For example, the compounds below have IC50 < 250 nM in the "Intracellular Calcium Measurement to Assess Antagonist Affinity" assay. In particular, compound 1.62 has an IC50 = 23 nM; compound 2.1 has an IC50 = 165 nM; compound 3.22 has an IC50 = 42 nM; and compound 5.61 has an IC50 = 48 nM.

Claims

WHAT IS CLAIMED:
1. A compound of structural formula I: structural formula I:
Figure imgf000119_0001
or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof wherein: A represents pyridinyl, pyrimidinyl, or pyridinonyi;
W and Z independently are absent or represent C(R2)2, -O-, NR2, CO, or S0Q-2J
R2 represents H, C i -6 alkyl, CF3 , OH, CHF2, or CH2F;
R3 represents CR2R4R5, (CH2)nC3-10 cycloalkyl, (CH2)nC6-10 aryl, (CH2)nC5-10 heterocycϊe,said cycloalkyl, and heterocyclyl optionally substituted with 1 to 3 groups of Ra;
or R2 and R3 can be combined with the nitrogen to which they are attached to form a C5.10 heterocyclyl optionally substituted with 1 to 3 groups of Ra;
R4 and R5 independently represent H, (CH2)nOR2, CHF2, (CH2)nCF3, (CH2)nC5-10 heterocyclyl, (CH2)nC6-10 aryl, C3.10 cycloalkyl, Cl -6 alkoxy, C2-6 alkenyl, C(O) 1-2R2, or C 1-6 alkyl; said alkyl, cycloalkyl, heterocyclyl and aryl optionally substituted with 1 to 3 groups of Ra;
R6 represents hydrogen, OR2, -O-,CF3, C(R2)2OR2, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-IO cycloalkyl, (CH2)nC6-10 aryl, (CH2)nC5-10 heterocyclyl, said alkyl, aryl and heterocyclyl optionally substituted with 1 to 3 groups of R&; R? represents Ci-ό alkyl, C3-10 cycioalkyl, (CH2)nC5-lO heterocyclyl, or (CH2)nC6-10 aryl, said alkyl, cycioalkyl, heterocyclyl and aryl optionally substituted with 1 to 3 groups of Ra;
Ra represents Cl _6 alkyl, halogen, hydroxyl, OR2 (CH2)nCF3, -O-, C3_6 cycioalkyl,
NR2C(O)R2, C(O)N(R2)2, ^2)2(^2, C(O)R2, NO2, CN, N(R2)2J C(O)OR2, SO2R2, OR2, (CH2)nC5-10 heterocyclyl, or (CH2)nC6-10 aryU said heterocyclyl and aryl optionally substituted with 1 to 3 groups of Cl .5 alkyl, halogen, hydroxyl, (CH2)nCF3,or CN; and
n represents 0 to 4, provided that when A is pyrimidinyl WZR6 is not OH; and when A is pyridinonyl WZRό is not hydrogen.
2. The compound according to claim 1 wherein R2 is hydrogen, and R? is represented by structural formula Ia:
Figure imgf000120_0001
Wherein X is N or CH; and Rl represents H5 Ci -6 alkyl, halogen, (CH2)nCF3, C3.40 cycioalkyl, C(R2)2OH, -O-, CN, (CH2)nOR2> (CH2)nC5-10 heterocyclyl, (CH2)nC6-10 aryl, or Cμ6 alkoxy; said alkyl, cycioalkyl, heterocyclyl and aryl optionally substituted with 1 to 3 groups of Ci-6 alkyl, halogen, hydroxyl, (CH2)nCF3,or CN.
3. The compound according to claim 2 wherein X is N.
4. The compound according to claim 2 wherein X is CH.
5. The compound according to claim 2 wherein Ia is linked to a carbon atom on A.
6. The compound according to claim 1 wherein A is pyridyl.
7. The compound according to claim 1 wherein A is pyrimidinyl.
8. The compound according to claim 1 wherein A is pyridinonyl.
9. A compound according to claim 1 represented by structural formula II:
Figure imgf000120_0002
II or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof:
wherein W and Z are absent, R7 is (CH2)nC6-10 aryl, ∞ (CH2)nC6-10 heterocyclyl optionally substituted with 1 to 3 groups of Ra, R6 is hydrogen, -O, Ci-6 alkyl, 0R2, (CH2)nmorpholinyl, (CH2)npyήdyl, (CH2)npiperidinyl, (CH2)nθxazolyl, (CH2)nisoxazolyl, (CH2)nphenyl, (CH2)npiperidinyl, (CH2)ninύdazolyl, (CH2)nPyήmidinyl, oyclopropyl, cyclobutyl, all optionally substituted with 1 to 3 groups of Ra, and R3 is CR2R4R5 wherein R2 of CR2R4R5 is hydrogen, and one of R4 and R5 is Ci _6 alkyl or hydrogen and the other is (CH2)nC6-10 &ryU or (CH2)nC6-10 heterocyclyl, said alkyl, aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra.
10. A compound according to claim 1 represented by structural formula IU:
Figure imgf000121_0002
or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof:
wherein W and Z are absent, R7 is (CH2)nC6-10 aryl. or (CH2)nC6-10 heterocyclyl said aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra, R6 is hydrogen, Ci -6 alkyl, OR2, (CH2)nmorpholinyl, (CH2)nPyήdyl, (CH2)npiperidinyl, (CH2)noxazolyl,
(CH2)nisoxazolyl, (CH2)nphenyl, (CH2)npiperidinyl, (CH2)n™idazolyI, (CH2)npyπmidinyl, cyclopropyl, cyclobutyl, all optionally substituted with 1 to 3 groups of Ra, and R3 is CR2R4R5 wherein R2 of CR2R4R5 is hydrogen, and one of R^ and R$ is Cj-6 alkyl or hydrogen and the other is (CH2)nC6-10 aryl, or (CH2)nC6-10 heterocyclyl, said alkyl, aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra.
11. A compound according to claim 1 represented by structural formula IV:
Figure imgf000121_0001
or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof:
wherein W and Z are absent, R7 is (CH2)nC6-10 aryl> or (CH2)nC6-10 heterocyclyl said aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra, R6 is hydrogen, C\.β alkyl, OR2, (CH2)nmorpholinyl, (CH2)npyπdyl, (CH2)npiperidinyl? (CH2)n<>xazolyl,
(CH2)nisoxazolyl, (CH2)nphenyl, (CH2)npiperidinyl, (CH2)niπHdazolyl, (CH2)npyrimidiriyl, cyclopropyl, cyclobutyl, all optionally substituted with 1 to 3 groups of Ra, and R3 is CR2R4R5 wherein R2 of CR2R4R5 1S hydrogen, and one of R4 and R5 is C 1-6 alkyl or hydrogen and the other is (CH2)nC6-10 aryl, or (CH2)nC6-10 heterocyclyl, said alkyl, aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra.
12. A compound according to claim 1 represented by structural formula V:
Figure imgf000122_0001
or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof:
wherein W and Z are absent, R? is (CH2)nC6-10 aryl> or (CH2)nC6-10 heterocyclyl optionally substituted with 1 to 3 groups of Ra, R6 is -O, and R3 is CR2R4R5 wherein R2 of CR2R4R5 is hydrogen, and one of R4 and R^ is C\,β alkyl or hydrogen and the other is (CH2)nC6-10 aryl, or (CH2)nC6-10 heterocyclyl, said alkyl, aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra.
13. A compound according to claim 1 represented by structural formula VI:
Figure imgf000122_0002
or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof:
wherein W and Z are absent, R? is (CH2)nCό-10 aryl, or (CH2)nC6- 10 heterocyclyl optionally substituted with 1 to 3 groups of Ra, Rό is hydrogen, C 1-6 alkyl, OR2, (CH2)nmorphoHnyl, (CH2)npyridyl, (CH2)npiperidinyl, (CH2)noxazolyl, (CH2)nisoxazoIyl, (CH2)nphenyl, (CH2)npiperidinyl, (CH2)nimidazolyl, (CH2)nPyrimidinyl, cyclopropyl, cyclobutyl, all optionally substituted with 1 to 3 groups of Ra and R3 is CR2R4R5 wherein R2 of CR2R4R5 is hydrogen, and one of R4 and R5 is Ci_6 alkyl or hydrogen and the other is (CH2)nC6-10 aryl> °r (CH2)nC6-10 heterocyclyl, said alkyl, aryl and heterocyclyl optionally substituted with 1 to 3 groups of Ra.
14. The compound according to claim 13 wherein R? is phenyl, pyridinyl, morpholinyl, pyrimidinyl, imidazolyl, or oxazolyl any one of which is optionally substituted with 1 to 3 groups of Ra R2 of CR2R4R5 1S hydrogen, and one of R4 and R5 of CR2R4R5 is CI -6 alkyl or hydrogen and the other is (CH2)nphenyl, (CH2)nPyridyl, (CH2)npyrimidinyl,
(CH2)ntriazolylf pyrazinyl, or (CH2)noxadiazolylf said phenyl, pyridyl, pyrimidinyl, triazolyl, pyrazinyl and oxadiazolyl optionally substituted with 1 to 3 groups of Ra,
15. The compound according to claim 14 wherein R? is an optionally substituted phenyl, R2 of CR2R4R5 }S hydrogen, and one of R4 and R5 of CR2R4R5 is C i -6 alkyl or hydrogen and the other is optionally substituted (CH2)nθxadiazolyl, said oxadiazolyl optionally substituted with 1 to 3 groups of Ra, and Rό is an optionally substituted Cl -6 alkyl.
16. A compound represented in Tables 1 through 5 or pharmaceutically acceptable salts and individual enantϊomers and diastereomers thereof.
17. A compound according to claim 16 which is:
2-(2-Fluoro-4-methylphenyl)-6-raoφholin-4-yl-N-[(15)-l-(4H-l,2,4-triazol-3-yl)ethyl]isonicotinamide; 2-(2,4-Difluorophenyl)-6-( 1 -hydroxy- 1 -methylethyl)-N- {( 1 R)- 1 -[ 1 -oxido-6-(trifluoromethyl)pyridin-3- yl]ethyl}isonicotinamide;
2-(2J4-Difluorophenyl)-6-(2-methylpyriraidin-5-yl)-N-{(li?)-l-[l-oxido-6-(trifluoromethyl)pyridin-3- yl]ethyl} isonicotinamide;
N- { ( 1 R)- 1 -[6-( 1 , 1 -Difluoroethy I)- 1 -oxidopyridin-3 -yl]ethyl } -2-(2,4-difluorophenyl)-6-(2,2,2-trifluoro- 1 - hydroxyethyl) isonicotinamide; 6-Isopropyl-5'-methyl-N-{(lR)-l-[2-(trifluoromethyI)pyrimidin-5-yl]ethyl}-2,2'-bipyridine-4- carboxamide;
N-[(lJ!ϊ)-l-(3-Methyl-l,2J4-oxadiazol-5-yl)ethyl3-2,6-bis(4-methylphenyl)pyrimidine-4-carboxamide;
5-(2,4-Difluorophenyl)-N- {( l/?)-l-[l -oxido-6-(trifluoromethyl)pyridin-3 -yljethyl } nicotinamide;
5-(4-Fluoropheny!)-6-isopropoxy-N-[(l/?)-l-(3-methyI-l,2,4-oxadiazol-5-yl)ethyl]nicotinamide; 5 -(4-fluoropheny I)- 1 -isopropy !-N- [( 1 R)- 1 -(3 -methyl- 1 ,2,4-oxad iazol-5-y l)ethy 1] -6-oxo- 1,6- dihydropyridine-3-carboxamide;
5 -(2-Fluoro-4-methy lphenyl)-N- [( 1 R)- 1 -(3 -methyl- 1 ,2,4-oxad iazol-5-y l)ethy 1] nicotinam ide 1 -ox ide ; 3-(4-Fluorophenyl)-N-[( IR)- 1 -(3-methyl-l ,2,4-oxadiazol-5-yl)ethyl]-2-oxo-2H-l ,2'-bipyridine-5- carboxamide;
5-(4-Fluorophenyl)-l-(3-hydroxy-3-methylbutan-2-yI)-Ν-[(lR)-l-(3-methyl-l,2,4-oxadiazol-5-yl)ethyl]- 6-oxo- 1 ,6-dihydropyridine~3 -carboxamide;
5-(4-Fluorophenyl)- 1 -[(2R)-3-hydroxy-3-methylbutan-2-yl]-N-[( 1 R)-I -(3-methyl-l ,2,4-oxadiazol-S- yl)ethyl] -6-oxo- 1 ,6-dihydropyridine-3-carboxamide; 5-(4-Fluorophenyl)-l-[(2S)-3-hydroxy-3-methylbutan-2-yl]-N-[(lR)-l-(3-methyl-l,2,4-oxadiazol-5- yl)ethyl] -6-oxo- 1 ,6-dihydropyridine-3-carboxamide
or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof.
18. A pharmaceutical composition comprising an inert carrier and an effective amount of a compound according to Claim 1.
19. The composition according to claim 18 further comprising one or more therapeutically active compounds selected from the group consisting of opiate agonists or antagonists, calcium channel antagonists, 5ΗT, 5-HTlA complete or partial receptor agonists or antagonists , sodium channel antagonists, N-methyl-D-aspartate (NMDA) receptor agonists or antagonists, COX-2 selective inhibitors, neurokinin receptor 1 (NKl) antagonists, non-steroidal anti-inflammatory drugs (NS AID), selective serotonin reuptake inhibitors (SSRI) and/or selective serotonin and norepinephrine reuptake inhibitors (SSNRI), tricyclic antidepressant drugs, norepinephrine modulators, lithium, valproate, norepinephrine reuptake inhibitors, monoamine oxidase inhibitors (MAOIs), reversible inhibitors of monoamine oxidase (RIMAs), alpha- adrenoreceptor antagonists, atypical anti-depressants, calcitonin gene-related peptide (CGRP) antagonists, beta-3 adrenergic receptor agonist (β3AR), benzodiazepines, corticotropin releasing factor (CRF) antagonists, neurontin (gabapentin) and pregabalin.
20. A method for treating or preventing chronic or acute pain, treating or controlling epilepsy, or enhancing the quality of sleep in a mammalian patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound according to formula I in claim 1 or a pharmaceutically acceptable salt thereof.
PCT/US2009/061409 2008-10-31 2009-10-21 P2x3, receptor antagonists for treatment of pain WO2010051188A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2009309019A AU2009309019B2 (en) 2008-10-31 2009-10-21 P2X3, receptor antagonists for treatment of pain
EP09824018.7A EP2358371B1 (en) 2008-10-31 2009-10-21 P2x3, receptor antagonists for treatment of pain
MX2011004570A MX2011004570A (en) 2008-10-31 2009-10-21 P2x3, receptor antagonists for treatment of pain.
EP14185280.6A EP2860178B1 (en) 2008-10-31 2009-10-21 P2X3 receptor antagonists for treatment of pain
CN200980153515.2A CN102271682B (en) 2008-10-31 2009-10-21 Be used for the treatment of the P2X of pain 3receptor antagonist
US13/125,935 US8598209B2 (en) 2008-10-31 2009-10-21 P2X3, receptor antagonists for treatment of pain
CA2741666A CA2741666C (en) 2008-10-31 2009-10-21 P2x3, receptor antagonists for treatment of pain
JP2011534616A JP5592388B2 (en) 2008-10-31 2009-10-21 Technical field of P2X3 receptor antagonist for the treatment of pain
ES09824018.7T ES2534199T3 (en) 2008-10-31 2009-10-21 P2X3 receptor antagonists for pain management

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19786908P 2008-10-31 2008-10-31
US61/197,869 2008-10-31
US22728509P 2009-07-21 2009-07-21
US61/227,285 2009-07-21

Publications (1)

Publication Number Publication Date
WO2010051188A1 true WO2010051188A1 (en) 2010-05-06

Family

ID=42129208

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/061409 WO2010051188A1 (en) 2008-10-31 2009-10-21 P2x3, receptor antagonists for treatment of pain

Country Status (9)

Country Link
US (1) US8598209B2 (en)
EP (2) EP2860178B1 (en)
JP (1) JP5592388B2 (en)
CN (1) CN102271682B (en)
AU (1) AU2009309019B2 (en)
CA (1) CA2741666C (en)
ES (1) ES2534199T3 (en)
MX (1) MX2011004570A (en)
WO (1) WO2010051188A1 (en)

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012020749A1 (en) 2010-08-10 2012-02-16 塩野義製薬株式会社 Triazine derivative and pharmaceutical compound that contains same and exhibits analgesic activity
WO2012020742A1 (en) 2010-08-10 2012-02-16 塩野義製薬株式会社 Novel heterocyclic derivatives and pharmaceutical composition containing same
WO2012032018A1 (en) * 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Heteroarylmethyl amides
WO2012053186A1 (en) * 2010-10-18 2012-04-26 Raqualia Pharma Inc. Arylamide derivatives as ttx-s blockers
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
US8362241B2 (en) 2009-04-28 2013-01-29 Amgen Inc. Inhibitors of PI3 kinase and/or mTOR
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
WO2013072758A1 (en) * 2011-11-15 2013-05-23 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
JP2014513122A (en) * 2011-04-30 2014-05-29 アッヴィ・インコーポレイテッド Isoxazolines as therapeutic agents
WO2014200078A1 (en) 2013-06-14 2014-12-18 塩野義製薬株式会社 Amino-triazine derivatives and pharmaceutical composition containing said derivatives
US8946439B2 (en) 2008-02-29 2015-02-03 Evotec Ag Amide compounds, compositions and uses thereof
US9056832B2 (en) 2010-09-17 2015-06-16 Purdue Pharma L.P. Pyridine compounds and the users thereof
EP2905282A1 (en) * 2014-02-05 2015-08-12 AXXAM S.p.A. Substituted thiazole or oxazole as P2X7 receptor antagonists
US9120752B2 (en) 2010-07-16 2015-09-01 Purdue Pharma, L.P. Pyridine compounds as sodium channel blockers
US9133122B2 (en) 2008-09-18 2015-09-15 Evotec Ag Amide compounds, compositions and uses thereof
US9150546B2 (en) 2009-02-13 2015-10-06 Shionogi & Co., Ltd. Triazine derivative and pharmaceutical composition comprising the same
WO2017009274A1 (en) * 2015-07-14 2017-01-19 F. Hoffmann-La Roche Ag 2-phenyl-6-imidazolyl-pyridine-4-carboxamide derivatives and their use as eaat3 inhibitors
US9550763B2 (en) 2012-02-09 2017-01-24 Shionogi & Co., Ltd. Heterocyclic ring and carbocyclic derivative
WO2017072083A1 (en) * 2015-10-28 2017-05-04 F. Hoffmann-La Roche Ag Pyridine or pyrimidine derivatives
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
US9718780B2 (en) 2012-03-16 2017-08-01 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
US9828369B2 (en) 2014-09-05 2017-11-28 Merck Sharpe & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
US9877957B2 (en) 2014-09-05 2018-01-30 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
WO2018041639A1 (en) * 2016-08-30 2018-03-08 Universität Bielefeld Method for producing chiral aminonitriles
CN107922391A (en) * 2015-08-12 2018-04-17 豪夫迈·罗氏有限公司 Pyridine and pyrimidine derivatives
US10023557B2 (en) 2015-07-01 2018-07-17 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
US10266515B2 (en) 2013-12-30 2019-04-23 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
US10273217B2 (en) 2015-10-06 2019-04-30 Hoffmann-La Roche Inc. Triazole derivatives
US10301284B2 (en) 2016-07-11 2019-05-28 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2019101647A1 (en) * 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 2-phenylpyrimidine-4-carboxamides as ahr inhibitors
US10457644B2 (en) 2016-05-27 2019-10-29 Hoffman-La Roche Inc. Pyrazol compounds as EAAT3 inhibitors
US10457663B2 (en) 2016-02-02 2019-10-29 Hoffmann-La Roche Inc. Pyrazol-pyridine derivatives
US10556870B2 (en) 2016-10-14 2020-02-11 Hoffmann-La Roche Inc. Imidazole compounds as EAAT3 inhibitors
US10568876B2 (en) 2014-09-05 2020-02-25 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
US10577332B2 (en) 2015-04-23 2020-03-03 Hoffmann-La Roche Inc. Tetrazole derivatives
US10689345B2 (en) 2015-03-30 2020-06-23 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as USP30 inhibitors
US10947222B2 (en) 2016-11-18 2021-03-16 Merck Sharp & Dohme Corp. Indole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
US11104690B2 (en) 2016-11-18 2021-08-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
WO2024003259A1 (en) * 2022-06-30 2024-01-04 Bayer Aktiengesellschaft Tead inhibitors
US11912684B2 (en) 2017-04-27 2024-02-27 Ishihara Sangyo Kaisha, Ltd. N-(4-pyridyl)nicotinamide compound or salt thereof

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010229144B2 (en) 2009-03-23 2012-07-12 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
WO2010111059A1 (en) 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3 receptor antagonists for treatment of pain
WO2010111058A1 (en) 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
US8580829B2 (en) * 2010-08-26 2013-11-12 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
US8575201B2 (en) * 2010-09-23 2013-11-05 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
EP2619196B1 (en) * 2010-09-23 2015-09-16 Boehringer Ingelheim International GmbH Oxadiazole inhibitors of leukotriene production
AR089853A1 (en) 2012-02-01 2014-09-24 Boehringer Ingelheim Int OXADIAZOL INHIBITORS FROM THE PRODUCTION OF LEUCOTRIENS FOR COMBINATION THERAPY, PHARMACEUTICAL COMPOSITION, USE
BR112016013734A2 (en) * 2013-12-16 2017-08-08 Asana Biosciences Llc COMPOUND, PHARMACEUTICAL COMPOSITION, KIT, AND USE OF A COMPOUND
WO2016084922A1 (en) * 2014-11-28 2016-06-02 塩野義製薬株式会社 1,2,4-triazine derivative and pharmaceutical composition thereof
PT3230281T (en) * 2014-12-09 2021-08-19 Bayer Ag 1,3-thiazol-2-yl substituted benzamides
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TW202246215A (en) 2015-12-18 2022-12-01 美商亞德利克斯公司 Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists
WO2017165426A1 (en) * 2016-03-22 2017-09-28 The Regents Of The University Of California Compositions and methods to promote wound healing
CN115093400B (en) * 2021-09-18 2023-09-05 北京华森英诺生物科技有限公司 AhR inhibitor, application and preparation method thereof

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024780A2 (en) 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidinone and pyridinone compounds and their use
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
WO2001012627A1 (en) 1999-08-19 2001-02-22 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US6436972B1 (en) 2000-04-10 2002-08-20 Dalhousie University Pyridones and their use as modulators of serine hydrolase enzymes
US6977266B2 (en) 2000-12-28 2005-12-20 Shionogi & Co., Ltd. Pyridone derivatives having affinity for cannabinoid 2-type receptor
WO2006119504A2 (en) 2005-05-04 2006-11-09 Renovis, Inc. Fused heterocyclic compounds, and compositions and uses thereof
WO2007001973A1 (en) 2005-06-28 2007-01-04 Astrazeneca Ab New use
WO2007010553A2 (en) 2005-03-24 2007-01-25 Arrow Coated Products Ltd Combined multi-layered water soluble film and process for producing the same
US20070049609A1 (en) 2005-09-01 2007-03-01 Roche Palo Alto Llc Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases
WO2007041087A2 (en) 2005-09-30 2007-04-12 Merck & Co., Inc. Nucleic acids encoding a functional mammalian purinoreceptor, p2x3, methods of production and use thereof
US20080004442A1 (en) 2006-06-29 2008-01-03 Dillon Michael P Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists
US20080021024A1 (en) * 2006-06-29 2008-01-24 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1297441A (en) * 1998-04-20 2001-05-30 Basf公司 Heterocyclically substd. amides used as calpain inhibitors
KR100850728B1 (en) * 2000-06-12 2008-08-06 에자이 알앤드디 매니지먼트 가부시키가이샤 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
WO2004011430A1 (en) * 2002-07-25 2004-02-05 Yamanouchi Pharmaceutical Co., Ltd. Sodium channel inhibitor
NL1026826C2 (en) * 2003-08-13 2007-01-04 Pharmacia Corp Substituted pyridinones.
GB0403155D0 (en) * 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
PE20060285A1 (en) * 2004-03-30 2006-05-08 Aventis Pharma Inc PYRIDONES SUBSTITUTE AS POL (ADP-RIBOSA) -POLYMERASE (PARP) INHIBITORS
JP2006052212A (en) * 2004-07-12 2006-02-23 Nippon Nohyaku Co Ltd Phenylpyridines or their salts, herbicide containing those as active ingredient and method for using the same herbicide
DE102005019712A1 (en) * 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone and its use
EP1912970A2 (en) * 2005-08-10 2008-04-23 Bayer Schering Pharma Aktiengesellschaft Acyltryptophanols for fertility control
MX2008002014A (en) * 2005-08-15 2008-03-27 Hoffmann La Roche Piperidine and piperazine derivatives as p2x3 antagonists.
EP2001476A4 (en) 2006-03-20 2010-12-22 Synta Pharmaceuticals Corp Benzoimidazolyl-parazine compounds for inflammation and immune-related uses
JP2008115175A (en) * 2006-10-13 2008-05-22 Otsuka Pharmaceut Co Ltd Heterocyclic compound
WO2008060568A2 (en) * 2006-11-15 2008-05-22 Neurogen Corporation Amide-substituted aryl piperidines
JP5178738B2 (en) * 2006-12-20 2013-04-10 メルク・シャープ・アンド・ドーム・コーポレーション Novel JNK inhibitor
US8338434B2 (en) * 2007-03-29 2012-12-25 Glaxosmithkline Llc Inhibitors of Akt activity
EP2002834A1 (en) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl and hetaryl amides as modulators of EP2 receptors
JP5552430B2 (en) * 2007-10-31 2014-07-16 メルク・シャープ・アンド・ドーム・コーポレーション P2X3 receptor antagonist for the treatment of pain
CA2703909A1 (en) * 2007-10-31 2009-05-07 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
CA2705405A1 (en) * 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh New compounds
JPWO2009119088A1 (en) * 2008-03-25 2011-07-21 武田薬品工業株式会社 Heterocyclic compounds
US8148408B2 (en) * 2008-05-09 2012-04-03 Abbott Laboratories Selective substituted pyridine ligands for neuronal nicotinic receptors
KR20110022089A (en) * 2008-06-27 2011-03-04 노파르티스 아게 Organic compounds
GB0818907D0 (en) * 2008-10-15 2008-11-19 Isis Innovation Histone lysine demethylase inhibitors

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649604B2 (en) 1996-12-05 2003-11-18 Amgen Inc. Substituted pyridone compounds and methods of use
WO1998024780A2 (en) 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidinone and pyridinone compounds and their use
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US6610698B2 (en) 1996-12-05 2003-08-26 Amgen, Inc. Substituted pyrimidine compounds and methods of use
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6420385B1 (en) 1996-12-05 2002-07-16 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
WO2001012627A1 (en) 1999-08-19 2001-02-22 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6436972B1 (en) 2000-04-10 2002-08-20 Dalhousie University Pyridones and their use as modulators of serine hydrolase enzymes
US6544986B2 (en) 2000-04-10 2003-04-08 Dalhousie University Pyridones and their use as modulators of serine hydrolase enzymes
US6977266B2 (en) 2000-12-28 2005-12-20 Shionogi & Co., Ltd. Pyridone derivatives having affinity for cannabinoid 2-type receptor
WO2007010553A2 (en) 2005-03-24 2007-01-25 Arrow Coated Products Ltd Combined multi-layered water soluble film and process for producing the same
WO2006119504A2 (en) 2005-05-04 2006-11-09 Renovis, Inc. Fused heterocyclic compounds, and compositions and uses thereof
WO2007001973A1 (en) 2005-06-28 2007-01-04 Astrazeneca Ab New use
US20070049609A1 (en) 2005-09-01 2007-03-01 Roche Palo Alto Llc Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases
WO2007041087A2 (en) 2005-09-30 2007-04-12 Merck & Co., Inc. Nucleic acids encoding a functional mammalian purinoreceptor, p2x3, methods of production and use thereof
US20080004442A1 (en) 2006-06-29 2008-01-03 Dillon Michael P Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists
US20080021024A1 (en) * 2006-06-29 2008-01-24 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors

Non-Patent Citations (39)

* Cited by examiner, † Cited by third party
Title
BLAND-WARD ET AL., DR. J. PHARMACOL., vol. 122, 1997, pages 366 - 371
BO ET AL., FEBS LETT., vol. 375, 1995, pages 129 - 133
BRAKE ET AL., NATURE, vol. 371, 1994, pages 519 - 523
BROUNS ET AL., AM J. RESPIR CELL MOL BIOL, vol. 23, 2000, pages 52061
BUELL ET AL., EMBO J., vol. 15, 1996, pages 55 - 62
BUELL ET AL., EUR. J. NEUROSCI., vol. 8, 1996, pages 2221 - 2228
BUMSTOCK, DRUG DEV. RES., vol. 28, 1993, pages 195 - 206
BURNSTOCK, G., PHARMACOL. REV., vol. 24, 1972, pages 509 - 581
BURNSTOCK, G.: "Cell Membrane Receptor for Drugs and Hormones: A Multidisciplinary Approach", 1978, RAVEN, pages: 107 - 118
BURNSTOCK, J. ANATOMY, vol. 194, 1999, pages 335 - 342
CHAPLAN ET AL., J NEUROSCI METH, vol. 53, 1994, pages 55
CHEN ET AL., NATURE, vol. 377, 1995, pages 428 - 430
CHEN ET AL., NATURE, vol. 377, 1995, pages 428 - 431
CHEN ET AL., NEUROREPORT, vol. 10, 1999, pages 2779 - 2782
COLLO ET AL., J. NEUROSCI., vol. 16, 1996, pages 2495 - 2507
DRIESSEN ET AL., BRAIN RES., vol. 666, 1994, pages 182 - 188
FERGUSON ET AL., J. PHYSIOL., vol. 505, 1997, pages 503 - 511
G. WYNN ET AL., AM J PHYSIOL GASTROINTEST LIVER PHYSIOL, vol. 287, 2004, pages G647 - 57
GARCIA-GUZMAN ET AL., FEBS LETT., vol. 388, 1996, pages 123 - 127
HAMILTON ET AL., BR. J. PHAMACOL., vol. 126, 1999, pages 326 - 332
LE ET AL., J. NEUROSCI., vol. 18, 1998, pages 7152 - 7159
LEWIS ET AL., NATURE, vol. 377, 1995, pages 432 - 435
NAMASIBAYAM ET AL., BJU INTL., vol. 84, 1999, pages 854 - 860
RALEVIC, V. ET AL., PHARMACOL. REV., vol. 50, 1998, pages 413 - 492
See also references of EP2358371A4
SEGUELA ET AL., J. NEUROSCI., vol. 16, 1996, pages 448 - 455
SOTO ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 223, 1996, pages 456 - 460
SOTO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 3684 - 3688
SURPRENANT ET AL., SCIENCE, vol. 272, 1996, pages 735 - 738
TORRES ET AL., MOL. PHARMACOL., vol. 54, 1998, pages 989 - 993
TSUDA ET AL., BR. J. PHARMACOL., vol. 127, 1999, pages 449 - 456
TSUDA ET AL., BR. J. PHARMACOL., vol. 128, 1999, pages 1497 - 1504
VALERA ET AL., NATURE, vol. 371, 1994, pages 516 - 519
VULCHANOVA ET AL., NEUROPHARMACOL., vol. 36, 1997, pages 1229 - 1242
W. RONG ET AL., J. NEUROSC, vol. 23, no. 36, 2003, pages 11315 - 21
WANG ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 220, 1996, pages 196 - 202
X. BIAN ET AL., J. PHYSIOL, vol. 551, no. 1, 2003, pages 309 - 22
Y. YIANGOU ET AL., NEUROKASTROENTEROL MOT, vol. 13, 2001, pages 365 - 69
ZHONG ET AL., BR. J. PHARMACOL., vol. 125, 1998, pages 771 - 781

Cited By (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946439B2 (en) 2008-02-29 2015-02-03 Evotec Ag Amide compounds, compositions and uses thereof
US8614213B2 (en) 2008-08-07 2013-12-24 Novartis Ag Cyclohexyl amide derivatives and their use as CRF-1 receptor antagonists
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
US9133122B2 (en) 2008-09-18 2015-09-15 Evotec Ag Amide compounds, compositions and uses thereof
US9688643B2 (en) 2009-02-13 2017-06-27 Shionogi & Co., Ltd. Triazine derivative and pharmaceutical composition comprising the same
US9150546B2 (en) 2009-02-13 2015-10-06 Shionogi & Co., Ltd. Triazine derivative and pharmaceutical composition comprising the same
US8362241B2 (en) 2009-04-28 2013-01-29 Amgen Inc. Inhibitors of PI3 kinase and/or mTOR
US8772480B2 (en) 2009-04-28 2014-07-08 Amgen Inc. Inhibitors of PI3 kinase and/or mTOR
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US10117858B2 (en) 2010-03-19 2018-11-06 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
USRE46757E1 (en) 2010-03-19 2018-03-20 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8476269B2 (en) 2010-03-19 2013-07-02 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US11911371B2 (en) 2010-03-19 2024-02-27 Novartis Ag Pyridine and pyrazine derivative for the treatment of chronic bronchitis
US9120752B2 (en) 2010-07-16 2015-09-01 Purdue Pharma, L.P. Pyridine compounds as sodium channel blockers
US9765029B2 (en) 2010-07-16 2017-09-19 Purdue Pharma L.P. Pyridine compounds as sodium channel blockers
EP2604260A1 (en) * 2010-08-10 2013-06-19 Shionogi&Co., Ltd. Novel heterocyclic derivatives and pharmaceutical composition containing same
KR101867110B1 (en) * 2010-08-10 2018-06-12 시오노기 앤드 컴파니, 리미티드 Triazine derivative and pharmaceutical compound that contains same and exhibits analgesic activity
WO2012020749A1 (en) 2010-08-10 2012-02-16 塩野義製薬株式会社 Triazine derivative and pharmaceutical compound that contains same and exhibits analgesic activity
US9718790B2 (en) 2010-08-10 2017-08-01 Shionogi & Co., Ltd. Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same
WO2012020742A1 (en) 2010-08-10 2012-02-16 塩野義製薬株式会社 Novel heterocyclic derivatives and pharmaceutical composition containing same
CN103153968B (en) * 2010-08-10 2016-02-03 盐野义制药株式会社 Triazole derivative and containing its pharmaceutical composition with analgesic activity
JP5594706B2 (en) * 2010-08-10 2014-09-24 塩野義製薬株式会社 Triazine derivative and pharmaceutical composition containing the same having analgesic action
KR20130138734A (en) 2010-08-10 2013-12-19 시오노기 앤드 컴파니, 리미티드 Triazine derivative and pharmaceutical compound that contains same and exhibits analgesic activity
US9212130B2 (en) 2010-08-10 2015-12-15 Shionogi & Co., Ltd. Heterocyclic derivative and pharmaceutical composition comprising the same
EP2604260A4 (en) * 2010-08-10 2015-01-07 Shionogi & Co Novel heterocyclic derivatives and pharmaceutical composition containing same
CN103153968A (en) * 2010-08-10 2013-06-12 盐野义制药株式会社 Triazine derivative and pharmaceutical compound that contains same and exhibits analgesic activity
CN103118680B (en) * 2010-09-09 2015-12-16 霍夫曼-拉罗奇有限公司 Heteroaryl carboxamides
US9090599B2 (en) 2010-09-09 2015-07-28 Hoffmann-La Roche Inc. Heteroarylmethyl amides
US8729105B2 (en) 2010-09-09 2014-05-20 Hoffmann La-Roche Inc. Heteroarylmethyl amides
KR101546595B1 (en) 2010-09-09 2015-08-21 에프. 호프만-라 로슈 아게 Heteroarylmethyl amides
CN103118680A (en) * 2010-09-09 2013-05-22 霍夫曼-拉罗奇有限公司 Heteroarylmethyl amides
WO2012032018A1 (en) * 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Heteroarylmethyl amides
JP2013537173A (en) * 2010-09-09 2013-09-30 エフ．ホフマン−ラ ロシュ アーゲー Heteroarylmethylamide
US9056832B2 (en) 2010-09-17 2015-06-16 Purdue Pharma L.P. Pyridine compounds and the users thereof
US9611222B2 (en) 2010-09-17 2017-04-04 Purdue Pharma L.P. Pyridine compounds and the uses thereof
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
JP2014177450A (en) * 2010-10-18 2014-09-25 Raqualia Pharma Inc Arylamide derivatives as ttx-s blockers
CN103249721A (en) * 2010-10-18 2013-08-14 拉夸里亚创药株式会社 Arylamide derivatives as TTX-S blockers
WO2012053186A1 (en) * 2010-10-18 2012-04-26 Raqualia Pharma Inc. Arylamide derivatives as ttx-s blockers
US9302991B2 (en) 2010-10-18 2016-04-05 Raqualia Pharma Inc. Arylamide derivatives as TTX-S blockers
CN103249721B (en) * 2010-10-18 2016-10-12 拉夸里亚创药株式会社 Aryl amine derivatives as TTX-S blocker
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
JP2014513122A (en) * 2011-04-30 2014-05-29 アッヴィ・インコーポレイテッド Isoxazolines as therapeutic agents
US9029409B2 (en) 2011-04-30 2015-05-12 Abbvie Inc. Isoxazolines as therapeutic agents
US9133131B2 (en) 2011-11-15 2015-09-15 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
US9539253B2 (en) 2011-11-15 2017-01-10 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
WO2013072758A1 (en) * 2011-11-15 2013-05-23 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
US9550763B2 (en) 2012-02-09 2017-01-24 Shionogi & Co., Ltd. Heterocyclic ring and carbocyclic derivative
US9718780B2 (en) 2012-03-16 2017-08-01 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
WO2014200078A1 (en) 2013-06-14 2014-12-18 塩野義製薬株式会社 Amino-triazine derivatives and pharmaceutical composition containing said derivatives
US9732060B2 (en) 2013-06-14 2017-08-15 Shionogi & Co., Ltd. Aminotriazine derivative and pharmaceutical composition comprising the same
US10065941B2 (en) 2013-06-14 2018-09-04 Shionogi & Co., Ltd. Aminotriazine derivative and pharmaceutical composition comprising the same
KR20160018807A (en) 2013-06-14 2016-02-17 시오노기 앤드 컴파니, 리미티드 Amino-triazine derivatives and pharmaceutical composition containing said derivatives
US11021463B2 (en) 2013-12-30 2021-06-01 Attune Pharmaceuticals, Inc. Therapeutic inhibitory compounds
US10259803B2 (en) 2013-12-30 2019-04-16 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
US10266515B2 (en) 2013-12-30 2019-04-23 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
CN106103432B (en) * 2014-02-05 2019-10-18 阿克萨姆股份公司 Substituted thiazole or oxazole P2X7 receptor antagonist
US10167281B2 (en) 2014-02-05 2019-01-01 Axxam S.P.A. Substituted thiazole or oxazole P2X7 receptor antagonists
WO2015118019A1 (en) * 2014-02-05 2015-08-13 Axxam S.P.A. Substituted thiazole or oxazole p2x7 receptor antagonists
RU2701858C1 (en) * 2014-02-05 2019-10-02 Акссам С.П.А. Substituted thiazoles or oxazoles as p2x7 receptor antagonists
CN106103432A (en) * 2014-02-05 2016-11-09 阿克萨姆股份公司 The thiazole being replaced or azoles P2X7 receptor antagonist
EP2905282A1 (en) * 2014-02-05 2015-08-12 AXXAM S.p.A. Substituted thiazole or oxazole as P2X7 receptor antagonists
US9718812B2 (en) 2014-02-05 2017-08-01 Axxam S.P.A. Substituted thiazole or oxazole P2X7 receptor antagonists
US10568876B2 (en) 2014-09-05 2020-02-25 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
US9877957B2 (en) 2014-09-05 2018-01-30 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
US9828369B2 (en) 2014-09-05 2017-11-28 Merck Sharpe & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
US10689345B2 (en) 2015-03-30 2020-06-23 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as USP30 inhibitors
US11053198B2 (en) 2015-03-30 2021-07-06 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as USP30 inhibitors
US11390584B2 (en) 2015-03-30 2022-07-19 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as USP30 inhibitors
US11066365B2 (en) 2015-03-30 2021-07-20 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as USP30 inhibitors
US10577332B2 (en) 2015-04-23 2020-03-03 Hoffmann-La Roche Inc. Tetrazole derivatives
US10308637B2 (en) 2015-07-01 2019-06-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
US10023557B2 (en) 2015-07-01 2018-07-17 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2017009274A1 (en) * 2015-07-14 2017-01-19 F. Hoffmann-La Roche Ag 2-phenyl-6-imidazolyl-pyridine-4-carboxamide derivatives and their use as eaat3 inhibitors
US10092546B2 (en) 2015-07-14 2018-10-09 Hoffman-La Roche Inc. Imidazole derivatives
CN107709311A (en) * 2015-07-14 2018-02-16 豪夫迈·罗氏有限公司 The carboxamides derivatives of 2 phenyl, 6 imidazolyl pyridines 4 and its purposes as EAAT3 inhibitor
CN107922391B (en) * 2015-08-12 2020-09-25 豪夫迈·罗氏有限公司 Pyridine and pyrimidine derivatives
CN107922391A (en) * 2015-08-12 2018-04-17 豪夫迈·罗氏有限公司 Pyridine and pyrimidine derivatives
US10273217B2 (en) 2015-10-06 2019-04-30 Hoffmann-La Roche Inc. Triazole derivatives
US10155741B2 (en) 2015-10-28 2018-12-18 Hoffmann-La Roche Inc. Pyridine or pyrimidine derivatives
WO2017072083A1 (en) * 2015-10-28 2017-05-04 F. Hoffmann-La Roche Ag Pyridine or pyrimidine derivatives
US10457663B2 (en) 2016-02-02 2019-10-29 Hoffmann-La Roche Inc. Pyrazol-pyridine derivatives
US10457644B2 (en) 2016-05-27 2019-10-29 Hoffman-La Roche Inc. Pyrazol compounds as EAAT3 inhibitors
US10781200B2 (en) 2016-07-11 2020-09-22 Attune Pharmaceuticals, Inc. Therapeutic inhibitory compounds
US10301284B2 (en) 2016-07-11 2019-05-28 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2018041639A1 (en) * 2016-08-30 2018-03-08 Universität Bielefeld Method for producing chiral aminonitriles
US10556870B2 (en) 2016-10-14 2020-02-11 Hoffmann-La Roche Inc. Imidazole compounds as EAAT3 inhibitors
US10947222B2 (en) 2016-11-18 2021-03-16 Merck Sharp & Dohme Corp. Indole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
US11104690B2 (en) 2016-11-18 2021-08-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
US11912684B2 (en) 2017-04-27 2024-02-27 Ishihara Sangyo Kaisha, Ltd. N-(4-pyridyl)nicotinamide compound or salt thereof
WO2019101647A1 (en) * 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 2-phenylpyrimidine-4-carboxamides as ahr inhibitors
US11524944B2 (en) 2017-11-21 2022-12-13 Bayer Aktiengesellschaft 2-phenylpyrimidine-4-carboxamides as AHR inhibitors
WO2024003259A1 (en) * 2022-06-30 2024-01-04 Bayer Aktiengesellschaft Tead inhibitors

Also Published As

Publication number Publication date
JP5592388B2 (en) 2014-09-17
US8598209B2 (en) 2013-12-03
EP2358371A1 (en) 2011-08-24
MX2011004570A (en) 2011-06-17
CN102271682B (en) 2015-12-16
EP2860178A3 (en) 2015-05-20
CN102271682A (en) 2011-12-07
AU2009309019A1 (en) 2010-05-06
ES2534199T3 (en) 2015-04-20
CA2741666A1 (en) 2010-05-06
CA2741666C (en) 2017-04-11
EP2358371A4 (en) 2012-05-30
AU2009309019B2 (en) 2014-11-13
EP2860178B1 (en) 2021-01-13
US20110206783A1 (en) 2011-08-25
JP2012507533A (en) 2012-03-29
EP2860178A2 (en) 2015-04-15
EP2358371B1 (en) 2015-02-11

Similar Documents

Publication Publication Date Title
AU2009309019B2 (en) P2X3, receptor antagonists for treatment of pain
EP2215049B1 (en) P2x3, receptor antagonists for treatment of pain
EP2215048B1 (en) P2x3 receptor antagonists for treatment of pain
AU2010229144B2 (en) P2X3, receptor antagonists for treatment of pain
EP2410858B1 (en) P2x3 receptor antagonists for treatment of pain
EP2410857B1 (en) P2x3, receptor antagonists for treatment of pain

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980153515.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09824018

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2497/CHENP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 13125935

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2741666

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2011534616

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/004570

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009309019

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2009824018

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009309019

Country of ref document: AU

Date of ref document: 20091021

Kind code of ref document: A